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ABSTRACT
The social and economic impact of medication-related problems (MRPs) of 
cardiovascular drugs has been under-reported in the community setting. 
Cardiovascular patients on multiple drug therapy do not know whether side-effects 
they experience are medication-related or due to their condition. The aim of this study 
was therefore to develop a system to detect medication side-effects of cardiovascular 
drugs and their impact on patients* social and economic wellbeing. The problem was 
overcome by developing a Socioeconomic Impact Profile (SEIP) questionnaire in 
which patients were asked if they experienced medication side-effects and what 
impact these MRPs have on their ability to work, socialise or use healthcare services.
The Socioeconomic Impact Profile (SEIP) consisted of 19 items in three domains. 
Each item was scored from 1 to 5 (l=all of the time, 2=most of the time, 3=some of 
the time, 4=a little of the time, 5=never). Higher scores indicated better 
socioeconomic wellbeing. Psychometric evaluation of the SEIP was carried out in 348 
patients with cardiovascular disease (mean age=58.8; median=58.5; age range=37-84; 
male* 175; female* 173) recruited from five pharmacies across South West England 
and South Wales. The SEIP was generally acceptable to most patients with a mean 
completion time of 5.7 minutes. A high level of agreement among expert panel 
members on all items of the SEIP was achieved during content validation (Kappa 
coefficient “k”* 0.85). Factor analysis was used to identify redundant items and also 
provide initial evidence of construct validity. Evidence supporting internal 
consistency reliability was excellent (Cronbach’s a *0.77-0.95).
To further examine the reliability of the SEIP, test-retest reliability was carried out in 
92 patients with cardiovascular disease [50 (42.3%) males; mean age* 57.7; 
median*57.0; range=39-78] from five community pharmacies in South Wales and the 
reliability coefficient was high (rs= 0.91-0.93). Evidence supporting the validity of the 
SEIP was also shown in 96 patients [49 (51.0%) males; mean age=63.1; median=63.0; 
age range*39-84] with a cardiovascular condition from the community pharmacy 
setting. Convergent validity was demonstrated as SEIP patient scores showed 
moderate to good correlation with the patient MIDAS (Myocardial Infarction 
Dimensional Assessment Scale) scores. Divergent validity was established as the
Short Form-12 health survey (SF-12) overall score demonstrated weak to moderate 
correlation with the SEIP scores. This study has established the practicality, reliability 
and validity o f the SEIP as a promising socioeconomic related tool, especially in 
cardiovascular patients with medication-related problems in the community setting. 
Future work needs to focus on promoting use o f the SEIP as part of the new 
community pharmacy initiatives in the UK for evaluation of treatment outcomes in 
patients with medication-related side-effects.
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CHAPTER 1
General Introduction
BACKGROUND
Cardiovascular disease
Cardiovascular disease is the number one cause of death globally, according to the 
World Health Organisation’s report (Gaziano, 2007). It is the leading cause of death 
in developed countries such as the UK and the US today, despite the fact that many of 
the major risk factors for coronary disease have been identified (Hobbs and Boyle, 
2004). An estimated 17.5 million people died from cardiovascular disease in 2005, 
representing 30% of all global deaths (Figure 1). It is the number one cause of death 
in America, responsible for more than 40% of annual deaths (Van den bemt et al., 
2000) and has remained the leading cause o f death in the UK responsible for about 
20% of deaths in 2001. 85% of those deaths occurred in people aged over 65 years, 
although the disease remains a significant cause of premature mortality, particularly 
amongst men aged 45-64 years (Yuen, 2003).
Cardiovascular diseases include myocardial infarction, angina, hypertension, 
congestive heart failure (CHF), stroke, atherosclerosis and other diseases of the 
circulatory system. The chronic nature of cardiovascular disease and its contribution 
to high medical resource utilisation, costs and high rates of morbidity and mortality 
make it an ideal disease category upon which managed care organisations may focus 
(Kaiser, 2002). In the recent Health Statistics report published by the UK office of 
Health Economics (Hawe, 2008), coronary heart disease (CHD) was the most 
prevalent fatal disease amongst the UK male working population and is responsible 
for about 14% of working years o f life lost for men. Ischaemic heart disease (IHD) 
remains the most common cause of death in adults and accounts for some 200,000 
deaths per year in the UK including 70% of sudden natural deaths and 127,000 infarct 
deaths (Scott, 1999). Around one-third of 50- to 59-year old men have evidence of 
IHD, and this proportion increases with age (Scott, 1999).
Economic burden of cardiovascular disease
Studies have shown that cardiovascular diseases impose a significant economic and 
humanistic burden on patients and society (Johnson and Bootman, 1997; Mackay and 
Mensah, 2004; Leal et al., 2006; Haase et al., 2006; Gaziano, 2007). In the United
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States o f America (USA) for example, the total annual expenditure for treating heart 
failure in 1991 was estimated to cost around $38 billion, with the majority o f  
spending related to direct hospital costs (O'Connell, 2000). A similar study carried out 
in 2002 showed that the annual estimation o f  the medical and disability costs o f  
cardiovascular disease-related disorders was $330 billion (Sheta, 2004). In 2003, 
cardiovascular disease cost the European Union €169 billion (Leal et al., 2006) and 
the most up to date data from the United States o f America shows that cardiovascular 
disease costs nearly €310.23 billion in direct and indirect annual costs (Haase et al.,
2006). In China, annual direct costs are estimated at €30.76 billion or 4% o f gross 
national income (Gaziano, 2007). In South Africa, 25% o f the country’s health care 
spending is devoted to cardiovascular disease (The Centre for Global Health and 
Economic Development. 2004).
F ig u re  1 WHO findings on cardiovascular diseases (2005)
Cancer + Chronic 
respiratory diseases ♦  
Diabetes
Communicable diseases, 
maternal and perinatal 
conditions and nutritional 
deficiencies
Injuries 9%
Cardiovascular diseases 30% Other chronic 
diseases 9%
Apart from the direct costs o f the disease, loss o f work time and decreased 
productivity account for a substantial amount o f the indirect costs. More recently, 
there has been much interest in systematically improving the quality and reducing the 
cost o f caring for patients with chronic illnesses such as cardiovascular disease 
(Weingarten et al., 2002). At present, emphasis has been placed on disease 
management as part o f the programmes initiated to improve the quality and efficiency
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of care for patients with chronic illness. Disease management is a multidisciplinary 
approach to care for chronic diseases that coordinates comprehensive care along the 
disease continuum across healthcare delivery systems (Ellrodt et al., 1997; Allenet et 
al., 2006).
Role of pharmacists in disease management
In most countries, community pharmacists are the most accessible healthcare 
professionals. Pharmacists have developed primary care roles in the management of 
chronic diseases among which cardiovascular diseases such as hypertension, 
ischaemic heart disease and congestive heart failure are the common area of focus 
(Allenet et al., 2006). Studies have shown that community pharmacists’ involvement 
in disease management often lead to early intervention for drug-related problems 
(Munroe et al., 1997). More recent evidence also suggests that interventions of 
community pharmacists in patient management has led to improvement of blood 
pressure control in the community setting (Carter and Zillich, 2003; Machado et al.,
2007). An example of this was a published review article by Cross and Franks (2005) 
on clinical outcomes associated with pharmacist involvement in patients with 
dyslipidemia. The review included a pilot study conducted by Madejski and Madejski 
(1996) to determine the effect of cholesterol screening in a community pharmacy in 
western New York, USA. The results of the study (T ablel.l) showed that 83% of the 
359 patients who were interviewed reported lifestyle modifications such as smoking 
cessation and dietary changes. According to Cross and Franks (2005), the study 
supported the positive impact of community pharmacists’ involvement in disease 
management (Smith et al., 1999; Cranor et al., 2003) and its potential impact in 
reducing overall healthcare expenditure (Munroe et al., 1997; Menzin et al., 2004).
Cardiovascular disease patients are often on multiple drug therapy for their disease 
management. They are in most cases prone to medication-related problems such as 
adverse drug reactions, inappropriate medication use, non-compliance due to side- 
effects of certain prescribed drugs and problems with over/under dosage (Morrow et 
al., 2004). According to Munroe et al (1997), “a major goal of disease management 
programmes is to combat drug-related morbidity and mortality to improve outcomes 
and decrease health care costs”. The economic burden of medication-related problems
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in the society has been well documented in the literature (Johnson and Bootman, 
1997; Ernst and Grizzle, 2001; Mullins et al., 2004). However a gap remains in the 
literature regarding the impact of medication-related problems on the health-related 
quality of life of cardiovascular patients, especially in a community setting.
Role of community pharmacists in medication management
Pharmacists have been involved in the development and implementation o f validated 
methods and services aimed at preventing, detecting, and solving actual or potential 
drug-related problems in patients and overall to assist patient needs in community 
settings (Patel and Zed, 2002; Machado et al., 2007). As part of the pharmaceutical 
care process, community pharmacists dispense the vast majority of prescriptions on a 
daily basis. Based on their depth o f drug knowledge and their accessibility to patients 
on a regular basis, pharmacists are in a unique position, in collaboration with other 
healthcare professionals (general practitioners, nurses etc) to improve therapeutic 
outcomes from medication by reducing adverse events, increasing medication 
appropriateness and improving medication adherence (Hugtenburg et al., 2004; Viktil 
et al., 2004; Zehnder et al., 2004).
Previous studies have also shown that involvement of hospital-based ambulatory 
clinic pharmacists has led to improvement of all-cause mortality and reduced non- 
fatal heart failure events in heart failure and improved signs and symptoms and 
reduced hospitalizations for individuals with asthma (Gourley et al., 1998; Solomon et 
al., 1998; Gattis et al., 1999; Vik et al., 2006). In addition, studies in the US have 
shown that pharmacists working in general practitioners’ offices contributed to a 
reduction in adverse drug events and improvements in medication adherence (Hanlon 
et al., 1996; Jameson and VanNoord, 2001; Petrilla et al., 2005). In the United States 
of America for example, observational studies have shown that community 
pharmacists identify problems in two percent of new prescriptions, avoiding adverse 
consequences in 21% of cases (Rupp 1992; Rupp et al., 1992). These studies also 
estimated that savings attributable to resolved medication problems ranged from
5
Table 1.1 Studies evaluating pharmacists role in disease management
Reference
Madejski and 
Madejski, 1996
Munroe et 
al,1997
Malone and
Alger-Mayer,
2003
Setting Target population Evaluable sample size Interventions Effect
One community 
pharmacy, USA
Patients with 
hypercholesterolaemia
539 patients Phone interviews o f patients; 
recommendation /reference to 
physicians; advice on diet education
Enhanced patient awareness o f hypercholesterolaemia 
and other associated cardiovascular risk; Positive lifestyle 
changes achieved in some patients.
Multicentre
community
pharmacies,
USA
Patients with asthma, 
hypertension, diabetes, 
and / or
hypercholesterolaemia
188 patients at three 
intervention 
pharmacies; 401 
patients for control 
study at five non­
participating 
pharmacies
Assessment o f patients’ adherence to 
medication & non-drug therapies; 
education o f patients about their 
medical conditions; medication 
administration, self-monitoring & 
adverse effects. Assessment o f drug 
therapy efficacy by subjective & 
objective monitoring of blood pressure, 
blood cholesterol, blood glucose, & 
peak flow rate, weight, pulse & 
respiratory rate. Regular 
communication with physicians o f any 
information obtained to serve as early 
warning system to negative clinical 
trends.
Total monthly costs for healthcare use were lower for the 
intervention than for the control.
One community Obese patients Pilot study; 15
pharmacy, USA attending an outpatient intervention and 15
nutritional programme control patients.
Patients were prescribed orlistat; Patients receiving pharmaceutical care had improved 
outcome with orlistat therapy. The intervention patient 
group had significantly greater persistence with orlistat 
therapy; no significant difference in the percentage of 
weight loss between groups.
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$3.50 per prescription to $122 per intervention (Loh et al., 1996; Christensen and 
Hansen, 1999; Westerlund et al., 2003).
In the United Kingdom, a new initiative was introduced in 2005 to improve the 
quality and range of services that community pharmacies offer. It is expected that this 
New Community Pharmacy Contractual Framework will help to support people with 
long-term conditions such as cardiovascular disease and promote health improvement. 
As part o f this new initiative, Medicine Use Review (MUR) was introduced to help 
people, especially on multiple drug therapy, to improve their knowledge and 
understanding of what their prescribed medications are for and also how to use their 
medicines. MUR, according to the UK Department of Health, will also help to reduce 
the number of hospital admissions caused by inappropriate use of medicines.
MEDICATION-RELATED PROBLEMS (MRPs) - A REVIEW OF 
THE LITERATURE
Scientific literature can be described as a bibliography of events describing the truth 
(Gaudet, 1998). According to William James, the pioneering American psychologist 
and philosopher in the 19th/20th century, “Truth happens to an idea; it becomes true, 
and is made true by events”. A literature review enlightens researchers about the 
work of other colleagues and encourages researchers to develop new hypotheses to 
confirm what is already believed to be true.
This chapter will be divided into three sections. These sections will focus on a 
literature review in the area of medication-related problems of cardiovascular drug 
therapy, its economic and societal impacts and its impacts on cardiovascular patients’ 
quality of life. A literature search was performed in Medline, and Embase using 
keywords such as drug-related problems, antihypertensive and side effects, beta- 
blockers and depression, antihypertensive and anxiety. These terms were also 
combined with other keywords such as quality o f life, evaluation, economic 
outcomes, and socioeconomic status. Although a large percentage of studies have 
been published on the concept of medication-related problems and different
7
instruments of assessment of medication-related problems, fewer studies have 
focused on a specific area of drug therapy where there is a high rate of these 
problems, for example in cardiovascular drug therapy. Further, there were few studies 
in the published literature evaluating the economic impact and quality of life in people 
with medication-related problems of cardiovascular drug therapy. Section I of this 
literature review will focus on 1) the concept o f medication-related problems; 2) the 
impact o f cardiovascular drugs-related side effects on patients’ quality of life; and 3) 
different instruments for assessing medication-related problems. Section II will focus 
on a critical appraisal of the published literature on both the societal and economic 
burdens of medication-related problems. Section III will review some of the existing 
cardiovascular disease-specific quality of life instruments to detect whether they can 
be used in the present study.
SECTION I
Concept of Medication-Related Problems- Historical Review
Different terminologies have been used to describe the concept of a medication- 
related problem. The term “medication error” is widely used in clinical settings to 
describe cases involving administration errors and those errors that involve drug 
dispensing (Van Mil et al., 2003). In the United States of America, where most of the 
research studies in this area have been carried out, The National Co-ordinating 
Council for Medication Error Reporting and Prevention (NCC-MERP) in 1998 used 
the term “medication error” to describe any preventable event that may cause or lead 
to inappropriate medication use or patient harm while the medication is in the control 
of a health care professional, patient or consumer (Shaw -Phillips, 2002).
In the United Kingdom, Krska et al. (2001) used the term “pharmaceutical care issue 
(PCI)” to describe problems which are either preventable or can be solved with the 
application of the pharmaceutical care process. During a conference in 
pharmaceutical care in 1998 in the United States of America, the American Society of 
Hospital Pharmacists (ASHP) adopted the term “medication-related problem” to 
describe “any event or circumstances involving medication therapy that actually or 
potentially interferes with an optimum outcome for a specific patient” and Cipolle et 
al (1998) described “drug therapy problem” as “any undesirable event experienced by
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the patient that involves or is suspected to involve drug therapy and that actually or 
potentially interferes with a desired patient outcome”. Other notable definitions 
include: the 1998 Granada I (group of Spanish experts) drug-related problem concept 
as a “health problem of the patient which provokes the action of any health provider 
as a consequence of drug therapy”. This definition was in contrast to the 2002 
Granada II definition of the concept as “a negative clinical outcome of 
pharmacotherapy” (Alvarez-de-Toledo, 2004). All the above definitions are patient- 
focused with a common interest in the patient’s health outcome. Johnson and 
Bootman (1997) in their article on a model of drug-related morbidity and mortality 
considered drug-related problems as a negative therapeutic outcome upon which the 
Granada II concept of drug-related problems could have been based.
Classification of medication-related problems
Since the beginning o f the classification system of drug-related problems in 1975, its 
concept description and the first establishment of classification categories in 1990, 
various researchers in the pharmaceutical care process across the world have 
developed, used and validated various classification systems of drug-related issues 
based on the area of focus and their research purpose (Femandez-Llimos et al., 2004). 
These risk assessment tools were developed for reasons such as prescribing 
improvement, reduction in medication-related problems and improved outcomes 
(Buerger, 1999). Some of these risk assessment tools have been applied in clinical 
practices to identify and document medication errors, some have also been used in 
both community settings and care homes to identify and resolve medication-related 
problems. The overall goal and objective of documenting drug-related problems that a 
patient experiences is to improve the quality of pharmaceutical care offered to them in 
order to ensure continuity of positive outcomes of drug therapy.
Van Mill et al (2004) published a review article on drug-related problem 
documentation tools and based on various criteria of their evaluation such as usability 
in pharmaceutical care practice, validation method and its hierarchical structure, only 
one out of fourteen documentation tools was found to fulfil the pharmaceutical care 
practice objective (Table 1.2). This section of the thesis is therefore focused on the 
implementation of these existing tools in various healthcare settings. The terms
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“Medication-related problem” and “drug-related problem” will be used 
interchangeably, however they are actually explaining the same concept. Drug- 
related problems can generally be described as the negative impact of a drug therapy 
on a patient’s desired health outcomes.
Hepler and Strand classification
During the early stages of the pharmaceutical care concept and developments in the 
United States of America, Helper and Strand (1990) grouped drug-related problems 
into eight main categories, namely:
• Untreated indications;
• Improper drug selection;
• Sub therapeutic dosage;
•  Failure to receive drugs;
•  Over-dosage
• Adverse drug reactions;
• Drug interactions;
• And drug use without indication
However, according to some published studies (Van Mill et al., 2004), this first 
classification system had some limitations. Nevertheless, it did form the cornerstone 
of today’s pharmaceutical care research and a starting point for many of the existing 
classification systems (Strand et al, 1990). The system was widely used in the early 
1990s and reported in many institutional and community settings (Briceland et al., 
1993; Ho, 1994; Curie et al., 1997)
Minnesota Pharmaceutical Care Project Classification
Due to a lack of robustness associated with the Hepler and Strand DRP classification 
system at the 1995 Minnesota Pharmaceutical Care Project, an improvement was 
made upon this previous work. The eight original DRP categories were reassessed 
and grouped into five domains:
• Drug Indication;
• Effectiveness;
• Safety;
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• Compliance,
• And Untreated indication.
These five groups could be considered as the standardised guidelines for tackling 
most pharmaceutical care issues today. They are more distinct than the previous 
categories because the drug-related problems and their causes were separated. 
However, this new classification was considered to be limited in its usability as 
neither the process nor the outcomes o f any intervention attempted to resolve the 
problems were included in this new system (Van Mil, 1999). This was later 
challenged by Cipolle et al (1998) when they published a classification system of 
DRP called “Drug Therapy Problems Coding System".
Drug Therapy Problems Coding System
This system was a modification of the 1995 Minnesota system with the original five 
approaches to the drug-related needs reduced to four (Santos and Madeira, 2003). 
These are:
• Drug Indication;
• Effectiveness;
• Safety,
• And compliance.
Although the Drug Therapy Problems classification scheme has been widely tested 
and used in practice in several studies in community settings both in Europe and 
America, the system lacked robustness because its authors did not attempt to include 
either interventions or the outcomes of intervention in the system (Van Mill, 2004).
The Problem-Analysis-Solution Coding System (PAS-Coding System)
The Problem-Analysis-Solution system (PAS-coding system) was developed 
primarily to quantify oral communication processes during counselling in pharmacy 
practice (Van Mil et al., 1999). The system was community pharmacy practice- 
oriented and had been used to document DRPs in various studies involving 
therapeutic outcome monitoring (TOM). Although the PAS system is community 
pharmacy oriented, its limited usability in practice might have been due to the 
following factors:
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• Time required for its use in community practice;
• Too elaborate and more research based,
• No distinct clarity between the main headings, thereby making the coding of
some of the problems experienced by patients difficult (Van Mil et al., 2004).
Problem-Intervention Documentation (PI-Doc)
The development of the Problem-Intervention-Documentation (PI-Doc) system was 
based on the need for a broader implementation of pharmaceutical care in the 
pharmacy (Schaefer, 2002). Before its development, the following criteria, as 
described by the author, were taken into consideration:
• Suitability for both scientific studies and pharmacy practice;
• User friendliness in routine practice;
• Consist of three parts: problem code, intervention code and outcome of 
intervention code;
• Structured like a decision tree with main groups and sub-groups supporting 
computer aided use;
• Open structure enabling introduction of additional coding levels without 
changing the basic structure;
• Clear and defined problems leading to one choice of coding only;
•  Coding should focus on the problem itself and not on its cause or 
consequence,
• Suitability for documentation necessary for the remuneration of cognitive 
services.
The PI-Doc system by far is the most widely used risk assessment tool for 
comprehensive documentation of interventions occurring in community pharmacy, 
especially in Germany and Denmark (Schaefer, 2002). There was, however, no clear 
distinction between the various problems and the cause. Indeed, according to the 
author, the system was not developed to explore the origin of drug-related problems 
but to give insight into how the problems could be tackled, and intervention 
undertaken by pharmacists in practice (Ellison, 2003).
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Other existing systems that have been used in many studies include: National 
Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP) 
taxonomy of medication errors, Hanlon’s Medication Appropriateness Index (MAI), 
and the Pharmaceutical Care Network Europe system (PCNE).
National Coordinating Council for Medication Error Reporting and 
Prevention (NCC-MERP)
In respect of the guidance issued by the NCC-MERP council after its development, 
the taxonomy was designed not as a reporting form of medication errors but as a tool 
for medication error analysis and categorisation (NCC-MERP, 1998). The NCC- 
MERP taxonomy has been used widely in North America especially the USA where, 
apart from the existence of such a system for DRP analysis and documentation, there 
have been in place other established systems for medication error reporting, such as 
the Joint Commission on Accreditation of Healthcare Organisation (JCAHO), FDA’s 
Med Watch, and USP’s MedMARx. Although the taxonomy has many practical 
benefits such as its possibility to code reported medication errors with the aid of the 
other systems cited above, and the possibility o f classifying errors according to the 
level of severity (Shaw -Phillips, 2002), it has some limitations, such as inability to 
document interventions and outcomes using the system. However, it provides a 
system of documenting the type of medication errors involved and their causes.
Medication Appropriateness Index (MAI)
The Medication Appropriateness Index (MAI) was designed in 1992 with the aim of 
creating an instrument that could address multiple elements of drug therapy 
prescribing, applicable to a variety of medications, clinical conditions and settings 
(Hanlon et al., 1992). The authors of this risk assessment tool took into consideration 
three of the key pharmaceutical issues (drug indication, effectiveness and safety) in 
addition to the cost-effectiveness of a drug in order to decide its appropriateness 
(METRIC, 2005). The authors also used implicit criteria to judge the appropriateness 
of medication prescribing and also to measure the magnitude of inappropriate 
prescribing for most dimensions of drug use that are clinically relevant. The MAI 
implicit criteria include:
•  Medication Indication;
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• Effectiveness;
• Dosage;
• Correct directions;
• Drug-drug interactions;
• Drug-disease interactions;
• Expense;
•  Practical directions;
• Therapeutic duplication,
•  Duration
The Medication Appropriateness Index has been used in many studies by the same 
group of researchers (Hanlon et al., 1992; Samsa et al., 1994; Schmader et al., 1994; 
Hanlon et al., 1996; Murray, 1997; Schmader et al., 1997), and also in medication 
reviews in clinical settings (Sorensen et al., 2003). However, the question about its 
reliability remains unanswered. Studies examining the reliability of the MAI produced 
inconclusive results, due to involving a small sample size. The authors summarised 
the MAI as follows: “while broadly applicable and easy to use, the MAI does not 
address several important medication use issues, including the causality of adverse 
drug reactions and variable patient compliance ”. The MAI instrument provides a 
foundation for identifying areas that need appropriateness in prescribing and is also 
useful in drug treatment decision- making. However, more evidence will be needed to 
establish the stability and acceptability of the instrument in other settings and 
populations (Fitzgerald et al., 1997).
Modified Medication Appropriateness Index (MMAI)
The Modified Medication Appropriateness Index (MMAI) was designed to examine 
the practicality /applicability of the original version in the community setting. As 
implied from the name, the tool is a modification of some of the items in Hanlon’s 
MAI (1992) implicit criteria. These modifications included a revised definition for 
“ineffective” and refined directions for instructions, procedures to assess drug 
interactions, and methods to determine medication expense (Fitzgerald et al., 1997). 
However, few published studies have used this tool to document drug 
appropriateness/ inappropriateness in the community setting (Fitzgerald et al., 1997;
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Kassam et al., 2003) and similar limitations to the original version were detected such 
as small sample sizes used in reliability tests. The instrument therefore needs 
validation in order to increase its reliability and wider acceptability.
Pharmaceutical Care Network Europe Drug-Related Problems 
System (PCNE_DRP)
The Pharmaceutical Care Network Europe Drug-Related Problems System 
(PCNE DRP) was developed with its first version in 1999. The system was initially
developed for research purposes internationally (Ellison, 2003). However, after
various conferences, the authors arrived at a consensus to develop a system that would 
be used in community pharmacies to document drug-related problems identified 
during pharmaceutical care processes in routine practice and practice research 
(McElnay, 2004). The system, according to the authors, has both the problems and 
causes separated, has an intervention section and outcome of intervention section. 
Also it has been hierarchically structured and has undergone several validation tests 
since its development in 1999 (Van Mil, 2003). Nevertheless, its validity is still 
questionable (Femandez-Llimos et al., 2004; Farris et al., 2005). Some of the 
limitations o f this system identified elsewhere include:
• Low usability and acceptability;
• Poor internal consistency;
• Continued overlap between some problems and cause,
• Problems with its construct validity
According to some authors, if the PCNE-DRP system is to be considered as European 
consensus for a drug-related problem coding system, it needs to undergo a thorough 
validation process in order to increase its usability and wider acceptability, not only in 
Europe but across the world.
Personal Digital Assistant (PDA)
The Personal Digital Assistant (PDA) is a risk assessment documentation tool 
developed in Canada as a drug-related problem and pharmacist-intervention 
documentation system in hospital pharmacies (Raybardhan et al., 2005). The drug- 
related problems classification scheme used in this system was modification of the
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eight pharmaceutical care model described earlier by Hepler and Strand (1990). 
Although the system was described as a very useful documentation tool, especially in 
clinical settings, its applicability in community settings has not been tested. Its use is 
limited to hospital settings and there is no published evidence of its validation process 
and usability rates.
Quality Use of medicines (QUM) coding system
Another drug-related problem documentation tool identified in this review is the 
Quality Use of Medicines (QUM) Coding System. This tool was developed by a 
group of experts in Australia to assess the quality and impact of pharmacists’ 
medication review (Sorensen et al., 2003). Its usability has been tested mainly in 
hospital settings with satisfactory inter-rater reliability. However, the system suffers 
from a number of limitations. For example, lack of intra-rater reliability test as 
pointed out by the authors themselves, and no published studies to examine its 
usefulness in other settings such as nursing homes, community settings etc.
For consistency in a suitable DRP coding system to be achievable, it is important that 
there should be guidelines and agreements to be followed during its development. 
Schaefer (2002) has proposed some criteria for consideration during such processes. 
In addition to these, Van Mil et al (2003) have defined five requirements for a drug- 
related problems classification system. Taking into consideration the eight criteria and 
these five requirements, a universally acceptable, comprehensive drug-related 
problem classification scheme can be developed. Adoption of the criteria proposed by 
Schaefer (2002) will ensure a well-defined system without overlap in problem codes 
and usable both in pharmaceutical care practice and practice research scenarios.
According to Buerger (1999), developing, refining and validating medication-related 
problem risk assessment tools is one thing; their implementation in real-world clinical 
situations to drive better prescribing and improved outcomes is another thing. There is 
also a need for more incorporation of some of the community-oriented risk 
assessment tools in community pharmacy practice. Most community pharmacists are 
not aware of such risk assessment tools. With the introduction of medication review 
as part of advanced services in the new pharmacy contracts in the United Kingdom,
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community pharmacists are now in a better position to access these tools to document 
medication-related side effects they come across while performing medicine use 
reviews for their patients. However, in order for pharmacists to familiarise themselves 
with these risk assessment tools, there is a need to develop pharmacists’ version of 
some o f the existing DRP classification schemes in order to increase their 
accessibility, comprehensiveness and acceptability.
Medication-related problems and HRQoL
While efficacy and safety o f drug therapy have been documented extensively, much 
less emphasis has been placed on assessment o f the patient’s own perception of 
treatment and its impact on his/her quality o f life. Studies have shown that 
cardiovascular drug treatment may have a negative impact on patient’s HRQoL 
(Bardage, 2000). Studies have also shown that there is low concordance between 
patient and physician regarding drug treatment and health evaluations due to 
distressing medication side-effects (Testa et al., 1993). In many cases, these side- 
effects have resulted in drug treatment withdrawal or low compliance (Buurma et al., 
2007). Burke, et al. (1997) estimated that 20-80% o f patients prescribed 
cardiovascular drugs fail to adhere to a drug treatment regimen sufficiently to realise 
full therapeutic benefits. Antihypertensive drug therapy, for example, is often 
associated with side-effects such as tiredness, mood change, sleep disturbances, 
impotence, dry mouth, and blurred vision, to mention a few (Table 1.3).
A patient’s perception o f these side effects therefore plays an important role in the 
success o f the therapeutic regimen (Bardage, 2000). Some patients perceive the use of 
their medications to be more troublesome than their seemingly asymptomatic disease 
(Battersby et al., 1995). It is universally accepted that “No drug is absolutely free 
from side effects”. An essential element of pharmaceutical care is that pharmacists 
should accept responsibility for the patient’s pharmacotherapeutic outcomes (ASHP, 
1993). ASHP (1993) suggested that part of pharmacists’ responsibility is to provide 
mechanisms for monitoring, detecting, evaluating, documenting and reporting adverse 
drug reactions and other medication-related problems. These also include intervention 
and provision of educational feedback to prescribers and other healthcare 
professionals and patients (ASHP, 1993).
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Table 1.2 Drug-Related Problem Classification Systems
DRP
System
Main
Categories
Based on Clear 
Definition
Hierarchical 
Problem Classification
Causes
Classification
Intervention
Classifications
Validation
published
Used in Published 
Study
Meyboom ABC of DRP (2000) 3 No No Integrated No No No
ASHP (1996) 13 Yes No Integrated No No Yes
Cipolle et al (1998) 7 Yes No No Yes No Yes
Granada Consensus (2002) 6 Yes No Integrated No No Yes
Hanlon (MAI) (1992) 10 No No Integrated No No Yes
Helper and Strand (1990) 8 Yes No No No No Yes
Krska et al (2002) 13 Yes No No integrated No Yes
Mackie (2002) 13 Yes No No No No Yes
NCC-MERP (2003) 14 Yes No Integrated Yes No Yes
PAS (1997) 5 No Yes Yes Yes Yes No
PCNE (2003) 6 Yes Yes Yes Yes Yes Yes
PI-Doc (2002) 6 No Yes Integrated Yes No Yes
SHB-SEP (2003) 10 No Yes Yes Yes No No
Westerlund (2002) 13 Yes No Integrated Yes Yes Yes
ASHP = A m erican Society o f  H ealth-System  Pharm acists. PCNE = Pharm aceutical C are N etw ork Europe. 
“ Integrated” = cause integrated in the problem description. PI-Doc = Problem  Intervention Documentation. 
NCC-MERP = National C oordinating C ouncil for M edication Error R eporting and Prevention.
PAS = Problem s, Assessm ent, and Solutions. SHB-SEP = H ealth  Base Foundation Subjective Evaluation Plan
Source: JWF Van Mil et al., (2004). The Annals of Pharmacotherapy, 38, 8
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Table 1.3 A nti hypertensive drugs and frequency o f  ad verse drug reactions
Adverse drug reactions (ADRs) and frequency of ADR (%)
Class of drug < 1% 1 % - 10% > 10%
Beta -  blockers 
e.g. Atenolol,
Chest pain, hypotension 
nightm ares, vivid 
dream s, cold extrem ities
C onfusion, d izziness, 
insom nia, fatigue, rash, 
d iarrhoea, nausea, w heezing
M ental depression, 
decreased sexual ability, 
bradycardia
Bumetanide
(diuretic)
H ypotension, rash, 
cram ps, pruritus, nausea, 
vom iting
D izziness, headache, 
m uscle cram ps, w eakness etc.
Hyperuricem ia, 
hypokalem ia etc.
Captopril
Clonidine
H ypotension, 
angioedem a, etc.
Insom nia, vivid dream , 
fever, pruritus, blurred 
vision, w eight gain etc.
C hest pain, tachycardia, 
insom nia, headache, rash, 
d izziness, fatigue, cough
M ental depression, headache, 
fatigue, pain, rash, loss o f  
libido, decreased sexual 
activity, im potence, w eakness
None
Anxiety, confusion, 
orthostatic hypotension, 
drow siness, dizziness,
Enalapril Insom nia, drow siness, 
confusion, depression, 
nervousness, im potence, 
blurred vision etc.
C hest pain (2% ), hypotension 
(6.7% ), headache (2-5% ), rash, 
d izziness (4-8% ), cough
None
Furosemide Rash, nausea, gout, etc. H eadache, d iarrhoea, 
photosensitivity , loss o f  
appetite, blurred vision.
Dizziness, orthostatic 
hypotension etc.
Hydralazine Dizziness, fever, rash, 
w eakness, m alaise etc.
H ypotension, redness or 
flushing o f  face, nasal 
congestion  etc.
A ngina pectoris, 
Flushing, headache, 
nausea, vom iting.
Moexipril Angina, chest pain, sleep 
disturbances, mood 
changes, anxiety etc.
H eadache, d izziness, fatigue, 
rash, diarrhoea, non productive 
cough (6% )
none
Perindopril H ypotension, psoriasis, 
im potence, dry eyes, 
blurred vision, taste 
disturbances.
H eadache, d izziness, rash, 
m ood and sleep disorder, 
fatigue, cough (incidence 
greater in w om en, 3:1), nausea 
and vom iting etc.
None.
Ramipril Hypotension, headache, 
dizziness, fatigue, 
insom nia, drow siness, 
depression, nervousness, 
rash, w eight gain, 
im potence etc.
None. Cough (12% ).
Trandolapril Insomnia, rash, sleep 
disturbances, anxiety, 
decreased libido, 
diarrhoea, vom iting, 
constipation, im potence
C hest pain, fatigue, m yalgia, 
cough (1 .9-35% ) etc.
None.
Source: Excerpts from Drug-Induced Nutrient Depletion Handbook 1999-2000: Pelton. R et al.
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Antihypertensive drugs and patients9 HRQOL
The effects o f antihypertensive treatments on patients’ HRQOL have been described 
in published studies to be complex, with persistence in a negative perception of drug 
treatment due to their side-effects ( Mayou, 1990; Bremner, 2003; Aqil et al., 2006). 
For example, calcium channel blockers such as felodipine or isradipine can cause 
severe ankle swelling as a late-onset side effect (Douglas and McLay, 1996), 
resulting in poor HRQOL of patients (Testa et al., 1998). Dry, persistent cough 
commonly associated with ACE inhibitors such as enalapril, has been demonstrated to 
have a negative influence on sleep patterns and in many cases has lead to either low 
concordance among patients or discontinuation from ACE inhibitor therapy (Israili 
and Hall, 1992; Fletcher et al., 1994). Studies have also shown that beta-blockers have 
an immediate negative impact on patients’ well being and therefore need to be 
carefully titrated with low doses when initiating treatment (Tregaskis and McDevitt, 
1990; Thomsen et al., 2007).
In the United Kingdom in 2006, use of beta-blockers came under scrutiny following a 
publication on re-evaluation of the benefits o f beta-blockers (Carlberg et al., 2004). 
As a result o f this, the British National Formulary (BNF) 51 suggested reconsideration 
of use of this class of antihypertensive drugs as a first choice in routine initial therapy 
for hypertension. In addition, studies have associated beta blockers with side-effects 
such as impotence (Ostergren et al., 1996), depression and decreased life satisfaction 
(Breckenridge, 1991), and an assessment of the impact of these side effects on such 
areas as emotional well being, performance at work and overall perception of well 
being needs a constant focus and attention (Karimova and Martin, 2003).
Cardiovascular drugs and fatigue
Cardiovascular drugs such as beta blockers and ACE inhibitors have been proved to 
reduce the mortality rate by 20% (Ko et al., 2002) in patients after myocardial 
infarction, heart failure etc. However, studies have shown that physicians do feel 
reluctant to prescribe these agents partly due to concerns about patients developing 
side-effects such as fatigue, depression, sexual dysfunction and tiredness (Koch- 
Weser and Frishman, 1981; Brouwer et al., 2005).
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Fatigue has been frequently reported as a side effect in patients on beta-blockers. 
Fletcher et al (1992) published the results o f a major trial using QOL evaluation 
methods; this was a multicentre, double-blind study o f six months duration in 540 
patients with mild to moderate essential hypertension randomly assigned to cilazapril, 
atenolol and nifedipine retard. Spontaneous reports revealed occurrence of fatigue in 
10% of patients in the atenolol group compared with 4% in both the cilazapril and 
nifedipine retard group. In another published study o f 10 trials that included 17682 
patients with 33.4% on beta-blockers and 30.4 % on placebo, there was a substantial 
reported incidence of fatigue among the beta-blockers group with a significantly 
increased risk of withdrawal from the trials due to fatigue (Julian et al., 1982).
Cardiovascular drugs and depression
Case reports linking beta-blockers with incidence of depression have been published 
in the literature; however there are not enough published studies to clarify the 
association between beta-blockers and depression. Despite this, a study carried out by 
Gerstman et al (1996) demonstrated a low incidence o f depression among patients on 
beta-blockers. Not surprisingly, Wang et al (2002) in a cross-sectional study 
comparing utilisation of antihypertensive prescriptions with patients’ responses to a 
structured interview concluded that depressive symptoms may be an under recognised 
but modifiable risk factor for compliance with antihypertensive medications.
SECTION II 
Economic impact of medication-related problems
The costs of medication-related problems cannot be overestimated. In addition to the 
direct costs such as laboratory tests and hospital admissions, there are also indirect 
costs, such as loss of productivity and treatment of ADRs (Lassetter and Wamick,
2003). The most comprehensive analyses o f the economic burden of medication- 
related mortality and morbidity in the US were conducted by Johnson and Bootman 
(1997); and Ernst and Grizzle (2001). Johnson and Bootman (1997) in a study on the 
cost of drug-related morbidity and mortality in the USA estimated that the annual cost 
of drug-related morbidity and mortality as a result o f medication-related problems in
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the ambulatory setting in the United States was $76.6 billion. Five years later, a 
similar study carried out by Ernst and Grizzle (2001) to update the previous findings 
o f Johnson and Bootman (1997) found out that the cost of drug-related morbidity and 
mortality had more than doubled, exceeding $177.4 billion in 2000, with hospital 
admissions accounting for nearly 70% ($121.5 billion) of total costs, followed by 
long-term-care admissions, which accounted for 18% ($32.8 billion). Ernst and 
Grizzle (2001) also found that costs associated with medication-related problems 
exceeded the expenditure for initial drug therapy. According to the annual report of 
the American Society of Consultant Pharmacists (ASCP), the economic impact of 
medication-related problems in persons over the age of 65 in the USA now rivals that 
of Alzheimer’s disease, cancer, cardiovascular disease, and diabetes (ASCP, 2002).
The economic burden of medication-related problems is a global issue (Lassetter and 
Wamick, 2003; Stroupe et al., 2004). Studies have demonstrated the significance of 
medication-related problems on both direct and indirect healthcare costs in various 
countries of the world (Plumridge and Wojnar-Horton, 1998; Van den bemt et al., 
2000). In the Netherlands in 2002, the annual estimation was 186-430 million Euro 
(Beijer and Blaey, 2002) while some estimates put the annual cost of medication- 
related problems to the UK at more than £380 million a year (Wiffen, 2002).
Direct medical costs o f medication-related problems
Medication-related complications, as a major cause of hospitalisations, have lead to a 
huge economic burden and significant human suffering (Palaian et al., 2006; Becker 
et al., 2006). A large proportion of studies so far have estimated direct costs of ADRs, 
such as the impact on hospital admissions, emergency room visits and also outpatient 
general practitioner visits. When estimating the direct costs of medication-related 
problems, especially adverse drug reactions, researchers frequently take into 
consideration the following: length of stay in hospitals, medical costs related to the 
treatment of ADRs, and in some cases, the non-medical costs related to travel 
expenditure (Lacoste-Roussillon et al., 2001; Becker et al., 2006). In 2002, ASCP 
estimated the total annual direct medical cost of medication-related problems at 
around $104.2 billion (ASCP, 2002). ADRs for example, are one of the leading 
causes of morbidity and mortality (Lazarou et al., 1998) and in some studies, were
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shown to be responsible for a significant number of hospital admissions, with 
reported cases ranging from 0.3% to as high as 11% (Beard, 1992). In 1993, it was 
estimated that approximately 2.9% to 5.6% of all hospital admissions were caused by 
ADRs and as many as 35% of the hospitalized patients experienced an ADR during 
their hospital stay (Murphy and Frigo, 1993; Pirmohamed et al., 2004; Thomsen et al., 
2007).
Another study conducted at two prestigious teaching hospitals in the US found that 
almost two percent of admissions experienced a preventable adverse drug event, 
resulting in an average increased length o f stay o f 4.6 days and an average increased 
hospital cost of nearly $4,700 per admission (Ernst and Grizzle, 2001) amounting to 
about $2.8 million annually for a 700-bed teaching hospital (Femandez-Llimos et al.,
2004). Krska et al. (2001) reported that 12-14 percent of hospital admissions in 
Scotland were as a result o f medication-related problems such as adverse drug 
reactions, and poor compliance with therapy among others. Several other studies have 
also shown low concordance and compliance with treatments as a result of distressing 
medication-related side effects experienced by patients during drug therapy (Cline et 
al., 1999; Jackevicius et al., 2002).
In another study, Yee et al (1997) reported that inappropriate drug treatment, another 
aspect of medication-related problems could have cost a hospital setting extra health 
care expenses if it had not had the benefit of a pharmacist’s intervention and his 
participation in clinical rounds that saved that institution an estimated $523,907.
Higher costs have also been observed in medical errors. Medical errors cost the U.S. 
approximately $37.6 billion each year. $17 billion of those costs are associated with 
preventable errors. About 50% of the expenditures for preventable medical errors are 
for direct health care costs (approximately four percent and two percent, respectively, 
of national health expenditure in 1996 or slightly higher than the direct and indirect 
costs of caring for people with HIV and AIDS). It has been estimated that for every 
dollar spent on ambulatory medication, another dollar is spent to treat new health 
problems caused by the same medication.
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SECTION III
Review of Cardio-Specific Quality of Life Instruments
Medication-related problems are not a disease but the outcome of drug treatment of 
any disease. A question arises: are existing cardio-specific HRQOL instruments 
sufficient to measure the impact of medication-related problems on patients’ quality 
of life? To answer this question, there is a need to review these instruments in order to 
identify gaps in any already existing knowledge in this area. It is also important to 
bear in mind that MRPs are not comparable with disease as stated earlier but are the 
outcomes of drug therapy. The existing cardio-specific quality of life instruments 
focus on the quality of life of patients in a certain disease state of cardiovascular 
disorder (Table 1.5). An example of what could be considered a core coronary heart 
disease (CHD) specific HRQOL instrument has been published, however, its 
psychometric properties such as validity and reliability have not been fully established 
(Avis et al., 1996).
The following disease specific and generic instruments have been used in various 
studies to measure HRQOL in cardiovascular disease. Table 1.5 describes their origin, 
weaknesses and strengths as well as their psychometric properties.
• Quality of Life after Myocardial Infarction (QLMI-2)
• The Seattle Angina Questionnaire (SAQ)
• The Quality of Life Index-Cardiac Version (QLI-CV)
• The Angina Pectoris Quality o f Life Questionnaire (APQLQ)
• The Summary Index (SI)
• The Myocardial Infarction Dimensional Assessment scale (MIDAS)
• Minnesota Living with Heart Failure Questionnaire (MLHF)
• Multidimensional Index of Life Quality (MILQ)
• The Short Form-12 Health Survey Questionnaire (SF-12)
Quality of life after Myocardial Infarction (QLMI-2)
The QLMI-2 has been considered to be the best known and most widely used disease- 
specific measure for the myocardial infarction patient group (Thompson et al., 2002;
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Asadi-Lari et al., 2003). This is a refined 27-item version of the original 26-item 
QLMI instrument otherwise known as MacNew Heart Disease Questionnaire. The 27- 
item instrument is grouped into three non-exclusive domains: emotional, physical and 
social (Lim et al., 1993; Valenti, et al., 1996). Each item has a 7-point Likert response 
scale scored from one to seven, where a higher score represents a better QOL; domain 
scores are taken as the average score of responded items in the domain.
The QLMI-2 has been validated and found to have better psychometric properties 
than the original QLMI with higher internal consistency (Hillers et al., 1994; 
Dempster and Donnelly, 2000). The instrument has been widely used in Australia and 
Canada, however, it is not in widespread use in the UK or the rest of Europe 
(Thompson and Jenkinson, 2002). According to these authors, although QLMI-2 has 
established psychometric property, its evaluative properties have yet to be 
investigated despite the fact that most of the domains of the original QLMI displayed 
a moderate to strong evaluative dimension (Ribera et al., 2006), high estimates of test- 
retest reliability and a moderate to high responsiveness (Dempster and Donnelly 
2000; De Gucht et al., 2004).
The Seattle Angina Questionnaire (SAQ)
This is a psychometrically solid and one o f the most widely used patient-assessed 
disease-specific health outcome measures developed to assess the functional status of 
patients with angina (Garratt et al., 2001; Thompson and Jenkinson, 2002). The SAQ 
has been tested for the measurement properties of reliability, validity and 
responsiveness in a US population (Spertus et al., 1994; Spertus et al., 1995; Pettersen 
et al., 2005). The SAQ is a 19-item questionnaire grouped into five domains: physical 
limitation, anginal stability, anginal frequency, treatment satisfaction, and disease 
perception. All five domains displayed sound psychometric properties (Dempster and 
Donnelly, 2000).
The physical limitation scale measures how daily activities are limited by symptoms 
of coronary artery disease; the anginal stability scale assesses change over the prior 
month in the frequency of angina at the patient’s most strenuous level of activity, 
while the anginal frequency scale quantifies the number of anginal episodes. The
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treatment satisfaction scale quantifies satisfaction with current treatment of angina 
(Dougherty et al., 1998).
There is a varying level of agreement on some of its psychometric properties by 
different authors. While Stewart (1992) stated that each domain of the SAQ has been 
independently validated and shown to be reliable and responsive to clinical change 
(Dougherty et al., 1998), Thompson and Jenkinson (2002) on the other hand, reported 
that two o f the domains (treatment satisfaction and anginal stability) are unsuitable for 
evaluative purposes for the following reasons:
• Low responsiveness estimate of the treatment satisfaction.
• Low test-retest reliability estimate of the anginal stability domain.
In addition, Thompson and Jenkinson (2002) revealed that the SAQ was neither 
developed for use in MI patients nor as a health-related quality of life measure, 
although it has been used in MI patients (Garratt et al., 2001) because seven of its 19 
items were found to relate to emotional health (Thompson and Jenkinson, 2002). 
Some advantages of using SAQ are that it takes less than 5 minutes to complete, it is 
brief and easily self-administered.
The Quality of Life Index-Cardiac Version (QoLI-CV)
This is a self administered, modified version of a renal-specific quality of life 
instrument. It was first designed for use with dialysis patients (Ferrans and Powers 
1985; Dougherty et al., 1998; Thompson and Jenkinson, 2002; Lee et al., 2004). The 
QLI-CV III contains 72 items equally divided into two parts. Part 1 measures the 
satisfaction of patients with various domains of life and part 2 measures the 
importance of those domains to the individual (Dougherty et al., 1998; Dempster and 
Donnelly, 2000). The content validity of the QLI-CV was established by an extensive 
review of published reports on issues related to quality o f life and on reports from 
cardiac patients concerning their quality of life (Ferrans and Powers, 1985).
Both the satisfaction and the importance part contain 36 items covering five domains: 
overall life satisfaction; health and functioning socioeconomic; psychosocial and 
spiritual; and family and relationships (Dempster and Donnelly, 2000). Its limitation
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includes low usability in cardiac patients and its limited discriminative and evaluative 
value (Dempster and Donnelly, 2000; Smith et al., 2000).
Angina Pectoris Quality of Life Questionnaire (APQLQ)
This is a 22-item instrument divided into four domains: physical activities, somatic 
symptoms; emotional distress; and life satisfaction (Smith et al., 2000). The 
instrument has established good psychometric properties for discriminative purposes. 
However, its limitation includes low test-retest reliability estimates and low 
responsiveness estimates.
The Summary Index (SI)
The Summary Index is a product of a combination of three health-related quality of 
life instruments (Dempster and Donnelly, 2000). The three combined instruments are: 
the Angina pectoris Quality of Life Questionnaire (APQLQ); the anginal impact 
questionnaire (Wilson et al., 1991); and the psychological general well being scale 
(Dupuy, 1984). The SI is a 51-item questionnaire, divided into six sections: impact of 
angina on daily life; physical exertion; vitality; alertness; self-control; and emotional 
function (Dempster and Donnelly, 2000). Although the instrument displayed good 
reliability and responsiveness properties, its use in clinical practice is limited because 
it is lengthy and not user friendly.
The Myocardial Infarction Dimensional Assessment Scale (MIDAS)
This is a 35-item myocardial infarction specific instrument measuring seven areas of 
health status: physical activity, insecurity, emotional reaction, dependency, diet, 
concerns over medication, and side effects (Thompson and Jenkinson, 2002). 
Although, according to the authors, MIDAS has high face, internal and constructs 
validity, the instrument still needs to undergo further psychometric evaluation in order 
to establish its wider usability in clinical practice.
Minnesota Living with Heart Failure Questionnaire (MLHF)
The MLHF is a 21-item widely used valid and reliable self-administered instrument. 
It has been recognised as one of the preferred health related quality of life instrument 
for patients with heart failure (Rector and Cohn, 1992; Berry and McMurray, 1999). It
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is used to assess the physical, socioeconomic and psychological impairments of 
patients with heart failure. MLHF was originally adapted from the following three 
instruments: Duke Health profile (Guillemin et al., 1993); the Minnesota Quality of 
life Questionnaire in Cardiac failure (Leal et al., 2005); and the Goldman Specific 
Activity Questionnaire (Salek, 2004).
Multidimensional Index of Life Quality (MILQ)
This is the only existing single HRQoL measure for cardiovascular patients. It 
contains 35 items covering nine different domains: mental health; physical 
functioning; physical health; cognitive functioning; intimacy; social functioning; 
productivity; relationship with health professionals; and financial status (Avis et al., 
1996). Although an article on its usability has been published, there is no empirical 
evidence o f its use in patients with CHD other than the original manuscript describing 
its development and psychometric properties (Oldridge et al., 2002).
The Short Form -12 health survey (SF-12)
The Short Form-12 Health Survey measures generic health concepts relevant across 
age, disease, and treatment groups (Lim and Fisher, 1999). It was designed in 
responding to the need for development o f a shorter instrument to the original SF-36 
(Garratt et al., 2001). The SF-12 includes eight concepts commonly represented in 
health surveys: Physical Functioning (PF); Role Functioning Physical (RFP); Bodily 
Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role 
Functioning Emotional (RFE); and Mental Health. Results are expressed in terms of 
two meta-scores: the Physical Component Summary (PCS); and the Mental 
Component Summary (MCS). SF-12 was designed for self-administration and has 
been used with a high degree of acceptability and data quality (Ware et al., 1995). The 
SF-12 uses two items each to estimate scores for four of the eight health concepts 
(physical functioning, role functioning physical, role functioning emotional, and 
mental health). Scores for the remaining four health concepts (bodily pain, general 
health, vitality, and social functioning) are estimated using one item each (Ware et al., 
1995).
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Table 1.4 Attributes o f  ex istin g  card io-sp ecific  quality  o f  life  instrum ents
CARDIO- COVERAGE ITEMS RATER RESPONSE Language PSYCHOMETRIC PROPERTIES
SPECIFIC (Time) OPTIONS Validation studies . . . . . . .
HRQOL Reliability Validity Responsiveness
INSTRUMENT 
& SOURCE
Quality o f life 
after myocardial 
Infarction (QLM1- 
2)(revised version 
of MacNew 
quality o f life 
(Hillers et al., 
1994)
Emotional, physical 
&
Social status
27 S e lf-
administered 
5-10 minutes 
Valenti et al, 
1996; Interview- 
administered 
(Farsi version)
Score : 1-7 Iranian (Farsi) version
(Asadi-Lari et al., 2003); 
Chinese version (Yu et 
al.,2007); Dutch version 
(De Gucht et al., 2004); 
German version (Hofer et 
al.,2003); English (US, 
Australian) version 
(Valenti et al., 1996; 
Hillers et al., 1994; Lim 
et al., 1993); Portuguese 
version (Leal et 
al.,2005); Spanish 
version (Brotons et 
al.,2000); Turkish 
version (Daskapan et al., 
2007)
Pearson’s 
correlation 
coefficient (0.75- 
0.87)
Internal
consistency
(0.50-0.83),
Intra class 
correlation (Farsi 
version) 0.92-0.95
Evaluative
Validity;
Discriminative
validity
Not reported
MacNew quality 
of life (MacNew 
QLMI)
(Dempster et al., 
2004; Taylor et 
al., 2000)
Self-esteem, 
restriction, fatigue, 
emotional function & 
confidence
26 Self­
administered
Score: 1-7 Not reported Not reported High inter- 
and intra 
reliability 
coefficient 
(Taylor et al., 
2000)
Not reported
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The Seattle angina Coronary artery 19
questionnaire 
(SAQ) 
(Spertus et 
al.,1994)
disease (CAD); 
Physical limitation, 
anginal stability, 
anginal frequency, 
treatment satisfaction, 
and disease 
perception.
Self­
administered 
< 5 minutes
Scales: 0 -100 UK version (Garratt et
Higher 
scores 
indicate 
Higher levels 
o f
Functioning.
al., 2001); Norwegian 
version (Pettersen et 
al.,2005)
Internal 
consistency- 
Norwegian version 
(0.75-0.92); intra -  
class correlation- 
Norwegian version 
(0.29-0.84)
Construct 
validity 
between SAQ 
and SF-36; 
factor analysis 
(UK version)
Tested in 60 
CAD patients, 
four o f the five 
SAQ scales 
showed 
significant 
improvement in 
functional 
status (Spertus 
et al.,1994)
Quality o f life 
index-cardiac 
version (QOLI- 
CV)
(Dougherty et al., 
1998; Taylor et al, 
2000)
Originally designed 
for dialysis patients. 
Five domains: overall 
life satisfaction, 
health & functioning, 
Socioeconomic, 
psychosocial & 
spiritual, family & 
relationships.
72 Self­
administered
Likert scales: 
0-30
Not reported High reliability; 
internal 
consistency 
(0.86-0.96) in 
angioplasty 
patients & 0.70- 
0.93 in anginal 
patients (Dempster 
et al., 2007)
Construct
validity
(factor
analysis)
Significant 
change in the 
health and 
functioning 
scale
(Dougherty et 
al., 1998)
Angina pectoris 
quality o f life 
(APQLO) 
(Dempster et al., 
2007)
Physical activities, 
somatic symptoms, 
emotional distress, & 
life satisfaction.
22 S elf­
administered
Not reported Original language= 
Swedish.
Danish version, Dutch 
version, Finnish version, 
French version, German 
version etc.
Internal
consistency
(0.82-0.90)
Concurrent 
validity with 
SF-36; 
discriminant 
validity 
between 
APLQ scales 
& total APLQ 
scores in CAD 
patients
Not reported
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Summary index 
(SI)
(Dempster et al., 
2007
Impact of anginal on 
daily life, physical 
exertion, vitality, 
alertness, self control, 
& emotional 
function.
51 Self­
administered
Not reported Not reported Test-retest
reliability
(0.69-0.84)
Internal
consistency
(0.91-0.98)
Discriminant
validity
Responsiveness
(0.25-0.44)
Myocardial 
infarction 
dimensional 
assessment scale 
(MIDAS) 
(Thompson and 
Jenkinson, 2002)
Physical activity, 
Insecurity, emotional 
reaction, dependency, 
diet, concerns over 
medication, side 
effects of medication.
35 Self­
administered
Score: 1-5 Mandarin for China Internal
consistency
(0.74-0.95)
Construct 
validity with 
SF-36
Not reported
Multidimensional 
index o f life 
quality (MILQ) 
A visetal., 1996
Mental health, 
physical health, 
physical functioning, 
cognitive functioning, 
social functioning, 
intimacy, 
productivity, 
financial status & 
health professional
35 Interview-
administered
Score: 1-7 
1= very 
dissatisfied 
7= very 
satisfied
Spanish version Internal 
consistency > 
0.76; test-retest 
reliability > 0.73 
(A visetal., 1996)
Construct
validity
Not reported
Minnesota living 
with heart failure 
questionnaire 
(MLHF) 
(Briancon et al., 
1997)
Physical, mental,
Socioeconomic,
disability.
21 Interviewer- 
administered, 
self­
administered, 
telephone- 
administered. 
5-10 minutes for 
self­
administered.
Scale: 0-5 French version, 
Czech version, 
Danish version, 
Croatian version, 
German version etc.
Test-retest 
correlation to 26 
patients on a 
transplantation 
waiting list 
(Briancon et al., 
1997)
Factor
analysis.
Not reported
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Aims of the present study
No published studies have investigated the social and economic implications of 
medication-related problems in people with chronic illness, such as cardiovascular, 
diabetes, asthma etc receiving long term multiple drug therapy. This study therefore 
aims to examine the impact of medication-related problems and medication side 
effects on socio-economic and quality of life of cardiovascular patients.
The majority of patients with chronic conditions are on repeat prescriptions of their 
medication provided their conditions are stable. Many of these patients do not see 
their general practitioners regularly. Community pharmacists are therefore in a unique 
position to identify medication-related problems in these patients through their pro­
active involvement in pharmaceutical care services such as medicine use review 
(MUR) and prescription intervention procedure. Provision o f pharmaceutical care 
services by community pharmacists have so far shown positive results in all the three 
components of health outcomes (economic, clinical and humanistic) with early 
prevention of potential harm to the patient. With the availability of a new instrument 
aimed at cardiovascular patients in the community setting, they will be able to 
ascertain whether side-effects patients experience are due to drug treatment. This 
instrument will also help community pharmacists to evaluate the impact of any 
reported cases of medication-related side effects on the quality of life of their patient.
Objectives:
• To determine frequency of medication-related problems of cardiovascular 
drugs in the community setting.
• To investigate the impact of medication-related problems on cardiovascular 
patients’ quality of life.
• To develop an instrument to measure the socio-economic impact of 
medication-related problems of cardiovascular drugs.
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• To evaluate the psychometric properties of this newly developed instrument 
such as content validity, factor analysis, practicality and applicability and test- 
retest reliability.
• And finally, to compare its validity with some of the existing cardio-specific 
and generic quality of life instruments.
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CHAPTER 2
Study Rationale and Methodological
Framework
34
INTRODUCTION
The general introduction to this thesis in chapter one outlined the lack of a 
socioeconomic measure that is tailor-made for use in assessing the socioeconomic 
impact of medication-related problems especially of cardiovascular drugs. Although 
some existing HRQOL instruments provide a comprehensive evaluation of the disease 
impact, they do not consider the influence of medication side-effect on a patient’s 
physical and psychosocial functional behaviour. Therefore, there are still gaps in the 
knowledge of measures that provide treatment outcomes especially those of 
medication-related side-effects. Considering the socioeconomic concept as part of a 
wider component of HRQOL measures, the impact of medication side-effects often 
affect more than three of these HRQOL measure components such as emotional 
status, social activities and work. Medication-related problems can impact other 
important areas o f a patient’s life such as healthcare services utilisation (Figure 2.1).
In the absence of a validated instrument with which to measure the socioeconomic 
impact of the side-effects of cardiovascular drugs, this chapter will present the 
rationale for the development of such a measure and review the appropriate 
methodological framework.
Figure 2.1 Socioeconomic concepts and medication-related problems
H ealthcare service utilisation
W ork
Social and 
em otional behaviour
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STUDY RATIONALE
As shown in the introductory part of this chapter, the rationale behind undertaking this 
present study is multifarious. The main reasons can be summarised as: 1) 
unavailability of a validated socioeconomic instrument; 2) insufficient data to actually 
carry out research in this area; and 3) different opinions on what constitutes the 
socioeconomic impact of medication-related issues. The socioeconomic impact of 
medication-related problems (SEIP-MRP) encompasses a number of different 
domains such as the socio-emotional distress o f MRP, impact on productivity, and use 
of healthcare services. The phrase “socioeconomic impact of medication-related 
problems” is a component of the health-related quality of life (HRQOL) concept. In 
this present study, it will be used interchangeably with “impact on patients’ quality of 
life” as they are expressing the same meaning.
At present, there are no instruments that assessed the socioeconomic impact of 
medication-related problems in cardiovascular disease. The commonly used available 
scales for cardio-specific HRQOL measurement as detailed in chapter one which may 
be applicable to the socio-economic concept have little relevance. They are actually 
measuring a related outcome but different to the socioeconomic impact concept. 
There is therefore a need for the development o f a valid and reliable instrument for 
measurement of socioeconomic impact of medication-related problems. Due to these 
shortcomings, the present study was undertaken to develop a socioeconomic measure 
that redressed some of these problems. The following suggestions were taken into 
consideration:
• To conceptualise a measure that will be universally accepted as a cardio- 
specific socioeconomic health status measure;
• To develop an instrument with a sound methodology and which will be based 
on constructs which the observed population consider to be important 
determinants of the socioeconomic effects of medication-related problems;
• To develop an instrument that will measure the socioeconomic impact of 
medication-related problems rather than a medical condition;
• The instrument developed will possess sound psychometric properties so that 
it will be widely acceptable in clinical research and health policy decision­
making in the area of drug therapy.
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This new instrument, in line with already established guidelines will undergo 
reliability and validity tests before it can be administered to patients with 
cardiovascular disease.
METHODOLOGICAL FRAMEWORK
Methodology is the navigator of research. It describes the process by which the 
researcher arrived at their results and conclusions. Methodology is important in 
determining whether the findings of a study can infer truth in the phenomena of 
interest (Gaudet, 1998).
Semantic issues
Semantic issues are those issues which arise when trying to implement new measure 
in a situation where there is non in existence to compare with. In this study, these 
issues relate to whose socioeconomic condition is affected, who provides the 
assessment and the type of instrument to be used.
Whose socioeconomic status is affected?
Despite the availability of effective drug therapy, many cardiovascular patients who 
are on long-term beta-blocker therapy may develop symptoms such as depression, 
fatigue, and sexual dysfunction. These conditions can be considered to be strong 
indicators o f the social and emotional well being of a human being. Developing a 
socioeconomic instrument will therefore help to capture these negative outcomes of 
drug therapy.
In HRQOL studies for example, assessment of an individual is ideally obtained by a 
self-report method (Adair et al., 2007). However, the main problem with this method 
in the context of measuring the impact of medication-related problems may be in 
obtaining a reliable and accurate assessment. Cardiovascular patients, for example 
may not know whether the side-effects are medication-related or due to their 
condition. For example, fatigue- a common symptom of heart failure may be 
misinterpreted as a side-effect of a beta-blocker in a patient initiated with this drug. 
The items that form the basis of a socioeconomic measure may therefore be taken 
from patients’ experiences of administration of a new drug to treat their condition.
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Technical issues
These relate to the administration of a questionnaire, scaling of responses and 
documentation of measurement properties.
Administration of Questionnaires
Use of questionnaires in carrying out research is an inexpensive way to gather data 
from a potentially large number of respondents. A well-designed questionnaire that is 
used effectively can gather information on the overall performance of the observed 
measure (Bowling, 2005a). There are several different methods of data collection 
using questionnaires including postal, telephone interview, or face-to-face 
administration. When a questionnaire is administered, the researchers’ control over 
the environment will be limited. This loss of control may have different effects on the 
quality of the data collected. Within different modes of questionnaire administration, 
there could be many biases influencing the accuracy of responses. Therefore 
knowledge o f such factors in advance of data collection should enable the researcher 
to minimise their impact on the quality of the data.
Interviewer-administered
Interviewer-administered questionnaires involve the use of a trained interviewer, who 
administers the questionnaire on a one-to-one basis to ensure compliance, higher 
response rate and minimise the occurrence o f missing items. According to Salek and 
Luscombe (1992), this method can be engaged in a situation where the respondent is 
illiterate, physically disabled or has visual problems. The interviewer must read aloud 
the questions and document responses without influencing the respondent’s views 
(Salek and Luscombe, 1992). This mode of administration also allows clarification of 
ambiguity. According to Bowling (2005a), “a friendly motivating interviewer can 
increase response and item response rates, maintain motivation with longer 
questionnaires, probe for responses, clarify ambiguous questions, help respondents 
with enlarged show cards of response choice options, use memory jogging techniques 
for aiding recall of events and behaviour, and control the order of the questions” .
However, this mode of administration has its limitations. The disadvantages include 
longer completion time, higher cost, and occurrence of bias. In addition to these, its
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use is limited when such issues such as privacy, quietness and confidentiality are 
taken into consideration in a situation where there is no consultation room to carry out 
this task.
Interviewer-delivered
This is a self-report mode o f questionnaire administration. Interviewer-delivered 
questionnaires require direct and full-time involvement from the interviewer to 
provide an initial instruction, hand over the questionnaire and respond to any 
questions from the respondents (Lua, 2002). Its advantages include: time and resource 
reduction and fewer burdens to professionals. However, the disadvantages of this 
method include low response rate and the occurrence of bias as a result of 
unwillingness o f respondents to acknowledge problems (Guyatt, 1993).
Mail-delivered
Mail-delivered mode of administration of questionnaires is less expensive and gives 
the respondents more privacy, confidentiality and time to complete the questionnaire 
(Lua, 2002). However, response rate with this mode of administration may be lower 
than expected with other modes of administration. This is the most burdensome mode 
as this demands that respondents are literate in reading the language o f the survey, 
that they do not have visual impairments and have the dexterity (e.g. of wrist, fingers) 
to self-complete the questions (Bowling, 2005a). In addition, bias can arise as a result 
of differences between respondents and non-respondents, no assurance of completion 
from the intended person and no opportunity to supplement the patient’s responses 
with observational data (Salek and Luscombe, 1992).
T elephone-administered
There is similarity between this mode o f administration and interviewer-administered 
questionnaires. The only difference is that the interviewer is not physically involved 
face-to-face with the respondent throughout the process. In addition, it is less resource 
intensive (Guyatt, 1993). This mode of administration requires basic verbal and 
language skills. Its disadvantages include staff training requirement, limited coverage 
for only respondents in possession o f a telephone facility. Also, telephone interviews 
make greater auditory demands and may be burdensome to some respondents 
(Bowling, 2005a).
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Electronic questionnaire administration
This mode o f administration requires access to a computer and /or Internet facilities 
(whether via an interviewer with a lap top personal computer (PC), or facilities in an 
office, clinic or home setting), basic computer literacy, and also familiarity with 
numbers and keyboards. They have literacy requirements in relation to reading the 
questions and replying, and can also have auditory requirements. However, electronic 
programmes can be designed to require a limited range of keys. They can also 
eliminate the problem o f missing data (Drummond et al., 1995). Studies have also 
been documented in individual experiments and in reviews that this mode of 
administration has more complete item response rates than paper and pencil methods 
(Johnson et al., 2001). However, its drawbacks included its high cost and short 
battery life on the computer. In addition, populations in some cultures may be 
apprehensive to use such a method and be intimidated by technology (Lua, 2002). It is 
therefore clear that modes o f questionnaire administration differ in many ways with 
regard to their strengths and weaknesses. In general, low education level, poor 
physical status and progressive disease can result in a low rate o f completion (Kaasa 
etal., 1998).
Scaling o f Responses
Scaling involves the construction o f instruments for the purpose of measuring abstract 
concepts. A wide variety of response options are available and different options are 
suitable for different types of question and for different types of measure. Simple 
scales might consist of an affirmative response or the choice o f dichotomous yes/no 
options. Evaluative instruments must be responsive to any important change, even if 
small. Scales are often chosen with multiple response options such as a 4 or 5-point 
Likert scale because of their easy administration and interpretation.
Frame of Reference
This is defined as a structure o f concepts, values, customs, views, etc., by means of 
which an individual or group perceives or evaluates data, communicates ideas, and 
regulates behaviour. In questionnaire development, the items in a questionnaire 
should be asked in the context of a specific and well-defined period of time. The
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frame of reference chosen must take into account the respondent’s ability to recall 
information.
Measurement Properties
Various measurement properties need to be assessed when evaluating a new 
instrument/measure (Figure 2.2). According to Bungay et al (2005), there are two 
psychometric properties that any measurement scale must possess: reliability and 
validity (Bootman et al., 2005) and in addition to these, useful measuring scales must 
be sensitive to change and accepted by the investigators and respondents. Examples of 
such psychometric properties that will be assessed in this present study include 
applicability and acceptability, comprehensiveness, practicality, reliability, and 
validity.
Figure 2.2 Types o f psychometric tests carried out in the evaluation of a new 
instrument
Applicability
Acceptability
Practicality
Responsiveness
Measurement
Properties
Comprehensiveness
Reliability
Validity
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In addition to what Bootman et al. (2005) suggested above when deciding which 
measure to use, Bowling (2005b) also added that the investigator should establish: 
whether a disease-specific or broad-ranging (generic) instrument is required; the 
appropriateness o f the instrument for the study population; and the acceptability of the 
instrument to the group under study (Hunt et al., 1980)
Applicability and acceptability for use
Applicability describes the content and emphasis of an instrument in terms of 
appropriateness of wording, clarity and simplicity o f language (Lua, 2002). It must 
also be acceptable to the intended respondents (Salek and Luscombe, 1992). Both 
investigators and respondents will have valuable opinions about the acceptability of 
the instrument. How easy the measure is to use, score, and interpret are valid 
concerns. In addition, the completion rate, the extent o f missing data, and the number 
and nature o f complaints about the tool are clues about the acceptability of the 
measure for use in a research or clinical setting (Bootman et al., 2005). According to 
these authors, acceptability is also expressed as respondent burden. Regardless of the 
administration format (self-administered, telephone interview, personal interview, 
observation, or postal survey), Bootman et al. (2005) stated further that failure to 
consider respondent burden can doom any survey project.
Practicality
An instrument should be feasible in its intended population and clinical setting. The 
length of the questionnaire must be appropriate for the population and there should be 
minimal burden imposed on both the respondents and professionals during data 
collection and analysis (Salek and Luscombe, 1992). This is especially vital with 
regard to the cost and time consumed in the process (Deyo, 1984). Considerations 
must also be made in terms o f the questionnaire mode of administration and whether 
it can be easily scored and understood. Questionnaire length, frequency of 
administration as well as staff and institutional burden would have to be taken into 
account. Patients would not generally tolerate lengthy and repeated measurement 
(Lua, 2002)
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Comprehensiveness
Comprehensiveness describes how thoroughly the domains of interest in a measure 
are sampled by the items or questions included in that measure. The coverage of a tool 
needs to be comprehensive so that sufficient information can be gathered to justify the 
produced outcomes. According to Osoba (1994), in HRQOL for example, evidence 
has shown that one-dimensional instruments are not comprehensive enough to 
measure health-related quality of life and in essence, emphasises is placed on the need 
for a multidimensional, more comprehensive tool. Similar to this, a comprehensive 
socioeconomic measurement should include both objective and subjective issues in 
addition to other concerns such as spirituality and body image.
Validity
Validity is concerned with whether the indicator actually does measure the underlying 
attribute or not. As suggested by Bungay and Ware (1993), a number of key questions 
must be answered if  researchers are to have confidence in the data captured with a 
newly developed health measure. These include:
• Do the questions in the instrument really measure the concept under study?
• Do respondents understand the questions being asked?
• Are the response categories appropriate for the questions?
Validity refers to the extent to which differences in test scores reflect the true 
differences in individuals under study (Bungay and Ware, 1993). Although it is the 
goal to elicit observed differences that are indeed true differences among respondents, 
factors such as how the measure is administered, who administers it, where it is 
administered, and when it is administered can affect responses across study 
participants. There are no standard guidelines for validating health measures, 
however, varying terminology has been used to assess validity of a measure such as 
content validity, criterion validity and construct validity (Bowling, 2005b). However, 
all types of validity are addressing the same issue o f the degree of confidence that can 
be placed on the inferences drawn from scale scores.
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According to the American Psychological Association (1974), the assessment of 
validity involves assessment against a standard criterion, however, due to 
unavailability of a “gold standard” of health against which health-status indices can be 
compared, the validation methods commonly used are the assessment of content and 
construct validity.
Content validity
Content validity of health measurement scales (HMS) has been described as how 
adequately the items sampled represent the range of each domain assessed by the 
instrument. Yaghmaie (2003) referred to the content validity of an instrument as the 
degree that the instrument covers the content that it is supposed to measure. Each item 
should fall into at least one of the content areas being measured. If it does not, then 
the item is not relevant to the scale’s objectives. A scale with good content validity is 
one that covers all aspects of the concept being addressed. To establish content 
validity, Bungay et al (1993) suggested that a comparison needs to be made between 
the items included in a scale and some definitional standard for which there is general 
acceptance.
Content validity is related to face validity though content validity should not be 
confused with face validity. The latter is not validity in the technical sense; it refers, 
not to what the test actually measures, but to what it appears superficially to measure 
(Bowling, 2005b). Content validity is more systematic than face validity, and a panel 
following literature reviews, focus groups, and exploratory interviews with the target 
population usually makes judgements about these issues. It is generally agreed that 
the content validity of subjective indicators should be judged by members of the 
target group being assessed (Patrick, 2003)
Criterion validity
This refers to whether the variable can be measured with accuracy. Traditionally, 
criterion validity is defined as the correlation of a scale with some other “criterion” 
measure of the topic under study, ideally a “gold standard” (Bowling, 2005b). Criteria 
or concrete validity is the extent to which the measures are demonstrably related to 
concrete criteria in the "real" world (Pennington, 2003).
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Criterion validity is divided into two types: concurrent and predictive validity. 
Concurrent validity is demonstrated where a test correlates well with a measure that 
has previously been validated. The two measures may be for the same construct, or 
for different, but presumably related, constructs (Pennington, 2003). Predictive 
validity in contrast is the extent to which a scale predicts scores on some criterion 
measure. Predictive validity shares similarities with concurrent validity in that both 
are generally measured as correlations between a test and some criterion measure.
Construct validity
Construct validity refers to whether a scale measures the unobservable construct that 
it purports to measure. A construct is not restricted to one set of observable indicators 
or attributes. It is common to a number of sets of indicators. Evaluation of construct 
validity requires examining the correlation o f the measure being evaluated with 
variables that are known to be related to the construct purportedly measured by the 
instrument being evaluated or for which there are theoretical grounds for expecting it 
to be related (Campbell & Fiske, 1959). Unlike other types o f validity testing, testing 
for construct validity involves assessing both theory and method simultaneously. It 
necessitates stating a conceptual definition of the construct to be measured, specifying 
its dimensions, hypothesising its theoretical relationship with other variables, and then 
testing it (Bowling, 2005b).
Convergent and discriminant validity are special types of construct validity. 
Convergent validity, is the degree to which an operation is similar to (converges on) 
other operations that it theoretically should also be similar to. For convergent validity, 
correlations should be high between similar or related measures of the same health 
concept (Bungay and Ware, 1993). For instance, to show the convergent validity of a 
cardio-specific HRQOL measure, the scores on the test can be correlated with scores 
on other tests that are also designed to measure quality o f life in heart disease. High 
correlation between the test scores would be evidence o f a convergent validity. 
Discriminant validity on the other hand describes the degree to which the 
operationalisation is not similar to (diverges from) other operationalisations that it 
theoretically should not be similar to. Campbell and Fiske (1959) introduced the 
concept of discriminant validity within their discussion on evaluating test validity. 
They stressed the importance of using both discriminant and convergent validation
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techniques when assessing new tests. A successful evaluation of discriminant validity 
shows that a test of a concept is not highly correlated with other tests designed to 
measure theoretically different concepts. Construct validity can be evaluated by 
statistical methods that show whether or not a common factor can be shown to exist 
underlying several measurements using different observable indicators. In many 
research studies, factor analysis has been used to demonstrate evidence of construct 
validity.
Factor analysis
Factor analysis is one of numerous statistical techniques used to analyse data. It has 
been widely used by psychometricians as a construct validation tool (Gorsuch, 1983). 
This technique allows its user to condense a large set o f variables or scale items down 
to a smaller, more manageable number of dimensions or factors. It is often used when 
developing scales and measures, to identify the underlying structure (Pallant, 2002). 
In research, factor analysis is primarily engaged to reduce a large number of variables 
to a smaller number o f clusters while retaining maximum spread among experimental 
units (Pallant, 2002). Many researchers have shown that this method can be used to 
provide an operational definition for an unobserved, hypothetical construct by using 
observed variables, or to test a theory about the nature of underlying variables (Ang 
and Huan, 2006)
Exploratory factor analysis
Factor analysis can be either exploratory or confirmatory. Exploratory factor analysis 
(EFA) groups together variables that are intercorrelated. According to Finch (2006), 
EFA is used when the researcher is primarily interested in trying to identify potential 
factors underlying a set of items, but may not have a strong a priori model that he or 
she would like to test. Tabachnick and Fidell (2001) pointed out that EFA is usually 
used in the early stages of research when hypotheses about relationships in a reduced 
data set can be generated.
Confirmatory factor analysis
In contrast to EFA, Confirmatory factor analysis (CFA) is a more complex set of 
techniques used later in the research processes to confirm hypotheses about the
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structure o f underlying set of variables. In this case, variables are specifically chosen 
to reveal underlying structural processes. CFA can also be applied in a situation where 
specific model linking items to factors is to be tested (Finch, 2006). Sometimes, data 
used in confirmatory factor analysis can be different from those used in exploratory 
FA.
There are different opinions on what factor analysis and principal component analyses 
are. Pallant (2002) has pointed out that researchers often use the terms ‘factor 
analyses’ and ‘principal components analyses’ interchangeably. These two sets of 
techniques are similar in many ways since both attempt to produce a smaller number 
of linear combinations of the original variables in a way that captures most of the 
variability in the pattern o f correlation. Some researchers argued that these two 
techniques do differ in a number o f ways. For example, Tabachnick and Fidell (2001) 
suggested that in principal components analysis the original variables are transformed 
into a smaller set of linear combinations, with all of the variance in the variables being 
used whereas in factor analysis, factors are estimated using a mathematical model, 
where only the shared variance is analysed.
Suitability o f  data fo r factor analysis
Pallant (2002) suggested that ‘sample size’ and ‘the strength of the relationship 
among variables should be taken into consideration before determining suitability of a 
particular data set for factor analysis. This was further elaborated by Hogarty et al.,
(2005) who suggested that researchers need to take into consideration among other 
factors the use of larger samples in the conduct o f factor analysis and its provision of 
more precise and stable estimates of factor loadings in the observed population.
Many researchers have proposed a rough guide for rating adequate sample sizes 
(Hogarty et al., 2005). For example, sample sizes o f 100 are considered to be poor, 
200 sample size is fair, 300 = good, 500 = very good, and 1000 or more = excellent. 
Gorsuch (1983) recommended minimum sample sizes that vary between 100 to 250. 
Tabachnick and Fidell (2001) suggested that there should be 300 or more cases for 
factor-analytic purposes (Reio and Wiswell, 2006). However, Pallant (2002) stated 
that many authors do concede that a smaller sample size such as 150 cases should be
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sufficient if solutions have several high loading marker variables such as 0.80 and 
above. In the light of these diverse recommendations, Hogarty et al. (2005) suggested 
that under certain conditions, smaller sample sizes than those generally recommended 
in the literature may be adequate to yield good recovery of factors.
Another issue that determines factorability of a data set is ‘the ratio of sample size to 
the number o f variable’. Although there is scholarly support for employing sample 
size-variable ratios as low as 5:1 for factor-analytic research, Gorsuch (1983) has 
recommended a 10:1 ratio; that is 10 cases for each item to be factor analysed; Cattell 
(1978) on the other hand has recommended a ratio ranging from 3:1 to 6:1; whereas 
Hair et al. (1995) have suggested a ratio of 20:1.
The strength o f the inter-correlation among the items is another issue to take into 
consideration before determining factorability of a data set. Tabachnick and Fidell
(2001) suggested that a correlation matrix should be inspected for coefficients greater 
than 0.30 and recommend factor analysis should not be considered as an appropriate 
technique for the given data set if few correlations above this level are found (Pallant, 
2002). To support this recommendation, it has been suggested that loadings in excess 
of 0.71 are excellent, 0.63 are very good, 0.55 are good, 0.45 are fair, and 0.32 are 
poor (Hogarty et al., 2005).
However, researchers often choose different values based on other preferences as 
many consider these rules not to represent an undisputed choice. Other measures that 
have been frequently used to determine the use o f factor analysis in a set of data are: 
the Bartlett’s test of sphericity (Bartlett, 1954) and the Kaiser-Meyer-Olkin (KMO) 
measure o f sampling adequacy (Kaiser, 1970; Kaiser, 1974). These two measures are 
common with SPSS- a statistical package that is often used in factor analytic 
purposes. Bartlett’s test of sphericity should be significant with a p value less than
0.05 and the KMO index ranges 0 to 1, with 0.60 suggested as the minimum value for 
a good factor analysis (Tabachnick and Fidell, 2001).
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Factor extraction
Factor extraction according to Pallant (2002) involves determination of the smallest 
number o f factors suitable to represent the inter-relations among the set o f variables. 
This method attempts to remove variance common to sets of variables from the 
original matrix o f association. There are multiple ways to extract factors, these 
include methods such as principal components analysis (PCA), principal factors (PF); 
Image factoring (IF) and principal axis factoring (PAF). The most commonly used 
approach is PCA and PAF. Gorsuch (1983) suggested that the researcher should 
consider carefully which method to use because differences can be meaningful. On 
the other hand, Tabachnick and Fidell (1996) recommended that researchers should 
adopt an exploratory approach experimenting with different numbers of factors until a 
satisfactory solution is found (Pallant, 2002).
O’Connor, (2000) pointed out some potential problems that may emerge when non- 
optimal numbers o f factors are extracted. For example, under-extraction can lead to 
compression o f variables into a small factor space, which can result in a loss of 
important information, or neglect of potentially important factors, or distorted fusing 
of two or more factors, and above all, an increase in error in the loadings. O’Connor 
(2000) further elaborated that over-extraction on the other hand may lead to diffusion 
of variables across a large factor space, and this potentially may result in factor 
splitting, factors with few high loadings or in researchers’ attributing excessive 
substantive importance to trivial factors.
Factor retention rules
According to Herson (2006), PCA is intended to simply summarise many variables 
into fewer components, and the latent constructs (i.e., factors) are not the focus of the 
analysis. This author explained further that when variables are factored, the total 
number of possible factors equal the number o f variables factored; assuming all of the 
variance in the original variables is not reproduced. Because many o f these factors 
may not contribute substantially to the overall solution or be interpretable, some of 
them are therefore considered not useful to retain in the analysis and as a result o f this 
can generally constitute a noise or error (Henson, 2006).
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Given that the goal of exploratory factor analysis (EFA) is to retain the fewest 
possible factors while explaining the most variance of the observed variables, Henson 
suggested that the researcher should extract the correct number of factors, as the 
decision will affect results directly. Many rules can be used to determine the number 
of factors to retain. These include: Kaiser’s criterion or the Eigen value>l rule; 
Catell’s scree test; Bartlett’s chi square test; minimum average partial (MAP) 
correlation; and parallel analysis (Turner, 1998). The most commonly used techniques 
is the eigenvalue > 1 rule and in most cases is the default option in most statistics 
packages (Thompson and Daniel, 1996). Henson (2006) therefore suggested that these 
rules do not necessarily lead to the same decision regarding the number of factors to 
retain
Kaiser’s criterion or eigenvalue >  1 rule
This is one o f the most commonly used extraction techniques. Using this rule, only 
factors with an eigenvalue of 1.0 or more are retained for further investigation 
(Pallant, 2002) and the eigenvalue of a factor actually represents the amount of the 
total variance explained by that factor. However, researchers have found that the use 
of this rule is problematic. Eigenvalue > 1 rule has been found to overestimates the 
number of components to retain (Pallant, 2002) and sometimes underestimates (Reio 
and Wiswell, 2006).
The use of eigenvalue > 1 rule has also been criticised however, as resulting in the 
retention of too many factors in some situations (Pallant, 2002) or some components 
generated may not be reliable, as was originally believed (Cliff, 1998). According to 
Reio and Wiswell (2006), eigenvalue > 1 rule tends to be less accurate when the 
number of variables exceeds 30 and can often grossly overestimate the number of 
factors.
Cattell’s scree test
This is a strongly promoted alternative rule of thumb as described by Cattell and 
Vogelmann in 1977 (O'Connor, 2000). This method involves eyeball searches of plots 
for sharp demarcations between the eigenvalues for major and trivial factors. It has 
been suggested that all factors above the elbow, or break in the plot should be retained 
as they contribute the most to the explanation of the variance in the data set (Pallant,
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2002). However, in practice, existence of such demarcations is doubtful (Reio and 
Wiswell, 2006) or there may be more than one demarcation point. Many published 
studies not surprisingly, have therefore shown low reliability of scree plot 
interpretations (O'Connor, 2000).
Bartlett’s chi -square test o f sphericity
This is commonly used in the SPSS statistics package to help assess the factorability 
of the data (Pallant, 2002). Bartlett’s test o f sphericity should be statistically 
significant with a p-value < 0.05 for the factor analysis to be considered appropriate. 
However, studies have shown that this test was very inconsistent. According to 
Henson (2006), the utility of Bartlett’s chi square test in exploratory factor analysis 
(EFA) studies may be very little as it is heavily influenced by sample size.
MAP (minimum average partial) test
This is a statistically based procedure that focuses on the relative amounts of 
systematic and unsystematic variance remaining in a correlation matrix after 
extractions o f increasing numbers of components (O’Connor, 2000). Before this 
procedure is used, the researcher must determine how many components or factors to 
extract before they begin their factor extractions. The MAP test involves a complete 
principal components analysis followed by the examination of a series of matrices of 
partial correlations (Henson, 2006). Unfortunately, the MAP test is seldom employed 
in published research probably due to the fact that it is one of the two less well-known 
procedures (O ’Connor, 2000). However, this extraction method is considered to be 
one of the two reliable methods in factor analysis
Parallel Analysis
This is considered to be one o f the most accurate extraction procedures in factor 
analysis. Parallel analysis involves extraction o f eigenvalues from random data sets 
that parallel the actual data set with regard to the number o f cases and variables 
(O'Connor, 2000; Reio and Wiswell, 2006). O ’Connor (2000) cited an example of a 
parallel analysis of a data set in which the original data set consists of 305 
observations for each of eight variables, then a series o f random data matrices of this 
size (305 x 8) would be generated, and eigenvalues would be computed for the 
original data and for each o f the random data sets. The eigenvalues derived from the
51
actual are then compared to the eigenvalues derived from the random data. Factors or 
components are retained as long as the zth eigenvalue from the actual data is greater 
than the /th eigenvalue form the random data.
Different parallel analysis programs exist. However, all parallel analysis programs use 
random number generators, and different programs or even different runs of the same 
program may produce slight differences in the results (e.g., a 0.04 difference in the 
95th percentile eigenvalues from one run to another) (O’Connor, 2000). For this 
research, we used a program called Monte Carlo PCA for Parallel Analysis.
Factor rotation and interpretation
According to the published literature, there are numerous strategies to perform factor 
rotations. These are performed to facilitate interpretation of the factor results. 
Basically, factor rotations can be either orthogonal or oblique (Tabachnick and Fidell,
2001). According to these two authors, results from orthogonal rotations are easily 
interpretable and reportable; but the researcher needs to assume that the underlying 
constructs are not correlated and therefore independent. On the other hand, oblique 
approaches are more difficult to interpret and report, however, they do allow for the 
correlation o f the factors (Tabachnick and Fidell, 2001).
In practice, both orthogonal and oblique rotations often produce similar solutions 
when the pattern o f correlations among the variables is clear. Henson and Roberts
(2006) suggested that in exploratory factor analysis, the contribution of a variable to a 
given factor is indicated by both factor pattern coefficients and factor structure 
coefficients. Thompson and Daniel, (1996) further noted that the factor structure 
matrix gives the correlations between all observed variables and all extracted factors. 
The two commonly used methods o f rotations are the varimax (orthogonal) and Direct 
Oblimin (oblique).
Reliability
A measure is judged to be reliable when it consistently produces the same results, 
particularly when applied to the same subjects at different time periods when there is 
no evidence of change (Bowling, 2005b). The reliability o f a scale can vary
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depending on the sample that it is used with. In general, the acceptable minimum 
value for a reliability coefficient for an instrument used for group comparison is 0.70 
(Pallant, 2002). Reliability may be estimated through a variety of methods which 
include: internal consistency (for example, split-half, item-item correlations and item- 
total correlations), test-retest, intra-rater, and inter-rater agreement and sensitivity to 
change.
Internal consistency reliability
This is the average degree of association or homogeneity between the items in the 
test. Each item within a test should be measuring different aspects o f the same factor 
while consistently contributing to the total score for the test. This method of reliability 
test can take the form of correlations between the items in the scale, or within each 
scale domain, or between the two halves of the scale where the scale can be divided 
into two equivalent parts (split-half reliability) (Bowling, 2005b). According to Boyle 
(1991), the term “internal consistency” has been used extensively to refer to the 
reliability o f a scale based on the degree o f within-scale item intercorrelation 
measured by either the split-half method, Cronbach’s alpha, as well as the Kuder- 
Richardson-20 and 21 (KR20 and KR21) coefficients.
Cronbach’s alpha is the most commonly reported form o f reliability coefficient and its 
calculation is based on the average correlation among the items and the number of 
items in the instrument. Its value ranges from 0 to 1. According to Bowling (2005b), a 
low coefficient alpha (e.g. below 0.50) indicates that the item does not come from the 
same conceptual domain.
Test - retest reliability
This is the correlation between scores obtained by the same person on two separate 
occasions. It is a form of stability o f the measure over time. The main problem with 
this is that the first administration may affect responses on the second and also there 
can be problems with interpretation of observed change, given the potential for 
observer errors with any scale, and the potential for genuine individual change 
between administrations which affects the estimate o f reliability (Bowling, 2005b).
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In addition, random fluctuations in performance give rise to variation between the two 
observations; therefore low test-retest reliability may not reflect the psychometric 
properties o f the test (Walker, 2002). Researchers differ in their opinions as to the 
length o f time period, but intervals between 2 and 14 days have been considered 
suitable in practice (Walker, 2002).
Inter-rater reliability
This relates to the degree o f concordance shown between two or more raters in 
assessing the HRQOL of a common cohort o f subjects using the same HRQOL 
instrument. It is only considered for interview and interview-administered measures 
and the likelihood o f chance agreement between raters must be taken into account 
with instruments using a categorical scale (Walker, 2002). Inter-rater reliability is 
determined from correlations between different raters’ responses and the reliability 
coefficients are calculated using Kendall’s index o f concordance (W) (Walker, 2002). 
The coefficient ranges from 0 to 1, with 1 indicating complete inter-rater agreement 
(Lua, 2002). In the case of categorical measures, the kappa coefficient is the statistic 
of choice. The Kappa coefficient is defined as the actual inter-rater agreement beyond 
chance divided by the potential inter-rater agreement beyond chance.
Mathematically, k = 0 -  C /  1 - C.
0  = observed agreement beyond chance 
C = chance agreement
1 = maximum level o f agreement that can be reached among raters.
If the kappa value falls below 0.40, the result is considered to be “poor”; kappa value 
above 0.40 but less than 0.60 is considered to be “fair”; also, if the value of kappa is 
above 0.60 but less than 0.80, this result is classified as “good”; and any value of 
kappa above 0.80 is classified as “excellent”.
Sample size
A question a researcher is often faced with is: how large should his sample be in order 
to conduct an adequate survey? There is no universally accepted number of cases to 
be included in a particular sample. According to Bailey (1987), much depends on: 1) 
the nature o f the population under study, 2) the purpose o f the study, and 3) the
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desired target difference if applicable. Sample size is governed by the power of the 
statistical test used. Both are critical to any study where HRQOL is an important 
endpoint. The power o f a statistical test is determined by effect size, reliability of the 
measurement and the significance level (Lua, 2002; Walker, 2002). The significance 
level can be chosen in advance and reliability can be evaluated as necessary.
In order to increase precision, representativeness and greater reliability of the data, 
many authors do recommend the use of a large sample. It has been suggested that the 
correct sample size depends upon the purpose o f the study, design of the study, data 
collection methods used, and the nature o f the population under scrutiny (Lua, 2002). 
However, due to the exploratory nature of this research, sample size calculations 
appear irrelevant in this research study.
Responsiveness to change
This is the ability o f an instrument to be responsive to actual changes that occur over 
time. It is a measure o f the association between the change in the observed score and 
the change in the true value of the construct. This involves correlating the 
instrument’s scores with other measures that reflect any anticipated changes. This is 
extremely important as an indicator o f validity in evaluative instruments (Walker, 
2002). The greater an instrument is sensitive to change, the more useful it is in a 
clinical trial situation, because it will be more sensitive to clinical intervention. 
Responsiveness can be poor due to floor and ceiling effects, which is where 
improvement or deterioration goes undetected in those subjects with either the best or 
worst HRQOL score respectively in the instrument under validation. Low 
responsiveness rather than small sample size may be responsible for an instrument 
reporting no difference when a true change has occurred leading to type 2 errors 
(Walker, 2002).
RESEARCH PLAN
The rationale and issues that need to be considered for the development of a new 
socioeconomic measure have been discussed in the previous section. The second 
section o f this chapter focuses on the research plan for the development of the SEIP 
and its establishment as a novel socioeconomic assessment instrument for use in
55
patients with medication-related problems especially o f cardiovascular drugs. Figure 
2.3 shows the conceptual framework of the research.
Literature Review
The first stage of the research was to carry out a comprehensive literature search 
setting the scene for this research programme. A systematic literature search for 
articles on the topic o f medication side effects and their socioeconomic impact was 
conducted.
Development of the SEIP
This part o f the research is divided into three stages: conceptualisation, item 
generation, and item reduction phase. The conceptualisation stage involved discussion 
o f the proposed model with experts in this field and four sources o f material were 
tapped for domain and item generation: (a) a review of the literature in the areas of 
medication-related problems, cardiovascular drug side-effects, and socioeconomic 
indicators; (b) a focus group with some health professionals with clinical experience 
in the area o f medication reviews and counselling; (c) a series o f semiformal 
interviews and discussions with community managed cardiovascular patients on 
chronic multiple drugs, most of whom were on four weekly repeat prescriptions of 
their medications from their local community pharmacies; and (d) internet-based first 
person narratives.
The Item generation stage on the other hand included generation of an initial pool of 
46 items / statements as well as conduction o f a rigorous literature search of reported 
cases o f medication side effects o f cardiovascular drugs. In addition, various generic 
and disease-specific quality o f life instruments were again examined for suitability of 
their contents in this measure being developed.
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Figure 2.3 Overview of the research programme
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Item generation was followed by four stages o f pre-testing to reduce the initial item 
pool. Some items were reworded, modified, merged or made totally redundant. In the 
first step, the 6 domains of SEIP as well as the initial 31 items were tested in an in- 
depth face-to-face interview with fifteen cardiovascular patients covering the three 
areas o f disease groups (hypertension, angina pectoris and heart failure). Participants 
were asked whether the items captured their language and whether they felt it was 
relevant to their socioeconomic condition. The development of the SEIP is fully 
documented in chapter 4.
Reliability and Practicality Study
The next phase o f this research comprises reliability and practicality studies that will 
be carried out concurrently. Two types o f reliability are to be established: test-retest 
reliability and internal consistency reliability. Test-retest reliability will be performed 
by administering the questionnaires on two occasions with a seven-day interval. It is 
assumed that there has been no significant change in respondents’ condition. Over this 
period, the questionnaire should not demonstrate a change and can therefore be 
considered to be reliable and not prone to large variation when there is no actual 
change to be measured. Internal consistency is also a type o f reliability that needs to 
be established and demonstrates that the items in the questionnaire relate to each other 
and are as a whole measuring what the questionnaire is intending to measure.
Validity Study
Validity can be determined in a number o f ways as already discussed earlier in this 
chapter. The SEIP will be assessed in terms o f its content validity (chapter four). 
Attempts were focused on assessing construct validity (both convergent and 
discriminant). The relationships between SEIP, MIDAS and SF-12 were looked at in 
the validation study. MIDAS and SF-12 were preferred for the assessment of 
construct validity o f SEIP rather than other well-known generic and cardio-specific 
instruments such as Minnesota Living with Heart Failure Questionnaire (MLHF) and 
the Quality o f life after myocardial infarction (QLMI-2) for the following reasons:
1. Although, MLHF and QLMI-2 had already established psychometric 
properties than MIDAS, only MIDAS had a domain that focused on 
medication side effects o f cardiovascular drugs and was therefore closely
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related to SEIP. Moreover, by using MIDAS in this comparative study, it 
supports evolvement of its psychometric properties.
2. SF-12 in comparison with SF-36 is quicker to complete and therefore not time 
consuming.
Data Processing and Analysis
Data processing and analysis will be carried out using the statistical package, SPSS 
for Windows. The edited data will be coded appropriately for analysis. The dilemma 
many young researchers face is choosing the correct statistical technique to analyse 
their data. Researchers should ask themselves four vital and important questions in 
order to analyse the results of the research effectively and successfully (Borg and 
Gall, 1983). These are:
1. What statistical tools are available?
2. Under what condition is each tool used?
3. What the statistical results mean?
4. How the statistical calculations are made?
There are two different types of statistical techniques commonly used in research:
1. The descriptive statistical method
2. The analytical statistical method.
The descriptive statistical method can be used to summarise or describe a collection 
of data so as to present meaningful information. Both of these techniques will be 
employed in this study. Another most important issue in this study was whether to use 
parametric or non-parametric technique depending on the nature of the data. 
According to Al-Mansoori (2003), before selecting appropriate statistical technique 
for use (parametric or non-parametric), the following assumptions should be 
considered:
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1. Random sampling: in the parametric technique for example, analysis of 
variance (ANOVA), t-tests, require random sampling of individuals. Non- 
randomisation o f sample selection may result in a lack of independence of the 
items or in heterogeneity of variances or non-normal distribution (Al- 
Mansoori 2003).
2. Homogeneity of variances: Tabachnick and Fidel1 (2001) stated that for any 
type o f analysis o f variance, there is the assumption that samples are obtained 
from populations o f equal variances. Al-Mansoori, (2003), in his thesis cited 
an example o f this in applying a t-test for the significance of the difference 
between two means or groups. According to this author, the statistical test is 
valid only if one can assume that the variances of the two samples are equal.
3. Normality: It is assumed that the populations from which the samples are 
taken are normally distributed (Tabachnick and Fidell, 2001). In addition to 
random sampling and equality o f variances o f samples, the data distribution 
must be normal if parametric tests such as ANOVA are to be valid and 
justified (Al-Mansoori, 2003). However in a lot o f research, scores on the 
dependent variable are not normally distributed. Fortunately, with large 
enough sample sizes (e.g. 30+), the violation of this assumption should not 
cause any major problems (Gravetter and Wallnau, 2000)
At this stage o f development, if data generated in this present study fails to meet the 
fundamental assumptions required for parametric analysis, the use o f non-parametric 
methods will be taken into consideration.
The type o f non-parametric test depends on the nature of the data. In addition to this, 
non-parametric techniques do not have stringent requirements and do not make 
assumptions about the underlying population distribution. However, they do have 
their disadvantages. According to Tabachnick and Fidell (2001), they tend to be less 
sensitive than their more powerful parametric cousins, and therefore may fail to detect 
differences between groups that actually do exist.
The following existing parametric and non-parametric techniques will be employed in 
this research work. They include: analysis o f variance (ANOVA), Mann-Whitney U
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Test, Wilcoxon Signed Rank test, Spearman Rank Order Correlation Coefficient, 
Kruskal-Wallis Test.
Analysis of variance (ANOVA)
Analysis o f variance is a parametric technique that is used in many research situations 
to compare the mean scores o f more than two groups. This technique compares the 
variance (variability in scores) between the different groups due to the independent 
variable, with the variability within each of the groups believed to be due to chance 
(Pallant, 2002). In ANOVA results, an F ratio are calculated which represents the 
variance between the groups, divided by the variance within the groups. According to 
Pallant, (2002), a large F ratio indicates that there is more variability between the 
groups (caused by the independent variable), than there is within each group (referred 
to as the error term).
The Mann-Whitney U Test
The Mann Whitney U Test is used to test for differences between two independent 
groups on a continuous measure. It has been considered to be one o f the most 
powerful o f the non-parametric tests (Al-Mansoori, 2003). This test is the non- 
parametric alternative to the t-test for independent samples (Pallant, 2002) and has 
been used to compare the difference between two independent populations. Instead of 
comparing means o f the two groups as in the case of the parametric t-test, Pallant
(2002) stated that this technique actually compares medians and the scores on the 
continuous variable are converted to ranks across the two groups.
In any research, testing o f hypotheses is very important. For example the purpose of t- 
tests and analysis o f variance is to test hypotheses. However, with these types of 
analyses there is always the possibility of reaching the wrong conclusion (Pallant,
2002). The literature has shown that there are two types o f errors that can be 
committed- Type 1 and Type 2 errors. In a Type 1 error, the null hypothesis (Hc) may 
be rejected when it is, in fact true. For example when a researcher hypothesises (Hi) 
that there is a difference in HRQOL of patients suffering from a disease, but there 
really is not. In a Type 2 error, the researcher fails to reject a null hypothesis when it 
is, in fact false (i.e. believing that the groups do not differ, when in fact they do). In 
order to avoid a Type 1 error, researchers always set the probability o f committing
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this error to 0.05 represented by P value as the “level of significance”. The larger the 
P value, the more likely it is that H0 will be falsely rejected (Al-Mansoori, 2003). On 
the other hand, a significance level of 0.05 or less indicates that H0 does not apply and 
that Hi is accepted (Al-Mansoori, 2003).
Kruskal-Wallis Test
This is the non-parametric alternative to a one-way between-groups analysis of 
variance that allows you to compare the scores on some continuous variable for three 
or more groups (Pallant, 2002). This technique is also considered by some authors to 
be an extension of the Wilcoxon rank sum test (Petrie and Sabin, 2005). The 
technique tests the null hypothesis (H0) as to whether K Independent Samples come 
from the same population or from identical populations with respect to the average. 
The test assumes that the variable under study has an underlying continuous 
distribution and it requires at least ordinal measurement of that variable. According to 
Petrie and Sabin (2005), under the null hypothesis of no differences in the 
distributions between groups, the sums of the ranks in each of the K groups should be 
comparable after allowing for any differences in sample size.
Spearman Rank Correlation Coefficient (rho)
This coefficient is a measure o f association between the scores, which require that at 
least one o f the variables is measured on an ordinal scale and neither of the two 
variables is normally distributed (Petrie and Sabin, 2005) and can also be used when 
the sample size is small. This technique is used to calculate the strength of the 
relationship between two continuous variables. It is the non-parametric alternative to 
Pearson’s product -moment correlation (Pallant, 2002).
Wilcoxon Signed Rank Test
This technique is designed for use with repeated measures when the respondents in a 
survey are measured on two occasions, or under two different conditions. It is the 
non-parametric alternative to the repeated measures t-test. Using this technique, the 
Wilcoxon actually converts scores to ranks instead of comparing means and also 
compares them at Time 1 and at Time 2 (Pallant, 2002). The Wilcoxon signed ranks 
test also takes account not only of the signs o f the differences but also their 
magnitude.
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Missing data
Missing data are ubiquitous in research and can seriously affect the results of the 
research. Carpenter and Kenward (2004) suggested that unplanned missing data 
inevitably introduce ambiguity into the inferences that can be drawn from a study and 
ignoring missing data or assuming that excluding missing data is sufficient may 
therefore result in reaching invalid and insignificant results. In this present study, 
issues that need to be considered on the types o f missing data will be included where 
concerned since they may result in loss of power and analytical bias and ultimately 
influence the interpretation of results (Lua, 2002).
Types of missing data
Acock (2005) described different classifications of missing values that may influence 
the optimal strategy for working with missing values. This includes: 1) missing by 
definition o f the subpopulation, 2) missing completely at random (MCAR), 3) missing 
at random (MAR), and 4) non-ignorable (NI) missing values. In missing by definition 
o f the subpopulation, an investigator needs to eliminate these values from the data 
before describing any problems with missing values. Furthermore, the researcher as 
well as the number of respondents who fit the definition of the study population 
should note the total sample size. Acock (2005) further suggests that it is important to 
distinguish between observations that are deleted by the nature of the subpopulation 
being studied and observations that should be included but which have missing 
values.
Data which are missing completely at random (MCAR), are normally ignorable 
because they do not introduce bias into the results (Lua, 2002). However, according to 
Acock (2005), the only limitation to MCAR is that it introduces uncertainty by the 
imputation process, which may reduce statistical power compared to having complete 
data.
Missing at random (MAR) on the other hand has the likelihood that missing data is 
not related to the participant’s score on the variable after controlling for other 
variables in the study.
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Most missing data handling techniques involve either treating the data as missing or 
using only the available data or by mean imputation (replacing missing value with the 
domain mean provided more than half of the domain items have been answered). It 
can also be tackled by a general imputation method, which reflects the most likely 
value for the item. Nevertheless, imputations can also be biased and may result in 
strange numbers (Lua, 2002).
SUMMARY
• This chapter has described the rationale behind the development of the 
Socioeconomic Impact Profile (SEIP);
• It has also elaborated extensively on the general methodology and data 
processing and analysis techniques that will be involved in each phase of the 
research plan, also discussed are different types o f psychometric properties 
that will be tested with this new measure;
• The next chapters will be focused on the followings:
o Chapter 3 -Evaluating medication-related problems of cardiovascular 
drugs in community pharmacy settings 
o Chapter 4 -Development and Content Validation of the Socioeconomic 
Impact Profile (SEIP) 
o Chapter 5 -Content Validation o f the Socioeconomic Impact Profile 
(SEIP)- Factor Analysis and Internal Consistency tests 
o Chapter 6 -Practicality, Test-Retest Reliability and Internal 
Consistency Reliability o f the SEIP 
o Chapter 7 -Validity (convergent and divergent) o f the SEIP 
o Chapter 8 -General Discussion
• And finally, specific details relating to methodology, data processing and 
analysis techniques in each phase o f the research will be discussed within the 
relevant chapters.
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CHAPTER 3
Evaluation of the Medication-Related 
Problems of Cardiovascular Drugs in 
Community Pharmacy Settings
65
INTRODUCTION
A person’s health can be influenced not only by social circumstances, but also by the 
outcome o f drug therapy. When people are diagnosed with heart disease for example, 
the treatment options may be in several different ways. The initial change they will 
have to make include cutting down on fat and cholesterol intake and stop smoking if 
they are smokers. Exercise will also become part of their lives, if possible. Drug 
therapy may be the next course o f action. Frequent use of drugs in this modem day is 
due to the high prevalence o f multiple morbidities and the increased availability of 
pharmacotherapeutic options (Vinks et al., 2006).
Vinks et al., (2006) also reported that the increasing adoption of the concept of 
evidence-based medicine could have contributed to polypharmacy because new drugs 
are usually studied as an addition to a cocktail o f drugs that until then had proven to 
be the best treatment. In the past few decades for example, the variety and scope of 
cardiovascular drugs have increased tremendously and new drugs are being approved 
annually. However, as a result o f multiple drug therapy, there is the possibility of 
frequent occurrence o f different medication-related problems such as adverse drug 
reactions, drug-drug interactions, contraindications and drug underutilisation (Murray 
and Callahan, 2003).
In the pharmacotherapy o f cardiovascular diseases for example, although people with 
hypertension or any other form o f cardiovascular disease live longer due to lifelong 
medication therapy (Bardage, 2000), many still experience medication-related 
problems such as inappropriate dosage regimen. Part o f pharmacists’ training is to 
identify dose appropriateness for each individual patient. Furthermore, pharmacists 
are trained to collaborate with other healthcare professionals in policy implementation 
and patient monitoring in order to achieve definite outcomes and desirable quality of 
life for their patients. Whenever medications are administered, there are possibilities 
for occurrence o f certain problems that may diminish a patient’s quality of life.
Apart from inappropriate drug prescribing (such as inappropriate dosage form, dosage 
interval or duration) by the prescribers, low compliance by the patient as well as poor 
concordance may have negative therapeutic outcomes and hence impact on the
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patient’s quality of life. Pharmacists should have the skills to prevent drug-related 
morbidity, which is in most cases associated with any of the above-mentioned 
medication-related problems.
Implementation of medication-related problems assessment tools in 
community pharmacy practice
The clinical and humanistic outcomes of medication-related morbidity are potentially 
substantial. According to Morris et al (2003), reducing preventable medication-related 
morbidity could potentially improve the quality of life of patients and improve the 
safety and quality of the health care system. There is therefore a need for 
incorporation of some of the community-oriented risk assessment tools in community 
pharmacy practice. Most community pharmacists are not aware of the existence of 
such tools. With the introduction o f medication review as part of advanced services in 
the new pharmacy contracts in the United Kingdom, community pharmacists are now 
in better position to access these tools to document medication-related side effects 
they identify while performing medicine use reviews for their patients.
In order for pharmacists to become better familiarised with these risk assessment 
tools, there is a need to develop pharmacist versions of some of the existing DRP 
classification schemes. Medication-related problems have been considered to have a 
major impact on public health. ADRs for example, are a common cause of admission 
to hospital and a leading cause o f morbidity and death (Routledge and O'Mahony,
2003). Many patients do not know whether the side effects they experience are 
medication-related or due to their condition. It is therefore difficult to assess what is 
due to disease state and what is due to prescribed drug treatment or over the counter 
medicines (OTC) inclusive. Pharmacists should therefore be competent to identify, 
prevent and resolve any MRPs, which might occur. Furthermore, an essential element 
of pharmaceutical care is that pharmacists should accept responsibility for the 
patient’s pharmacotherapeutic outcomes.
AIMS OF THE PRESENT STUDY
One of the main priorities o f drug therapy management is to ensure that the prescribed 
treatment is well tolerated and the patient feels better and satisfied. Naturally, once a
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drug is prescribed, the patient has the utmost responsibility to use the drugs for his or 
her own benefit. However, non-adherence to medications due to side-effects is 
common. Documenting drug-related problems frequently associated with multiple 
drug use in chronic conditions can improve the quality of pharmaceutical care hence 
ensuring continuity of positive outcomes o f drug therapy. However, documenting 
medication-related issues identified by community pharmacists during pharmaceutical 
care processes in daily pharmacy practice has not been easy due to certain limitations. 
Buerger (1999) noted that developing, refining and validating medication-related 
problems risk assessment tools is one thing; their implementation in the real-world 
clinical situations to drive better prescribing and improved outcomes is another thing. 
Schaefer et al., (2002) suggested that a suitable coding system for drug-related 
problems must be user friendly in its applicability in the provision of pharmaceutical 
care on a daily basis and also has to fulfil certain criteria in order to render it to wider 
acceptability.
In 1999, a consensus was reached by expert panels in the area of pharmaceutical care 
to create a medication-related problem classification scheme with wider usability and 
acceptability. This led to the creation of an instrument called the Pharmaceutical Care 
Network Europe Drug-Related Problem System (PCNE DRP). Although the system 
has undergone several validation processes since the development of its first version 
in 1999 up to the latest version 5.00, its validity is still questionable. It is therefore 
hoped in this chapter to identify and document frequency and type of patient-reported 
medication-related problems of cardiovascular drugs using the PCNE-DRP V5.00.
M ETHODS
This was a prospective multicentre study o f patients with cardiovascular conditions 
attending five community pharmacies in South Wales, UK during July and August 
2005. During this period, medication records o f cardiovascular patients on repeat 
prescriptions were reviewed. Patients on cardiovascular drugs were identified using 
the patient medication records system from the participating pharmacies and were 
subsequently invited for medication review. Dosage appropriateness, side effects, 
relevant drug interactions and compliance with drug therapy were checked among
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others. The identified medication-related problems were documented on the PCNE- 
DRP V5.00 classification scheme.
Patient inclusion criteria
The patients on repeat prescriptions with four or more cardiovascular drugs were 
recruited from five community pharmacies in South Wales UK. As criteria for 
recruitment, patients should:
• Have been on repeat prescription o f cardiovascular drugs for three months 
minimum;
• Be non- institutionalized;
• Be aged 20 and above;
• Belong to any o f the cardiovascular diseases groups (hypertension, angina, 
and post MI)
• Agree to sign informed consent-forms at the intake.
Pharmacy inclusion criteria
Community pharmacists with active interest in the project and who are actively 
involved in medication surveillance were recruited. Criteria for their inclusion were:
• Pharmacists should keep patient medication record electronically;
• Offer a repeat prescription service particularly to the patient groups of interest 
mentioned above and;
• Should have a private consultation area in the pharmacy.
Data collection
Participating pharmacists were given copies of the PCNE-DRP V5.00 reporting forms 
to document any medication-related issues they encountered during their daily 
pharmaceutical care activities with patients on cardiovascular drugs. The researcher 
(a UK registered pharmacist) visited the pharmacies two days per week to assess the 
Patient Medication Records of cardiovascular patients in order to identify any drug 
related issues. At each visit, the researcher also performed face-to-face medication 
reviews with cardiac patients on repeat prescriptions who visited the pharmacies for
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their medications. For each patient, a drug use profile from their PMR was printed 
listing all prescribed drugs dispensed 3 months to the date of inclusion. Dosage 
appropriateness, potential drug interactions (such as drug-drug, drug-disease, drug- 
age and drug duplications) and compliance with drug therapy were checked and 
documented on the PC N E D R P report form. Any health or other medication issues 
were also addressed.
Classification of Medication-Related Problems
Medication- related problems were defined in accordance with the definition of the 
Pharmaceutical Care Network Europe- Drug Related Problems classification scheme: 
a drug-related problem is an event or circumstance involving drug therapy that 
actually or potentially interferes with desired health outcomes (Van Mil, 1999). 
Operational classification of MRPs was therefore performed based on the fifth version 
o f PCNE_DRP classification scheme (Appendix 1). This classification had already 
been used and validated for some years as a routine classification by a network of 
researchers in an attempt to standardize the classification procedure (Ellison, 2003; 
Alvarez-de-Toledo, 2004). The fifth version of this documentation tool has both 
problems and causes codes separated as well as separate intervention and outcomes 
sections (see appendix 1). The problems domain was categorized into seven sections, 
which were hierarchically structured. The main categorizations used include:
1. Adverse reactions
2. Drug choice problem
3. Dosing problem
4. Drug use problem
5. Interactions
6. Adverse events
7. Patient related problems.
According to Blix et al. (2006), ‘'one medication may introduce more than one MRP, 
some o f  them depend on each other. For example, a given drug may have caused an 
interaction; a dose reduction may be needed, and monitoring o f the drug by 
laboratory tests may also be required. Thus, three MRPs could be related to the drug. 
However, the patient might perceive only one MRP- the actual drug itself ’.
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In this present study, the reported frequencies of MRPs were based on the counting of 
all recorded MRPs.
DATA PROCESSING AND ANALYSIS
The data was processed and analysed using SPSS 12.0 for Windows. Descriptive 
statistics are shown as means with range or standard errors. The patients’ medication- 
related problems were categorised on the PCNE DRP V5.00 report forms into seven 
hierarchically structured groups. Potential interactions identified were classified using 
the British National Formulary. Relationships between some sociodemographic 
characteristics such as gender, age and number of drugs taken and medical condition 
were examined using Spearman’s rank order correlation with significance level set at 
5%. In addition two-way between-groups analysis o f variance (ANOVA) was carried 
out to test the difference between two groups namely (male and female).
RESULTS 
Patient demographic characteristics
A total o f 120 patients were recruited into the study o f whom 58 (48.3%) were 
female, with a mean and median age of 63.2 and 65.0 (range 22-85) respectively. 
Seventy-eight (65.0%) of the study participants were hypertensive, twenty-two 
(18.3%) were taking medications for angina pectoris while the remaining twenty 
(16.7%) were community-managed post myocardial infarction patients. Forty-eight 
(40.0%) patients suffered from one or more co-morbidity (Table 3.1). Apart from 
suffering from a cardiovascular disease, 11(9.2%) patients were taking medications 
for asthma, 3 (2.5%) were on antidepressants, 12 (10%) were diabetic and 14(11.5%) 
suffered from arthritis-related illness. The mean number o f medications taken by the 
study participants was 5.80 ± 1.9 SD. A total o f 157 (52.3%) of all medication-related 
problems were discovered by pharmacists during routine pharmaceutical care services 
they provided to their patients while 32 (10.7%) cases of MRPs were self-reported by 
the patients
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Medication-Related Problems
Table 3.2 below shows that the number of MRPs detected was positively correlated 
with the number of medications taken by the participating patients (rs = 0.16, P = 
0.005) but no correlation was found between the MRPs detected and their medical 
condition (rs = 0.02, P = 0.775) suggesting that the predominant factor in determining 
medication-related problem is polypharmacy and not the disease itself.
Table 3.1 Demographic characteris tics of the study participants (n=120)
Characteristics Number (%)
Age (years)
Mean 63.2
Median 65.0
Range 22-85
Sex
Male 62 (51.7)
Female 58 (48.3)
No of drugs taken
Mean 5.80 ±1.9
Median 5.00
Problem discovered
By patient 32(10.7)
By pharmacy 157(52.3)
Medical condition
Hypertension 78 (65.0)
Angina 22(18.3)
Post MI 20(16.7)
Co morbidity
Respiratory 11 (9.2)
Gastrointestinal 1 (0.83)
Depression 3 (2.5)
Sleeping problems 6 (5.0)
Diabetes 12(10.0)
Arthritis 14(11.5)
Genitor-urinary problem 1 (0.3)
No co-morbidity 72 (60.0)
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Furthermore, the mean number of drugs taken by the 120 patients was significantly 
positively correlated with their age (rs = 0.268, P < 0.005) (Figure 3.1) but not related 
to their medical condition (rs = -0.03, P = 0.593). This was supported by the results 
from two-way analysis of variance (ANOVA) conducted to explore the impact of 
gender and age on the number of drugs taken by the patients. For this purpose, 
patients were divided into three groups according to their age (Group 1: 22-60 years; 
Group 2: 61-70 years; Group 3: 71 years and above). There was a statistically 
significant main effect for age [F (2, 118)= 11.01, p=0.001] and gender [F (1, 118) = 
6.39, p=0.012] as well as the interaction effect [F (2, 118) =6.31, p=0.002] meaning 
that male and female patients in the study differed in terms of the number of drugs 
they were taking. Furthermore, there was a difference in the number of drugs taken 
among the three age groups of the study participants (Table 3.3). Older patients 
received a greater number o f medications and older females’ a greater number of 
medication than their male counterparts (Figure 3.1).
Variables
Medication- 
Related Problem
Medical
Condition
Age in 
years
No of drugs 
taken
Medication Related 
Problem l.00
Medical Condition 0.02 l.00
Age in years 0.33** -0.01 l.000
No of drugs taken 0.16** -0.03 0.27** 1.000
** Spearman’s Correlation is significant at the 0.01 level (2-tailed).
Positive significant correlation shown between age and MRPs (Table 3.2) could be 
explained by older patients being prescribed a greater number of drugs.
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Table 3 .3  C om parisons t  of the impact of gender and age on the number of drugs taken by the study participants
Age group Gender Mean (SD) *Levene’s Test of Equality of error Variances Tests of Between-Subjects Effects
22-60 Males 5.55 (1.43) F Dn Df2 Sig Source df F Sig
Females
Total
5.08(1.52)
5.32(1.48) 2.19 5 118 0.056 Gender 1 6.39 0.012
61-70 Males
Females
Total
5.31 (1.89) 
6.13(2.21) 
5.72 (2.05)
Age group 3 2 11.01 0.000
71 + Males
Females
Total
5.89(1.78) 
7.13(1.95) 
6.51 (1.87)
Gender *age 
group 3
Error
2
118
6.31 0.002
*Tests the null hypothesis that the error variance of the dependent variable is equal across groups.
t  Analysis of Variance.
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Figure 3.1 Comparison of the number of drugs taken by males and females in different age groups.
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Table 3.4 shows the frequencies of categories of MRPs. Out of the total of 300 
PCNE DRP report forms completed with the patients, MRPs were identified in 187 
(62.7%) cases and the remaining 112 (37.3%) cases showed that patients did not have 
problems with the use of their medications (Figure 3.2). Overall, “Potential drug 
interactions" accounted for 110 (36.7%) o f the most frequently occurring medication- 
related problems. Twelve (4.0%) cases of the reported MRPs showed that some 
patients suffered from side effects of a non allergic nature to their medications, in 
particular patients on a parallel import (PI) o f felodipine 5mg tablets (istin R) 
complained o f a rash they had never had before and this drug had to be substituted for 
the original brand or in cases where the original brand was not available, they were 
referred to their general practitioner. Furthermore, 18 (6.0%) cases of “inappropriate 
prescribing o f drugs” were identified and 11 (3.7%) cases of either “the drug dose was 
too high or too frequent regimen” was also identified. Eighteen (6.0%) cases were 
associated with “drug not taken or administered at all”, 9 (3.0%) cases of reported 
MRPs involved “wrong drug taken/administered”, 4 (1.3%) cases involved 
“inappropriate drug duplication” and 6 (2.0%) cases of “contraindication for drug” 
were reported.
Table 3.4 Reported cases of Medication-Related Problems during the study
Description Frequency (%)
Medication-related problem (n=187)
Side effect suffered (non allergic) 12(4.0)
Drug dose too high or regimen too frequent 11(3.7)
Drug not taken /administered at all 18(6.0)
Wrong drug taken/ administered 9 (3.0)
Potential interaction 110(36.7)
Inappropriate drug 18(6.0)
Inappropriate drug duplication 4(1.3)
Contraindication for drug 6 (2.0)
No medication-related problems
No of cases 112(37.3)
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Figure 3.2 Categories of reported Medication-Related Problems
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C I=  C o n tra ind ica tion  for drug.
M e d ic a tio n s  involved
Table 3.5 shows examples o f  reported cases o f "non-allergic side effects" in this 
study. For example a situation where a patient who was initiated on candersartan 4mg 
(angiotensin-II receptor antagonists) experienced headache, flushing and swollen 
gums, or a patient who was prescribed a parallel import version o f amlodipine 5mg 
for blood pressure experienced swollen leg and rashes on his upper arms, were 
referred to their GP. Another patient on parallel import (PI) o f candersartan suffered 
headache as a result o f intolerance to the brand and was later stabilised on the original 
brand.
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Table 3.5 Examples of reported cases of “non-allergic side effects”
R e p o rte d  
ca se  no
M ed ica tio n  invo lved T y p e  o f  s id e  effec t su ffe red  by  p a tie n t
N 007 A m lodipine 5m g 
(calcium  channel 
blocker)
Sw ollen legs afte r taking m edication for a couple o f  days.
N 010 Lipanthyl m icro 
(fenofibrate)
U pset stom ach (diarrhoea)
N 015 A m lodipine lOmg 
(parallel im port)
Persistent headache since taking the parallel im port 
brand.
N 016 ISM O  40 (isosorbide 
m ononitrate)
Itchy rash on h is upper arms. Problem  started since 
tak ing  the brand isosorbide m ononitrate.
N 0 I9 N itrom in spray 
(glyceryl trin itrate 
400m cg)
H eadache afte r using this brand. Preferred nitrolingual 
brand.
B R 006 A torvastatin  20m g (PI) D oes not to lera te  the parallel im port brand. Experience 
stom ach upset.
B R 003 Lasix 40m g 
(fu rosem ide)
U pset stom ach w ith this brand. Prefers the generic APS 
brand.
N 023 C andersartan  8m g Suffers headache with the parallel im port brand. Prefers 
the original A m ias brand.
N 037 Felogen X L lOmg 
(felod ip ine)
S uffers headache with the brand. Prefers plendil brand
N 008 C andersantan  4m g H eadache, flushing, sw ollen gum s and red eyes after 
tak ing  m edication.
B R 008 R am ipril lOmg Fatigue and occasional dry cough
N 009 Losartan lOOmg H eadache after initiation with m edication
Furthermore, Table 3.6 shows examples o f cases involving inappropriate drug use. 
Two patients were prescribed furosemide- a loop diuretic to lower blood pressure. 
However, they were initiated on 40mg to be taken at 6pm in the evening. This dosage 
regimen may affect patients' quality o f life by interfering in their sleep. The patient’s 
GPs were contacted and changes in the dosage regimen were suggested and corrected 
by their GP. The drug groups mostly associated with potential drug interactions in this 
study included prescriptions o f anticoagulants such as warfarin and aspirin and 
combination therapy o f statins and fibrates in patients with hyperlipidaemia (Tables 
3.7.1 to 3.7.13). Other reported cases of MRPs included potential interaction between 
ramipril (ACE-inhibitor) and diclofenac (anti-inflammatory drug), amiodarone (anti- 
arrhythmics) and warfarin (anticoagulant), amiodarone and flecainide (anti- 
arrhythmics).
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Table 3.6 Examples of reported cases of inappropriate drug use by observed patients
Case no Medication involved Type of inappropriate drug use
BR002 Furosemide 40mg (diuretic) Patient takes one tablet at 6pm
N001 Furosemide 40mg 69 year old female patient takes furosemide 
tablets at 6pm in the evening
N006 Nifedipine (Adalat LA) 
20mg
Patient was prescribed twice daily dose of 
adalat LA brand instead of adalat retard 
brand.
N021 Simvastatin lOmg Patient was taken the tablets in the morning 
instead of at night.
BR004 Felodipine MR lOmg Patient was prescribed twice daily dose of 
the modified release brand instead of once 
daily dose usually in the morning.
Table 3.7.1 Examples o f identified cases of potential drug interactions 
Patient no: BR016 Age: 58yr Gender: male
PMR: Warfarin 5mg as directed Epanutin (Phenytoin) lOOmg capsules, 2 daily
Warfarin 3mg as directed Omeprazole 20mg, one daily
Warfarin lmg as directed Simvastatin 40mg one daily
Epilim Chrono (sodium valproate M/R) 300mg 2 BD
Tramacet (paracetamol and tramadol) tablets as directed
Drugs involved Potential drug interactions
Warfarin + Tramacet (tramadol 
and paracetamol)
Anticoagulant effect o f warfarin is increased and may 
increase risk o f bleeding
Warfarin +Epanutin (phenytoin) Anticoagulant effect may be increased.
Warfarin + Omeprazole Anticoagulant effect may be increased.
Warfarin + Simvastatin Anticoagulant effect may be increased.
Warfarin + Clopidogrel Increased risk o f bleeding
Epilim + Tramacet Anticonvulsant effect antagonised.
79
Table 3.7.2 Examples of identified cases o f potential drug interactions
Patient no: NP064 
Age: 70yrs, 
Gender: female
PMR: Furosemide 40mg one each morning 
Simvastatin 40mg one at night 
Stemetil (prochlorperazine) 5mg three times daily 
Clarithromycin 500mg twice daily
Furosemide + Stemetil 
Simvastatin + clarithromycin
Increase risk of arrhythmias due to hypokalaemia 
Risk of myopathy due to increase plasma level of statin
Table 3.7.3 Examples of identified cases of potential rug interactions
Patient no: BR082 
Age: 49 years 
Gender: Male
PMR:
Amlodipine lOmg one each morning 
Aspirin 75mg one daily 
Atorvastatin 20mg one daily 
Bendroflumethiazide 2.5mg one daily 
Doxazosin 4mg two daily 
Levothyroxine lOOmcg one daily 
Levothyroxine SOmcg one daily 
Levothyroxine 25mcg one daily 
Ramipril lOmg capsules one daily 
Avandamett 2mg/500mg two twice daily
3*  bendroflumethiazide 2.5mg Increased postural hypotensive effect of FIRST DOSE
+ o f alpha blocker
Doxazosin 4mg
3* bendroflumethiazide 2.5mg Bendroflumethiazide 2.5mg reduces hypoglycaemic
+ effect of avandamet
Avandamet 2mg/500mg
t  Avandamet = rosiglitazone 2mg and metformin 500mg; 3 * =  interaction level warning signal
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Table 3.7.4 Examples of identified cases of potential drug interactions
Patient no:BR002 PMR
Age: 69 years Atenolol lOOmg one each morning
Gender: female Bendroflumethiazide 2.5mg one each
morning
Lansoprazole 15mg capsules one daily
Warfarin lmg as directed
Warfarin 3mg as directed
Warfarin 5mg as directed
3*Zoton (lansoprazole) + warfarin Zoton may increase anticoagulant effect of 
warfarin
Table 3.7.5 Examples o f identified cases o f potential drug interactions
Patient no: BR015 PMR
Age: 66 years Aspirin dispersible 75mg one daily
Gender: female Bendroflumethiazide 2.5mg one each morning
Diclofenac sodium EC 50mg one three times
daily
Losartan 50mg one daily
Simvastatin 40mg one at night
Movicol sachets one daily
3* Aspirin
+
Diclofenac
Increased risk o f bleeding
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Table 3.7.6 Examples of identified cases o f potential drug interactions
Patient no: BR010 PMR
Age: 68 years Ferrous sulphate 200mg three times daily
Gender: female Ascorbic 50mg tablets one daily
Citalopram lOmg one at night
Gliclazide 80mg half a day
Doxazosin 4mg one daily
Losartan lOOmg one daily
Aspirin 75mg one a day
Atorvastatin 20mg one daily
Bendroflumethiazide 2.5mg one each morning
Avandamet 4/1000mg one twice a day
Aspirin + citalopram Increase risk of bleeding 3*
Bendroflumethiazide + doxazosin Increased postural hypotensive effect 3*
Bendroflumethiazide + avandamet Reduced hypoglycaemic effect of avandamet 3*
Table 3.7.7 Examples o f identified cases o f potential drug interactions
Patient no: BR080 
Age: 80 years 
Gender: female
PMR
Furosemide 40mg one each morning 
Digoxin 125 meg one daily 
Warfarin lmg one daily as directed 
Perindopril 2mg one daily 
Simvastatin 40mg one at night 
Gabapentin 300mg one twice a day 
Co-codamol 30mg/500mg one four times a day
Warfarin + simvastatin 
Digoxin + furosemide
Simvastatin increases anticoagulant effect 3* 
Digitalis toxicity increased by hypokalaemic 
effect of furosemide 3*
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Table 3.7.8 Examples of identified cases o f potential drug interactions
Patient no: BR176 
Age: 86 years 
Gender: female
PMR
Tildiem (diltiazem) MR 60mg one twice a day 
Omeprazole GR 10MG one daily 
Simvastatin 20mg one at night 
Levothyroxine 50mcg one daily 
Candesartan 8mg one daily
Tildiem + simvastatin 3* Increased plasma level of statin/risk of myopathy
Table 3.7.9 Examples o f identified cases of potential drug interactions
Patient no: NP 058 
Age: 40 years 
Gender: male
PMR
Aspirin dispersible 75mg one daily
Clopidogrel 75mg one daily
Gabapentin 300mg two each morning, two at
night and one midday
Lisinopril 2.5mg one daily
Rosuvastatin lOmg one daily
Tramadol capsules 50mg one four times a day
Aspirin + Clopidogrel 
Gabapentin + tramadol
Increased risk o f bleeding 3* 
Anticonvulsant effect antagonised 3*
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Table 3.7.10 Examples of identified cases o f potential drug interactions
Patient no: NP 079 
Age: 46 years 
Gender: male
PMR
Aspirin dispersible 75mg one daily 
Ramipril lOmg one each morning 
Doxazosin 2mg one twice a day 
Atenolol lOOmg one each morning 
Bendroflumethiazide 2.5mg one each morning
Doxazosin + Atenolol
Doxazosin + Bendroflumethiazide
Ramipril + Atenolol 
Bendroflumethiazide + Ramipril
Increased postural hypotensive effect of first dose 
o f alpha blocker 3*
Increased hypotensive effect of first dose o f alpha 
blocker 3*
Enhanced hypotensive effect 1* - 2*
Enhanced hypotensive effect 1* - 2*
Table 3.7.11 Examples of identified cases of potential drug interactions
Patient no: NP 005 
Age: 77 years 
Gender: male
PMR
Atenolol 50mg one a day; Atenolol 25mg one a day 
Simvastatin 25mg one at night; Perindopril 4mg 
one each morning; Glucosamine 1500 one daily; 
Paracetamol 500mg capsules two four times a day; 
Amlodipine 5mg one a day 
Senna 7.5mg one to two at night 
Aspirin 75mg two each morning 
Diclofenac EC 50mg one three times a day
Aspirin + diclofenac Increased risk o f bleeding 3*
Atenolol + Perindopril Enhanced hypotensive effect 2*
Atenolol + Amlodipine Enhanced hypotensive effect 2*
Perindopril + Amlodipine Enhanced hypotensive effect 2*
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Table 3.7.12 Examples of identified cases o f potential drug interactions
Patient no: NP 063 
Age: 60 years 
Gender: female
PMR
Beclomethasone aqueous nasal spray 
Half-Inderal (propranolol) LA 80mg one each morning 
Co-codamol 30/500 one four times a day 
Metformin 500mg one four times a day 
Atorvastatin 20mg one a day
Half -  Inderal (Propranolol)
+
Metformin
Beta blockers increase hypoglycaemic effect- mask 
warning signs 3*
Table 3.7.13 Examples o f identified cases of potential drug interactions
Patient no: NP 085 PMR
Age: 56 years Novomix 30 flexipen inj as directed
Gender: female Aspirin 75mg one each morning 
Atenolol 50mg one each morning 
Rosuvastatin lOmg one daily 
Bendroflumethiazide 2.5mg one each morning 
Valsartan 160mg one each day 
Glimepiride 2mg one daily 
Rosiglitazone 8mg one each day
Rosiglitazone + Novomix Manufacturer o f rosiglitazone advises AVOID 4*
Atenolol + bendroflumethiazide Enhanced hypotensive effect 2*
Atenolol + Valsartan Enhanced hypotensive effect 2*
Valsartan + bendroflumethiazide Enhanced hypotensive effect 2*
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Causes of medication-related problems
A total o f 187 causes of medication-related problems were identified (Table 3.8). The 
most common causes identified (118; 63.1%) included pharmacokinetic problems. 16 
cases (8.6%) o f MRPs were as a result of “Inappropriate drug selections" and 18 cases 
(9.6%) were due to “inappropriate dosage selection". Furthermore, Pharmacists 
revealed that in 23 cases (12.3%) “Patient had concerns with drugs" led to the 
identified MRPs. Dispensing errors such as wrong drug or dose dispensed were also 
responsible for 9 (4.8%) of the MRPs reported (Figure 3.3).
Table 3.8 Causes of Medication-Related Problems identified during the study (n=187)
MRP causes Frequency (Percentage)
Inappropriate drug selection 16(8.6)
Inappropriate dosage selection 18(9.6)
Pharmacokinetic problems 118(63.1)
Manifest side effect, no other cause 2(1.1)
Instructions for use /taking not known 1 (0.5)
Patient has concerns with drugs 23(12.3)
Dispensing error (wrong drug or dose dispensed) 9 (4.8)
Total 187
Pharmacist interventions to solve reported MRPs
There was no intervention in 28 cases (9.3%) out of the 300 cases (Table 3.9). 
Pharmacists recorded 272 interventions in 112 patients (Figure 3.4). O f these 272 
interventions made, 138 (50.7%) were made at patient/carer level. Fifty- one of the 
138 (36.9%) recommendations at patient/carer level involved medication counselling 
and 87 of the remaining 138 (63.1%) interventions at patient/carer level were directed 
towards the prescriber (referral to prescriber). O f the total 112 interventions made at 
the prescriber level, the pharmacists proposed 53 interventions to the prescriber or 
physician and all were approved (Table 3.10). However, only one intervention 
proposed by the pharmacist was not approved by the prescriber and the outcomes of 
other 32 interventions proposed were not known during the period o f the study. At the
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drug level, for 15 cases the pharmacists’ intervention involved a switch o f drug to 
another dosage or formulation. Other interventions proposed included brand switching 
especially with parallel import drugs.
Figure 3.3 Causes o f MRPs 
PKP
□
IDOS
PK P = P harm acok ine tic  p rob lem ; ID O S= Inappropria te  dosage  selection
ID S= Inapp rop ria te  d rug se lec tion ; D E= D ispensing  erro r; PC D = Patient has concerns w ith d rug 
1NK= Ins truction  for use not know n; M SE = M anifest side effect, no o ther cause
Table 3.9 Interventions to MRPs identified in the study
Interventions Number (percentage)
N o in te rv e n tio n 28 (9.3)
Prescriber asked for information 26 (8.7)
Intervention proposed, approved by prescriber 53(17.7)
Intervention proposed, not approved by prescriber 1 (0.3)
Intervention proposed, outcome unknown 32(10.7)
Patient (medication) counselling 51 (17.0)
Patient referred to prescriber 87 (29.0)
Dosage changed to........ 5 (1 .7 )
Formulation changed to....... 10(3.3)
Other intervention 7 (2.3)
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Table 3.10 Medication-related problems and the pharmacist's interventions
Medication-related problems
Interventions
Side effect suffered 
(non allergic)
Inappropriate
drug
Inappropriate 
drug duplication
C ontra-indication Drug dose 
for drug too high
Drug not 
taken
W rong 
drug taken
Potential
interaction
Prescriber asked for 
inform ation
8 3 3 2 0 2 0 8
Intervention proposed, 
approved by prescriber
11 8 0 4 6 3 2 19
Intervention proposed, 
not approved by 
prescriber
0 0 0 0 0 0 0 1
Intervention proposed, 
outcom e unknown
1 4 1 5 1 2 2 16
Patient (m edication 
counselling)
23 2 7 1 12 0 0 6
Patient referred to 
prescriber
16 15 3 2 2 7 2 40
Dosage changed to . ... 0 I 0 I 0 1 1 1
Form ulation changed 
to
0 1 0 0 I 0 7 1
O ther interventions 1 0 0 0 1 0 2 3
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F igure 3.4  MRPs interventions
F C T  O IN T
IP/AP
IP/NAP
I P/ON K
PC
PRP= Patien t referred  to  p rescrib er PC= Patient counselling  NI= N o in terven tion  
DCT= D osage changed  to . .. FCT= F orm u lation  changed  to . .. 01NT= O ther in terventions 
PA1= P resc rib e r asked  for in fo rm ation ; IP/AP= In tervention  proposed , approved 
IP/NAP= In terven tion  p roposed , no t ap p roved ; IP/ONK= In tervention  p roposed , ou tcom e unknow n
O u tco m es  o f  in te rv e n tio n
Out o f  the total o f 272 interventions proposed by the pharmacists who participated 
either at patient/carer level, prescriber's level or drug level based on the PCNE_DRP 
V5.00 classification scheme, over half (150; 55.1%) o f them resulted in satisfactory 
outcome (Table 3.11). In addition, 117 (43.0%) interventions were partially solved 
and 5 interventions remained unsolved partly due to lack o f cooperation o f the 
respective prescriber or no need or possibility o f  solving the problem (Figure 3.5).
Table 3.11 Outcomes o f  intervention
Outcomes Number (percentage)
Problem totally solved
Problem partially solved
Lack o f  cooperation o f physician
No need or possibility to solve problem
150 (55.1) 
117(43.0) 
2 (0.7) 
3(1.1)
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F igure 3 .5  Outcomes of intervention
NNSP
PPS= Problem partially solved LCP= Lack o f cooperation o f physician
PTS= Problem totally solved NNSP= No need or possibility to solve problem
M R P s re p o r te d  by th e  th re e  p a tie n t  g ro u p s
Out o f the total o f 187 cases o f medication-related problems discovered in the 
patients, 70 (37.2%) cases o f  potential drug interactions occurred among the 
hypertensive patient group, 18 (9.5%) among the anginal group and 22 (11.7%) 
among the post MI group (Table 3.12). Table 3.12 further revealed that a total o f 20 
cases o f drug choice problem (such as “inappropriate drug”, “inappropriate drug 
duplication”, and “contra-indication for drug”) were identified among hypertensive 
patients, 4 cases in angina patients and 4 in post MI patients. Also, a total o f 21 cases 
o f drug use problem (“drug not taken/administered at all”, “wrong drug 
taken/administered”) were detected in hypertension patient group. In addition, 1 case 
o f “drug use problem” in anginal patient and 5 cases in post MI patients were also 
detected.
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Table 3.12 MRPs identified in the three patient groups
No o f cases of MRPs in three patient groups
Type of Medication-Related Problems Hypertension Angina Post MI
Side effect suffered (non allergic) 5 4 3
Inappropriate drug 12 2 4
Inappropriate drug duplication 3 1 0
Contra-indication for drug 5 1 0
Drug dose too high or regimen too frequent 6 3 2
Drug not taken/administered at all 14 1 3
Wrong drug taken/administered 7 0 2
Potential interaction 70 18 22
No medication-related problem present 73 23 16
Causes of reported MRPs in the three patient groups
Table 3.13 summarises the distribution of Cause of MRPs identified among the three 
observed patient groups while Table 3.14 shows in details what cause of MRPs was 
responsible for what type o f medication-related problem.
Table 3.13 Causes o f MRPs identified in three patient groups
Condition
Hypertension Angina Post MI
Inappropriate drug selection 12 1 3
Inappropriate dosage selection 10 4 4
Pharmacokinetic problems 75 21 22
Manifest side effect, no other cause 1 1 0
Instructions for use /taking not known 0 1 0
Patient has concerns with drugs 16 2 5
Dispensing error (wrong drug or dose 
dispensed) 7 0 2
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Apart from “pharmacokinetic problems”, other common predictors of medication- 
related problems identified in this study included “inappropriate drug selections”, 
“inappropriate dosage selection”, “dispensing error” and “patient has concerns with 
drugs”. For example, inappropriate drug selection (15 cases) and “patient has 
concerns with drugs” (3 cases) were the two predictors of 18 cases of inappropriate 
drugs identified during the study (Table 3.14). An example of this involved a 75 year 
old female patient who found it difficult to swallow verapamil 80mg tablets 
prescribed by her general practitioner. After consultation with her prescriber, it was 
resolved to switch her medication from a tablet formulation to a liquid preparation.
Furthermore, 12 reported cases o f “non allergic side effects” in the study were as a 
result o f 1) inappropriate dosage selection (7 cases); 2) pharmacokinetic problem (2 
cases); 3) instruction for use/taken not known (1 case); and 4) patient has concerns 
with drugs (2 cases). All the 11 cases o f “drug dose too high” were classified as a 
result o f inappropriate dosage selection. Also, cases where the patients had concerns 
with drugs such as direction for use, drug formulation issues contributed to some of 
the 18 reported cases o f the “drugs were not taken/administered” (Table 3.14).
DISCUSSION
The characteristics of the study participants showed several differences such as large 
variation in the type o f medical conditions these participants suffered from, co- 
morbidity and how the problems were discovered. Perhaps not surprising, the number 
o f patients who were on different medications was quite high. This is probably due to 
the fact that hypertension is the most common chronic health problem especially in 
Western society (Graham-Clarke and Hebron, 1999). According to the Blood Pressure 
Association (2007), hypertension affects 16 million adults in the United Kingdom and 
about 4 million people are on drug therapy for this condition on a daily basis (Blood 
Pressure Association, 2007). In addition a number of studies have identified and 
documented medication-related problems in patient groups similar to those included 
in this study (Westerlund et al. 1999a; Westerlund, et al. 1999b; Paulino et al., 2004; 
Blix et al., 2006).
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Table 3.14 Relationship between Medication-related problems and their causes
Medication-related problems
Cause of MRPs Side effect suffered 
(non allergic)
Inappropriate
drug
Inappropriate 
drug duplication
C ontra-indication 
for drug
Drug dose 
too high
Drug not 
taken
W rong 
drug taken
Potential
interaction
Inappropriate drug 
selection
0 15 0 1 0 0 0 0
Inappropriate dosage 
selection
7 0 0 0 11 0 0 0
Pharm acokinetic
problem
2 0 1 5 0 0 0 110
M anifest side effect, 
no other cause
0 0 2 0 0 0 0 0
Instruction for use / 
taken not known
1 0 0 0 0 0 0 0
Patient has concerns 
with drugs
2 3 0 0 0 18 0 0
D ispensing error 
(w rong drug or dose 
dispensed)
0 0 0 0 0 0 9 0
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For example, a study published by Titley-Lake and Barber (2000) showed that 63.7% 
of patients who participated in the study had suffered one or more drug-related 
problem and four years later, a similar study by Paulino et al (2004) showed that an 
average o f 5.9 potential drug-related problems per patient was identified.
Medication-Related Problems
Although, according to some authors, most o f the medication-related problems may 
seem not to have direct clinical consequences, they could be associated with 
compliance problem hence a decrease in therapeutic benefits in the long run (Paulino 
et al., 2004). Westerlund et al (1999a) found that 2.5% of the observed population 
suffered a drug-related problem. The fact that in this present study the proportion of 
hypertensive patients with MRPs is much higher indicates that this patient group is at 
increased risk of experiencing medication-related problems especially in the 
community setting probably as a result of multiple antihypertensive drug therapy 
involved. This study also confirms that hypertensive patients are an important target 
group for pharmacy intervention such as medicine use review (part of an enhanced 
pharmacy contract recently introduced in the United Kingdom).
The proportion of potential drug interaction in this study was higher than other 
identified MRPs. The cause o f this is probably due to pharmacokinetic problems. 
These occur when one o f the prescribed drugs alters the absorption, distribution, 
metabolism, or excretion o f another, thus increasing or reducing the amount of the 
first drug available to produce its pharmacological effects. Many of these drug 
interactions are harmless and many of those which are potentially harmful only occur 
in a small proportion o f patients. Moreover, the severity o f an interaction varies from 
one patient to another and often involves drugs with a small therapeutic index and 
those which require careful control of dosage. In this study, all the five pharmacies 
where data were collected had in place a sound system o f identifying potential drug 
interactions whereby the pharmacist is alerted o f any drug interactions involved in the 
patient's prescribed medicines. For example, the warning signals were divided into 1 * 
(one star), 2**  (two stars), 3*** (three stars), and 4**** (four stars).
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These stars warning signals indicate the level of seriousness of the potential drug 
interactions involved. The four stars (4****) warning signals were considered to be 
potentially very serious and always received the pharmacist’s immediate attention. In 
such situations, the pharmacist exercised caution in interpreting the suspected drug 
interaction in order to avoid undue panic, in particular for patients who were stabilised 
on a specific drug for a considerable period o f time.
Pharmacist intervention
In this study, pharmacists evaluated the likelihood that medications were causing 
drug-related problems and intervened with the GP and patient, where appropriate. 
Most of these interventions involved advice on drug dosage adjustment, brand 
switching where necessary, verbal instructions about their medical condition, drug 
therapy, diet and exercise. On patient/carer level for example, “patient (medication) 
counselling” and “patient referred to prescriber” were the most common pharmacy 
interventions. This can be explained by the nature of the MRPs identified, and hence 
the associations found between MRPs and the subsequent interventions. In most of 
the cases where patients experienced upset stomach or rash as a result o f brand 
switching (for example, parallel import of amlodipine tablet vs original brand), 
patients were reassured of the fact that the main active ingredient in both drugs were 
the same, however they were advised to stop taking the medication and referred to the 
prescriber for an alternative medicine or change in their prescribed medication. 
Furthermore on the prescriber level, it is important to highlight the fact that when an 
intervention was proposed by the pharmacist, in most cases, it received the 
prescriber’s approval. Similar studies have also supported this notion of pharmacists 
proposing an intervention and getting positive response from the prescriber 
(Schumock et al., 1994; Granas and Bates 1999; Westerlund et al., 1999a).
The fact that pharmacists did not intervene in 28 cases may be explained by the 
association between the lack of intervention and having a side effect as the identified 
MRPs. A previous study has reported that in 32% of cases when an adverse drug 
event occurs and is reported to a health care provider, the drug is continued as before,
with no further intervention from the healthcare provider (Gray et al., 2001; Lassetter 
and Wamick, 2003; Paulino et al., 2004).
SUMMARY
• This study has shown that a systematic intervention by community 
pharmacists would result in detection o f a high number of medication-related 
problems relevant for patient health outcomes.
• This study has highlighted that patients with more changes in their drug 
regimens (such as new drugs added, use of parallel imports medications, 
changes in dosage) and patients on multiple drug therapy are more likely to 
experience MRPs.
• This study has demonstrated that the use of a drug-related validation tool in 
community pharmacy practice would help to prevent MRPs, in particular in 
areas such as cardiovascular disease where patients are normally prescribed 
multiple drug therapy.
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CHAPTER 4
Development and Content Validation of the 
Socioeconomic Impact Profile (SEIP)
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INTRODUCTION
The study presented in chapter three has revealed that patients on multiple drug 
therapy especially in cardiovascular diseases are prone to medication-related 
problems (MRPs) such as medication side effects. These MRPs could dramatically 
affect a patient’s health-related quality o f life (HRQOL) leading to social and 
emotional distress. The question that needs to be asked is: do these medication-related 
problems have any socio-emotional or socio-economic consequences? In order to 
answer this question, a literature search was performed to look for any reported cases 
that might have focused on such issues.
Over the past three decades, a number of instruments have been developed to measure 
the impact o f a disease state on social, economic and total wellbeing of patients (Scott 
et al., 1999; Yu et al., 2004), however, little or no published work has been carried out 
on the social and economic impact of medication-related problems. An instrument is 
therefore needed to document medication side effects in chronic conditions, such as 
cardiovascular diseases, and its social and economic impacts on patients. To date, 
many studies have shown that depression, fatigue and sexual dysfunctions are 
indicators o f social well being and emotional status of human beings (Bardage, 2000). 
As such, some of these studies have strongly associated these indices to common side 
effects of beta blockers therapy though with limited evidence (Ko et al., 2002). 
Measuring the social and economic impacts of medication-related problems will 
therefore be helpful in guiding policymakers, health service researchers and clinician 
interested in this area to determine which area of drug therapy need more focus and 
attention. In addition, patients are likely to benefit if the information obtained through 
the use o f such an instrument is accessible to clinician as this will ensure that those 
questions which contribute to a person’s HRQOL can be monitored and considered 
when treatment protocols are drafted, thereby enabling comprehensive and holistic 
treatment decision taking.
Antihypertensive drugs and patients9 health-related quality of life 
(HRQOL)
The effect o f antihypertensive treatments on patients’ HRQOL have been described to 
be complex in various published studies with persistence in negative perception of
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drug treatment due to their side effects (Bremner, 2003). For example, calcium 
channel blockers such as felodipine or isradipine can cause severe ankle swelling as a 
late—onset side effect (Douglas and McLay, 1996) resulting in poor HRQOL of 
patient (Testa et al., 1998). Dry, persistent cough commonly associated with ACE 
inhibitors such as enalapril has been demonstrated to have negative influence on sleep 
patterns and in many cases has lead to either low concordance among patients or 
discontinuation from ACE inhibitor therapy (Israili and Hall, 1992; Fletcher et al., 
1994). Studies have also shown that beta-blockers have an immediate negative impact 
on patients’ well being and therefore need to be carefully titrated with low doses when 
initiating treatment (Tregaskis and McDevitt, 1990).
In the United Kingdom in 2006, use o f beta-blockers came under scrutiny following 
a publication on the re-evaluation of the benefits of beta-blockers (Carlberg et al., 
2004). As a result o f this, the British National Formulary (BNF) 51 suggested 
reconsideration of use of this class of antihypertensive drugs as a first choice in 
routine initial therapy for hypertension. In addition, studies have associated beta 
blockers with side effects such as impotence (Ostergren et al., 1996), depression and 
decreased life satisfaction (Breckenridge, 1991), and an assessment of the impact of 
these side effects on such areas as emotional well being, performance at work and 
overall perception of well being needs a constant focus and attention.
Cardiovascular drugs and compliance
Studies have shown that drug therapy for cardiovascular disease is lifesaving and 
necessary to limit the complications o f the disease. However, distressing side effects 
from drug treatment as mentioned above often contribute to withdrawing from 
medication or low compliance (Bardage, 2000). In the treatment of hypertension for 
example, several side effects and symptoms such as tiredness, mood changes, and 
sleep disturbances, blurred vision, dry cough and impotence associated with these 
medications are also indicators of socio-economic and emotional status which can 
adversely affect the HRQOL of patients. All these attributes were therefore taken into 
consideration at this stage o f development o f the new measurement instrument, the 
Socioeconomic Impact Profile (SEIP).
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Clearly, in order to minimise medication-related problems among cardiovascular 
patients and improve adherence with antihypertensive medications, certain 
interventions are needed. However, if such interventions are to be successfully 
designed, targeted and cost-effective, it is critical to understand the social and 
economic consequences of these medication-related problems and identify ways for 
their modification. One way of doing this is to develop a standardised instrument that 
is aimed at systematically measuring these social and economic impacts.
METHODS  
Development of the instrument
The Socioeconomic Impact Profile (SEIP) was designed to investigate the social and 
economic consequences of medication-related problems especially in patients on 
long-term use o f cardiovascular drugs. A multi-source and multi-stage process (Figure
4.1) was used to develop and finalise the draft instrument. Given that the primary goal 
of developing a new instrument is to create a valid measure of an underlying construct 
(Clark and Watson, 1995), a critical first step in scale development is to develop a 
precise and detailed conception o f the target construct and its theoretical context. 
With this in mind, the Version 1 (pilot version) of the questionnaire was developed 
after undergoing three developmental stages: conceptualisation phase; item generation 
phase; and item reduction phase.
Phase 1: Conceptualisation
In this phase o f development, the proposed model was discussed with some 
community pharmacists with clinical practice experience. The information from the 
discussion with these experts was used to elaborate a survey for identifying 
medication-related problems o f cardiovascular drugs they encounter during 
pharmaceutical care process in their pharmacies. This was followed by a bibliography 
review in the areas of medication-related problems and cardiovascular drugs side 
effects in order to identify the most relevant aspects describing the impact of 
cardiovascular drugs side effects on the patients’ social and economic wellbeing. The 
MEDLINE database and Google scholar search engine generated samples of items 
describing symptoms and side effects of antihypertensive drugs.
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Figure 4.1: Developmental stages o f SEIP version 1
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Some o f these symptoms such as depression, fatigue and sexual dysfunction were 
attributable to beta blockers. Each symptom was further assessed in terms of its 
importance for the patient and the frequency with which it is reported in the 
community pharmacy during the pharmaceutical care process. Furthermore, ideas 
about this concept were also sought from research pharmacists and a heart failure 
specialist nurse. Comments were sought on any medication-related issues that these 
community pharmacists might have come across during pharmaceutical care 
processes in their pharmacies.
In addition, in depth semi-structured interviews were held with fifteen community 
managed cardiovascular patients (hypertensive, angina and heart failure patients). The 
questions used to elicit thoughts on medication side-effects and their impact on social, 
emotional and economic life in patients interviewed targeted phrases or ideas that 
addressed the areas o f life most affected by medication side effects. The interviews 
lasted between 15 and 20 minutes. After transcribing the interviews, relevant 
phrases/expressions were obtained. Finally, first person narratives posted by 
individuals with side effects to some cardiovascular drugs such as statins- 
anticholesterol agents on the internet and reporting on impact o f these medication- 
related side effects on their quality o f life were systematically sampled and analysed.
Phase 2: Item Generation
It has been suggested that the content o f  an initial item pool during an item generation 
stage should be over inclusive and item wording should be carefully studied before 
testing the item pool along with variables that assess closely related constructs (Clark 
and Watson, 1995). The conceptualisation procedure o f the Socioeconomic Impact 
Profile (SEIP) was followed by generation o f an initial pool o f 42 items / statements. 
Many o f these included verbatim quotations as described above. Others included 
rigorous literature search o f reported cases o f medication side effects of 
cardiovascular drugs. In addition, various generic and disease-specific quality of life 
instruments were examined for suitability and relevance o f their contents to the 
measure being developed. Some o f the generated items consisted o f statements
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written in the first person, for example, “I have lost interest in things I usually enjoy”, 
and the way patients described themselves.
After eliminating redundancies, the concepts were grouped using a card-sort approach 
and consensus discussion with experts resulting in six SEIP domains: (A) patient’s 
perception o f treatment (e.g., *i have felt like all energy drained out o f me” or *i have 
lost interest in sexual activity”), (B) impact on sexual functioning and physical 
activity (e.g., “my sexual desire has decreased” or “I feel calm and peaceful after 
walking a mile or doing some exercise”), (C) accessibility to health services (e.g., “I 
have been admitted to hospital “ or “I have stayed in hospital for a couple of days”), 
(D) work-related limitations (e.g., *i have cut down on the amount of my working 
time” or “I have taken some days off sick”), (E) impact on social activities (e.g., *i 
prefer to stay at home than visiting friends and family”), and (F) brand switching 
(e.g., “ I have had allergic reactions such as hives, rash etc.”).
Some o f the items referred to medication side effects and emotional distress were 
experienced by patients (e.g. beta blockers and insomnia, impotence; antihypertensive 
drugs and tiredness, depression). Other items made reference to the use o f healthcare 
services as a result o f medication-related problems. Items were included that reflected 
the impact on patient’s productivity as a result o f adverse drug reactions or any 
medication-related problems encountered in the course o f drug therapy.
Phase 3: Item Reduction
An initial qualitative reduction o f the identified items/statements was carried out, in 
which statements considered inappropriate, ambiguous or redundant were excluded. 
Some o f the remaining items were slightly rephrased, merged or modified to fit the 
intended purpose. The decision to retain or remove an item was also based on the 
following four principles:
•  Responsiveness: the item is expected to be sensitive to change over time.
•  Universality: the item should capture behaviours/feelings o f individuals 
across the observed groups and a broad age range;
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•  Wording/ambiguity: the item should be clearly worded and understood and is 
unlikely to evoke a variety of interpretations.
•  General Acceptability: the item should resonate with focus group participants 
and should be felt appropriate for the target population.
Finally, the identified items were edited to create a self-administered preliminary 
questionnaire for a sample o f 15 cardiovascular patients covering the three areas of 
disease groups (hypertension, angina pectoris and heart failure). Participants were 
asked whether the items captured the way they would describe themselves and 
whether they felt it was relevant to their social and economic condition. Suggestions 
were made for additions and revisions o f items and only those items relating to the 
concept being measured were retained.
This finally led to the construction of an initial 31- item instrument covering six 
socio-economic related domains: 1) social interaction and emotional behaviour (10 
items); 2) reactions to cholesterol lowering agents (5 items); 3) use of health services 
(5 items); 4) work (4 items); 5) change of medication (4 items); and 6) satisfaction 
with medication treatment (3 items). In addition, each domain of the SEIP version 1 
(pilot version) included response scaling with either a 5-point or 4-point scale. For 
example, a 5-point frequency type response anchors was used in domain 1 (i.e. 
*‘never", “a little o f the time", “some o f the time", “most o f the time" and “all o f the 
time”.). On the other hand, another form o f 4-point frequency type response anchors 
was used in domain 2 (i.e. “never", “seldom", “frequently", and “more frequently"). 
As with domain 1, a 5-point frequency type response option was adapted for domain 3 
(“no, not at all", “seldom", “sometimes", “a little", and “a lot”).
The 31-item instrument was then subjected to assessment o f validity by some experts 
in order to create a version o f the questionnaire that would provide a valid 
representation of the criterion to be measured. To allow for a more individualized 
assessment, participants in the validity assessment were required to rate their 
agreement or disagreement with each statement using a 4-point Likert-type scale 
ranging from 1 (strongly agree) to 4 (strongly disagree). This agree-disagree response
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format was chosen over possible alternatives (never-always) as being the most 
appropriate for the types of items used.
Validation o f SEIP - Content Validity
Content validity o f health measurement scales has been described as how adequately 
the items sampled represent the range o f each domain assessed by the instrument. 
Yaghmaie (2003) referred to content validity o f an instrument as the degree that the 
instrument covers the content that it is supposed to measure. Barker et al (2002) 
pointed out that validity is a fundamental component of any research initiative and 
without conducting a validity assessment o f any instruments; many researchers 
believe you do not have anything.
The content validation procedure in this study should raise two major questions: 1) is 
the instrument really measuring the kind o f behaviour that is assumed by the 
investigator? 2) Does it provide an adequate sample o f that behaviour? Ozsogut 
(2001) suggests that content validity is best assessed with a definitional or semantic 
judgement by a group o f panel members. The key issue to bear in mind is, whether the 
instrument has the right focus and emphasis for the construct being measured for the 
intended population.
To assess the content validity o f SEIP, both qualitative and quantitative study design 
were used. Pharmacists o f various professional backgrounds and one cardiac nurse 
and a language expert were recruited to form an “expert panel” for the validity 
assessment. Their composition was: twelve community pharmacists, four research 
pharmacists, one cardiovascular specialist nurse, one linguistic expert and two cardiac 
patients. Validation instruments included the Version 1 (pilot version) o f the SEIP and 
the content validation rating forms.
Quantitative assessm ent o f SEIP by the expert panel
For the quantitative assessment study, the version 1 o f the SEIP and the content 
validity rating forms were sent out to the expert panel for completion prior to a panel 
meeting. The panel was asked to assess the questionnaire on a 4-point scale (1 =
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strongly agree, 2 = agree, 3 = disagree and 4 = strongly disagree) using the following 
five criteria:
• Clarity -  the item must be clear, unambiguous and straightforward in its 
intentions;
•  Completeness -  the item must show a degree o f relevance, and fully reflect the 
intended meaning, focus and emphasis;
• Linguistic clarity -  the item / statement should be straightforward and easily 
understood by anyone with a minimum knowledge o f reading and writing and 
should be jargon - free;
• Relevance -  reflect the target population and their condition that is being 
measured;
• Scaling -  fitting with the way items / statements are structured.
They were also told to make any written comments about any ambiguities in the 
questionnaire and suggestions concerning rewording, rephrasing or redundancy o f any 
item.
Qualitative assessment o f SEIP by the expert panel
The qualitative assessment method involved an expert panel meeting conducted after 
the quantitative analysis o f the questionnaire. All the participants in the quantitative 
part o f the study were asked whether they would be willing to take part in a round 
table discussion. Only two community pharmacists and one research pharmacist were 
able to attend the expert panel meeting. This session was held at the Welsh School of 
Pharmacy, lasted for 90 minutes and the members o f the expert panel gave consent for 
being audio taped. In addition, face-to-face interviews with two cardiovascular 
patients and a specialist heart failure nurse were conducted to broaden the 
acceptability o f the outcomes. The results o f the quantitative assessment of the 
questionnaire by the expert panel were discussed during the meeting.
Following the meeting, further adjustments were made to the question structure to 
remove the ambiguities. Those experts who participated in the meeting were again 
sent another validity assessment form to re-evaluate the new version o f the 
questionnaire. The questionnaire was then pilot tested among patients on repeat
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prescriptions o f cardiovascular drugs in five community pharmacies to further assess 
psychometric properties of the instrument such as factor analysis and internal 
consistency reliability test (chapter five).
Data Processing and Analysis
The expert panel meeting and the interviews were recorded and transcribed verbatim. 
Descriptive statistics were used to express the demographic characteristics o f the 
expert panel members. The information was analysed by assessing the degree of 
concordance among experts for each o f the five criteria response scale (clarity, 
completeness, language clarity, relevance, and scaling) by calculating the mean and 
standard deviation. Level o f agreements among the panel members was further 
assessed by determining the Cohen kappa coefficient value. Under normal 
circumstances, Cohen kappa is used to determine the level of agreement between two 
raters. But in cases where the numbers o f raters are greater than two, Cohen kappa 
macro syntax is computed. Kappa coefficient is defined as the actual inter-rater 
agreement beyond chance divided by the potential inter-rater agreement beyond 
chance.
Mathematically, k = 0 -  C /  l -C .
0  = observed agreement beyond chance 
C = chance agreement
1 = maximum level o f agreement that can be reached among raters.
If the kappa value falls below 0.40, the result is considered to be “poor”; kappa value 
above 0.40 but less than 0.60 is considered to be “fair”; also, if the value o f kappa is 
above 0.60 but less than 0.80, this result is classified as “good”; and any value of 
kappa above 0.80 is classified as “excellent”.
RESULTS
Developm ent of the SEIP  
Item generation and reduction phase
Based on literature reviews and interviews with community pharmacists during the 
item generation phase, 42 items were identified (Table 4.1). During the item reduction
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phase, 17 o f these items were reworded (e.g. the title o f domain A -“patient perception 
o f treatment” became “social interaction and emotional behaviour”, and domain D - 
“work-related limitation” was shortened to “work” etc.). Four other items were 
modified (e.g. item A 2 - i  have lost interest in things I usually cared about or 
enjoyed”, or item A 8-“I had constant headache after I started to take my medicine”), 
four items were merged into two (e.g. all items on domain B-“Impact on sexual 
functioning and physical activity” were moved to domain A since these items were 
examples o f medication side effects which domain A actually captured.). Six items 
remained unchanged (e.g. items A l, A4, A6, C l, C2, and D2.) while nine items were 
made redundant (Table 4.2).
The title o f domain 1 (patient perception o f treatment) was reworded to “social 
interaction and emotional behaviour” as the contents indicated patients’ emotional 
reactions to the side effects o f their medicines. The SEIP Version 1 therefore 
comprised a total o f thirty one items covering six socioeconomic-related domains: 1) 
social interaction and emotional behaviour, 2) reactions to cholesterol lowering 
agents, 3) use o f health services, 4) work, 5) change o f medication, and 6) satisfaction 
with medication treatment.
Content Validity
Socio-demographic characteristics of the expert panel members
Twenty individuals o f different professional background were contacted to form the 
members o f an expert panel for the content validation process. Eight were male and 
12 were female. Their professional backgrounds were as follows: twelve community 
pharmacists, four research pharmacists, one cardiovascular specialist nurse, one 
linguistic expert and two cardiac patients.
Quantitative assessment results
Eighteen content validity rating forms were returned from the panel with comments 
and suggestions (Table 4.3). Two pharmacists did not complete but returned the 
forms.
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Table 4.1 Statements compiled during Item generation Phase o f  the SEIP
As a result of medication side effects
1. I feel anxious and tense inside for no obvious reason. 2. 1 have difficulty swallowing the pills
3. I have lost interest in things I usually care about or enjoyed 4. I have problems opening or closing the containers.
5. I feel like all the energy has drained out o f me. 6. 1 have problems getting the medication out o f the containers
7. 1 have horrible nightmares and night terrors. 8. 1 have problems reading the labels on the containers.
9. 1 feel constipated for 4 or 5 days with no pain 10. 1 have stopped taking my medications.
II. 1 feel unpleasantly cold in my hands and feet. 12. 1 have been admitted to hospital
13. I have a troublesome cough that will not go away. 14. I have stayed in hospital for a couple o f days.
15. 1 have a constant headache after taking my medicine. 16. I have called the NHS Direct number for an emergency.
17. I have swollen legs for a couple o f days. 18. 1 have made an urgent appointment with my local surgery.
19. My sexual desire has decreased. 20. 1 have made an urgent appointment with my pharmacist.
21. I have lost interest in sexual activity. 22. I have made an urgent appointment to see my general practitioner.
23. I get tired during sexual activity. 24. I prefer to stay at home than visiting friends and family.
25. I have erection problems. 26. 1 am afraid of going to the cinema, leisure centres, church etc.
27. I have had allergic reactions such as rash , hive etc. 28. 1 think about myself being an embarrassment to people around me.
29. I have had an upset stomach. 30. 1 feel I am a nuisance to my friends.
31. 1 wake up at night to urinate more. 32. 1 have cut down on the amount of my working time.
33. 1 feel dryness in my mouth and the need to drink more water. 34. 1 have taken some days off sick.
35. 1 have gained some weight. 36. 1 am limited in the kind o f work/activities I can do.
37. I have lost weight. 38. I have taken longer to do the work/activities I used to do.
39. I cannot see properly with my eyes. 40. 1 have no memory o f events I did on the previous day.
41. I have suffered hair loss. 42. My speech is slurred.
Table 4.2: SEIP items following Item Reduction Phase (sample items to illustrate the 
__________ process) ________________________________________________________
Domains and items Outcom e of Item Reduction Phase
A. P atient perception o f treatm ent Reworded
A 1. 1 have felt anxious and tense inside for no obvious reason. Unchanged
A2. I have lost interest in things 1 usually cared about or enjoyed. Modified
A3. 1 have felt like all energy drained out o f me Modified
A4. I have had horrible nightmares and night terrors. Unchanged
A5. 1 have felt constipated 4 or 5 days with no pain. Discarded
A6. I have felt unpleasantly cold in my hands and feet. Unchanged
A7. I have had troublesome cough that would not go away. Modified
A8.1 have had constant headache after I started to take my medicine. Modified
A9. My legs got swollen for a couple o f days. Discarded
B. Im pact on sexual functioning and physical activity Discarded
B 1. My sexual desire has decreased. Merge with A
B2. I have lost interest in sexual activity. Merge with A
B3. 1 have had erection problems. Merge with A
B4. I feel calm and peaceful after walking a mile or doing some exercise. Discarded
C. Accessibility to health services Modified
C 1. I have been admitted to hospital Unchanged
C2. 1 have stayed in hospital for a couple o f days. Unchanged
C3. 1 feel embarrassed to talk about the side effect with my doctor. Discarded
C4. 1 feel embarrassed to talk about the side effect with my local pharmacist. Discarded
D. W ork-related  lim itations Reworded
D1. I have cut down on the amount o f my working time. Reworded
D2. I have taken some days off sick. Unchanged
D3. I am limited in the kind o f work /activities 1 can do. Modified
D4. I have taken longer to do the work /activities I used to do. Discarded
E. Im pact on Social activities M erge with D
E l . I prefer to stay at home than visiting friends and family. Discarded
E2. I am afraid o f  going to cinema, leisure centres, church etc. Discarded
F. B rand switching Reworded
F I . I have had allergic reactions such as rash, hive etc. Discarded
F2. I have had stomach upset diarrhoea and felt sick. Discarded
F3. 1 have had problem swallowing the pills. Discarded
F4. I have stopped taking my medications. Discarded
i
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Table 4.3: Expert panel members’ response rate
Participants Quantitative data 
N = 1 8
Qualitative data 
N = 6
Research pharmacists 4 (20%) 1 (16.6%)
Community pharmacists 10(50%) 2 (33.3%)
Cardiac nurse 1 (5%) 1 (16.6%)
English language expert 1 (5%) 0
Cardiac patients 2(10%) 2 (33.3%)
Table 4.4 shows the mean scores o f the five criteria used by the expert panel members 
to rate all the items in the questionnaire. The analysis of each item’s rating score 
generated by eighteen experts showed good expert consistency as regards the items’ 
level o f clarity and relevance. Table 4.5 describes the panel responses to the five 
criteria response scale o f the SEIP. When they were asked whether the title of the 
questionnaire was clear, unambiguous and straightforward, three panel members 
(16.7%) strongly agreed, nine (50.0%) agreed and three (16.7%) disagreed. Three of 
the respondents did not complete this area o f their rating.
On the issue o f completeness o f sentence, the experts were asked to take into 
consideration whether the questionnaire included complete and meaningful sentences 
which were easy to understand without requiring extra time to complete by patients, 
two panel members (11.1%) strongly agreed, eleven (61.1%) agreed and two (11.1%) 
disagreed. Three (16.7%) were not sure how to answer this question and therefore did 
not complete this aspect o f the question.
The experts could not agree on the issue of linguistic clarity o f the questionnaire. 
When they were asked whether the instrument is understandable, simple and clear 
language that is jargon-free, one (5.6%) of them strongly agreed, six (33.3%) agreed 
with this view while eight (44.4%) disagreed and one (5.6%) strongly disagreed. Two 
(11.1%) did not complete this section. In this scenario, half of the expert panel (most 
o f them were practising community pharmacists) thought the title o f the questionnaire
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was too scientific for a lay patient to understand. Suggestions were made for 
improvement and to make the questionnaire simpler.
Table 4.4 The mean scores o f the five criteria used in the validity process of SEIP 31 
items by the expert panel (n=18)____________________________________
Variables Mean (SD)
Clarity Completeness Linguistic clarity Relevance Scaling
Q l 1.80 (0.41) 1.85 (0.37) 2.10(0.31) 2.00 (0.00) 2.00 (0.00)
0 2 1.55 (0.51) 1.65 (0.49) 2.20 (0.52) 2.00 (0.00) 1.95 (0.22)
Q3 1.80 (0.52) 1.90 (0.31) 2.10(0.45) 1.95 (0.22) 1.95 (0.22)
Q4 1.90 (0.31) 1.90 (0.31) 2.00 (0.32) 1.95 (0.22) 1.95 (0.22)
Q5 1.85 (0.49) 1.70 (0.57) 2.15(0.59) 1.90 (0.31) 1.90 (0.31)
Q6 1.95 (0.39) 1.90 (0.31) 2.35 (0.49) 1.90 (0.31) 2.00 (0.00)
Q7 1.75 (0.55) 1.75 (0.55) 2.15(0.59) 1.80 (0.41) 1.90 (0.31)
0 8 1.80 (0.41) 1.85 (0.49) 2.30 (0.57) 1.40 (0.50) 1.95 (0.22)
Q9 1.80 (0.41) 1.85 (0.49) 1.90 (0.45) 1.95 (0.22) 1.85 (0.37)
Q10 1.75 (0.44) 1.60 (0.50) 2.10(0.64) 1.85 (0.37 1.85 (0.37)
O il 1.90 (0.31) 1.90 (0.31) 2.00 (0.46) 1.85 (0.37 1.90 (0.31)
Q12 1.75 (0.44) 1.75 (0.55) 2.10(0.55) 1.90 (0.31) 1.90 (0.31)
Q13 1.95 (0.22) 1.85 (0.37) 2.25 (0.55) 1.90 (0.31) 2.00 (0.00)
Q14 2.05 (0.22) 2.00 (0.32) 2.05 (0.39) 2.00 (0.00) 1.95 (0.22)
QI5 1.95 (0.22) 1.90 (0.31) 2.00 (0.32) 1.95 (0.22) 1.95 (0.22)
Q16 1.80 (0.410 1.75 (0.44) 1.75 (0.44) 1.95 (0.22) 1.75 90.44)
Q17 1.95 (0.22) 1.90 (0.31) 1.95 (0.39) 1.75 (0.45 1.90 (0.31)
Q18 1.75 (0.44) 1.75 (0.44) 1.80 (0.52) 1.90 (0.31) 1.75 (0.44)
Q19 1.95 (0.39) 2.05 (0.22) 2.20 (0.41) 1.75 (0.45) 2.00 (0.00)
Q20 2.00 (0.00) 1.80 (0.52) 2.05 (0.51) 2.00 (0.00) 1.85 (0.37)
Q21 1.95 (0.22) 1.95 (0.22) 1.95 (0.39) 1.85 (0.37 1.95 (0.22)
Q22 1.95 (0.22) 1.95 (0.22) 2.00 (0.00) 1.95 (0.22) 2.00 (0.00)
Q23 1.90 (0.31) 1.90 (0.31) 2.00 (0.32) 2.00 (0.00) 1.90 (0.31)
Q24 1.75 (0.44) 1.75 (0.44) 2.20 (0.41) 1.90 (0.31) 2.05 (0.39)
Q25 1.95(0.22) 1.95 (0.22) 2.10(0.31) 2.05 (0.39) 1.95 (0.22)
Q26 1.95 (0.22) 1.95 (0.22) 2.10(0.31) 1.95 (0.22) 1.95 (0.22)
Q27 2.05 (0.22) 2.00 (0.32) 2.15(0.37) 1.95 (0.22) 1.90 (0.31)
Q28 2.00 (0.00) 1.55(0.51) 2.15(0.59) 1.90 (0.31) 1.70 (0.47)
Q29 1.95 )0.22) 1.80 (0.52) 2.00 (0.46) 1.70 (0.47 1.85 (0.37)
Q30 2.00 (0.00) 1.90 (0.31) 2.05 (0.39) 1.85 (0.37 1.90 (0.31)
Q31 2.00 (0.00) 1.70 (0.57) 2.25 (0.55) 1.90 (0.31) 1.90 (0.48)
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The level o f agreement also varied on whether the included items showed a degree of 
relevance and reflected sample areas of interest to the observed patient population 
.The response rates were as follows: three (16.7%) strongly agreed, thirteen (72.2%) 
agreed and one (5.5%) disagreed.
Table 4.5 Agreement level o f the expert panel to five criteria response scale
Response
option
Number (%)
Clarity Completeness Language Clarity Relevance Scaling
Strongly
agree
3(16.7) 2(11.1) 1 (5.6) 3 (16.7) 2(11.1)
Agree 9 (50.0) 11 (61.1) 6(33.3) 13 (72.2) 14(77.8)
Disagree 3 (16.7) 2(11.1) 8 (44.4) 1 (5.5) 1(5.5)
Strongly
disagree
0 0 1 (5.6) 0 0
Missing
value
3(16.7) 3(16.7) 2(11.1) 1 (5.5) 1(5.5)
Total 18 (100)
Qualitative assessment results
An expert panel meeting was organised after the results o f the quantitative 
assessments had been analysed. Only three out o f the eighteen expert panels were able 
to attend this meeting. Those present were shown the results from the quantitative 
assessments including comments and suggestions that were proposed for further 
deliberations (Table 4.6). The results of the quantitative assessment were further 
discussed among the expert panel members who participated in the discussion 
meeting until consensus was reached and all members agreed on the contents of the 
final version o f the SEIP. During the discussion meeting, it was suggested that a 
broader, more generic title was needed for the instrument if it were to be administered 
to lay patients in general. As it is impossible to assess whether side effects suffered by 
cardiac patients are due to their medication or their medical condition, suggestions
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were made to add a column to ask patients about their thought on the cause of the side 
effects they experience. Several amendments were further made to the questionnaire 
to reflect suggestions made by some expert panels during the panel discussion. Some 
questions were further removed in order to reduce the length of the questionnaire and 
some questions had extra options added or removed from them.
Table 4.6 Comments and suggestions about the questionnaire from some of the expert panel
Expert panel Comments and suggestions
CP 1 
CP 2
CP 2
RP 1 
CP 3
NURSE
The title -  “I feel would put a lot of people off. It is too complicated.
“Although the title of the questionnaire is relevant to the person conducting 
the survey, a member of the general public may not understand the term - 
socioeconomic impact profile. A broader, more general title is needed”.
“The instructions are fine, as it is clear, concise and to the point”
“Title is unlikely to be understood by the less educated”
“Good title for professionals to understand”
“Not too sure if the title (SEIP) will confuse people -  what does it mean? 
Could put people off showing interest in the survey”
“I feel the title is a bit off-putting for the lay person. Why do they need to 
know the title, it is just a questionnaire as far as they are concerned”
“It is not made clear in the paragraph if this is a one-off survey or if there is 
a time scale for repeating it”.
“I feel the scale for income does not go down far enough-what if they earn 
less than £5000 per annum?”
“In the section “use of health services” our patients would probably ring us 
not NHS direct”
“Where it says “what is your condition”- patients may have multiple 
pathology so perhaps it should have been what your cardiac/heart condition 
is?
“Marital status-many people live together so I do not know what they would 
put there”.
CP- community pharmacist, RP -  research pharmacist
The new version o f the SEIP now consisted o f 24 items (Table 4.7). These items 
were grouped into 5 domains: 1) medicated-related problems and socio-emotional 
distress (13 items); 2) impact on healthcare services utility (6); 3) work and
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productivity impacts (3); 4) change in medication (1); and 5) satisfaction with change 
in medication treatment (1).
Table 4.7: Structure o f the new version o f SEIP
SEIP domain No of items
1. Medication-related problems and socio-emotional distress 13
2. Impacts on healthcare services utility 6
3. Work and productivity impacts 3
4. Change in medication 1
5. Satisfaction with change in medication treatment 1
Kappa coefficient
In order to determine the level of agreements among all the participants in the expert 
panel meeting, data obtained from the completed validity rating forms by the panel 
members were coded and analysed using the Statistical Package for the Social 
Sciences (SPSS) version 12. The level of agreement among the six members of the 
panel as determined by Cohen kappa coefficient value was excellent (k = 0.85; P < 
0.0001), supporting the content validity of the instrument (Table 4. 8).
Table 4.8: .e v e l  o f  a g re e m e n t a m o n g  t ie  e x p e r ts  u s in g  k a p p a  s ta tis tic s
No
o f
raters
N o
o f
item s
Percent
o f
raters
K appa
V alue
Standard
E rror
P L ow er 95%  
C onfidence 
Lim it
U pper 95%  
C onfidence limit
6 24 0.93 0.85 0.69 0.0001 0.72 0.98
DISCUSSION
The present study deals with the development o f a specific questionnaire designed to 
assess the impact of medication-related problems on social and economic wellbeing 
of chronically ill patients on cardiovascular drugs. Badia et al. (2007) suggested that
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the main advantage of a specific questionnaire with respect to a generic instrument is 
that the former allows one to assess domains relevant to the impact o f medication side 
effects on patients’ social and economic wellbeing.
In the developmental phase o f the questionnaire, a methodology based on a literature 
review and round table discussion with experts in this area was used, thus yielding 
complementary results that reinforce the robustness o f the data in this study. Other 
authors have used these methodologies as well in the development o f questionnaires, 
with equally positive results (Priesto et al., 2005; Badia et al., 2005).
There was a varying level o f agreement among the expert panel who completed and 
returned the questionnaire. During a panel discussion meeting, the results of the 
quantitative assessment by all o f the eighteen expert panel members were discussed 
and comments were made. From the point o f view o f research pharmacists, the title of 
the questionnaire needed to be more scientific whereas community pharmacists 
thought that the title should be simple for a lay person to understand. According to a 
comment from one o f the community pharmacists, “although the title of the 
questionnaire is relevant to the person conducting the survey, a member of the general 
public may not understand the term socioeconomic impact profile. A broader, more 
general title is needed”. Another community pharmacist commented on the title - “I 
feel the title would put a lot o f people off -  it’s too complicated”.
According to some o f the community pharmacists who completed the assessment 
form, items included in section A (social interaction & emotional behaviours) of the 
questionnaire captured common side effects o f  most cardiovascular drugs and 
therefore were appropriate to be included. However, it was agreed to merge section B 
(reactions to cholesterol lowering agents) with section A (social interaction & 
emotional behaviour). The reason for this was that items on cholesterol lowering 
agents related to side effects of statins, which are also cardiovascular drugs. 
Moreover, section A (social interaction & emotional behaviours) de facto focuses on 
side effects o f most cardiovascular drugs.
In erms o f the psychological effects o f medication, a patient on a new cardiovascular 
drug for example, a beta blocker, may be told by his general practitioner o f possible
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side-effects o f such a medicine before it is prescribed, thus a suggestion was made to 
add an additional column to section A (social interaction & emotional behaviour) to 
ask patients whether they think the side-effects they experience are due to their 
current medication, or their medical condition. Regarding the content validity, there 
was a varying level o f agreement among the experts and the patients who rated each 
item and the questionnaire in total. The majority o f the experts agreed that the content 
of the questionnaire was clear and straightforward, relevant and reflected sampled 
areas o f interest to the observed population. However, strong objections were made to 
the linguistic clarity. Improvements were therefore made on this area, although the 
majority o f  those objections on linguistic clarity came from community pharmacists, 
thus there could be some professional bias in their comments. However, the statistical 
analysis o f the content validity results demonstrated that the questionnaire was in 
concordance with its task to measure what it was actually designed to do, having the 
required focus and emphasis for what was being measured.
Summary
•  The SEIP is the first instrument to be used to evaluate the socioeconomic 
impact o f medication-related problems among cardiovascular patients
• Both the results o f its qualitative and quantitative assessments by the expert 
panel have demonstrated that the instrument possesses favourable 
measurement properties by supporting its content validity.
•  Therefore, to enhance wider acceptability of the instrument, further 
psychometric tests will be carried out among cardiovascular patients in 
community pharmacies to further establish its validity (factor analysis), 
reliability and applicability.
CHAPTER 5
Construct Validation of the Socioeconomic 
Impact Profile (SEIP) -Factor Analysis and 
Internal Consistency
INTRODUCTION
A measuring instrument is usually designed with certain underlying constructs in 
mind. If it were thought for example, that patients may be anxious and depressed 
about their condition after drug treatment, and that this would affect their social and 
economic wellbeing, one might wish to include an assessment of anxiety or 
depression (Karimova and Martin, 2003). However, it is generally accepted that 
concepts such as anxiety or depression cannot be measured in any direct, simple and 
objective manner using a single question (Zigmond and Snaith, 1983). Instead, one or 
more questions must be composed with a view to tapping into the presumed 
underlying concept o f anxiety, which is regarded as a "latent construct” that can only 
be indirectly measured.
In order to measure the social and economic wellbeing o f patients and its correlation 
with medication-related side effects, an instrument is needed with sufficient 
measurement properties. It is hoped that this chapter will examine the most important 
property, factor analysis o f the SEIP.
Factor analysis
Factor analysis is a multivariate analysis method which aims to explain the correlation 
between a large set o f variables in terms o f a small number of underlying independent 
factors. It is used to explore the relationships between items o f a new questionnaire 
and to assess the degree to which items measure the same concept. It is assumed that 
each o f the variables measured depends upon the underlying factors but is also subject 
to random errors. As a wider component o f construct validity, factor analytic 
technique has been well documented in chapter two o f this thesis. In research, factor 
analysis is primarily engaged to reduce a large number o f variables to a smaller 
number o f clusters while retaining maximum spread among experimental units 
(Pallant, 2002). Many researchers have shown that this method can be used to provide 
an operational definition for an unobserved, hypothetical construct by using observed 
variables, or to test a theory about the nature o f underlying variables (Ang and Huan, 
2006).
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Exploratory factor analysis (EFA)
Factor analysis can be either exploratory or confirmatory. Exploratory factor analysis 
(EFA) groups together variables that are intercorrelated. According to Finch (2006), 
EFA is used when the researcher is primarily interested in trying to identify potential 
factors underlying a set of items, but may not have a strong a priori model that he or 
she would like to test. Tabachnick and Fidell (2001) pointed out that this kind of 
factor analysis is usually used in the early stages o f research when hypothesis about 
relationships in a reduced data set can be generated.
On the other hand, Fayers and Hand (1997) explained that the fundamental objective 
o f exploratory factor analysis (EFA) is to group together those variables which are 
highly correlated with each other but are also relatively uncorrelated with other 
variables; these groups are then regarded as potential evidence o f an underlying 
structure. Fayers and Hand (1997) also stated that EFA has been widely used as a 
form o f construct validation. That it to say, if an instrument is believed to be 
measuring several different underlying constructs (such as anxiety, depression, or 
emotional distress) then one would expect it to be possible to group the questionnaire 
items into the corresponding clusters, solely on the basis of the item-to-item 
correlations. Factor analysis should therefore produce evidence of the “factor 
structure” o f the items. If the expected factors are produced, “construct validity” is 
claimed for the instrument (Fayers and Hand, 1997).
Confirm atory factor analysis (CFA)
Confirmatory factor analysis (CFA) tests the goodness-of-fit o f a pre-specified factor 
model (Fayers and Hand, 1997). It is considered by many proponents o f Structural 
Equation Modelling (SEM) to be a far more appropriate method for construct 
validation (MacCallum et al., 1993; Fayers and Hand, 1997; Kline, 2005). These 
authors further stated that CFA enables testing o f adequacy of fit o f the data to the 
postulated underlying construct. Confirmatory factor analysis (CFA) is a more 
complex set o f techniques used later in the research processes to confirm hypothesis 
about the structure o f underlying set o f variables. In this case, variables are 
specifically chosen to reveal underlying structural processes. CFA can also be applied
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in a situation where specific model linking items to factors is to be tested (Finch, 
2006).
In this present study, EFA will be applied as a means o f exploring the structure of the 
SEIP. EFA will also be used to confirm that the instrument appears to possess an 
appropriate structure (construct validity), and to help further develop the instrument 
by revealing items that may be dropped from the questionnaire because they 
contribute little to the presumed underlying factors.
M ETHODS
The socioeconomic Impact profile (SEIP) was pilot tested among 175 cardiovascular 
patients on repeat prescriptions from five community pharmacies across England and 
Wales. Patients’ consent was sought while waiting for their repeat medications in 
these pharmacies. Those who agreed to take part were given the questionnaire to 
complete and some who could not wait to fill in the questionnaire in the pharmacy 
agreed to return the completed questionnaire to the pharmacy either by post or in 
person.
Exploratory factor analysis
The returned questionnaires were coded and exploratory factor analysis was 
performed on the 24 -item  SEIP using SPSS 12.0 statistical software. Since all SEIP 
questions are worded positively, there was no need to invert any negatively worded 
questions before carrying out the factor analysis. Therefore a high score for any item 
represents an excellent health state (improvement with increasing score). All items 
were subjected to Principal Components Analysis (PCA) for item reduction. The 
criteria chosen to determine that an extracted factor accounted for a reasonably large 
proportion o f the total variance was based on an eigenvalue greater than 1. The factor 
analytic techniques used in this chapter have been described extensively in chapter 
two.
A maximum likelihood factor extraction procedure was chosen since this method of 
factor condensation is the most widely used approach in published studies (Martin and 
Thompson, 2000). Orthogonal (Varimax) rotation was performed initially to aid the
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interpretation o f the components and the results were compared to an oblimin non- 
orthogonal factor rotation procedure due to the possibility that extracted factors are 
likely to be correlated (West, 1991). Determination o f a significant item-factor 
loading was set at a coefficient level of 0.30 or greater, this level based on a rationale 
o f generating a more complete interpretation o f the data set, this being a level 
consistent with the published work in this area (Martin and Thompson, 2000; 
Karimova and Martin, 2003; Mccue et al., 2003). Extracted factors were tested for 
internal reliability. The significance o f the association between the factors themselves 
and between the factors and responses to certain questions o f the questionnaire was 
assessed using the non-parametric test bivariate correlations (Spearman’s rho), where 
appropriate.
Factor extraction
The pilot version o f the socioeconomic impact profile (SEIP) contained following 
content validity, five sections totalling to 24 items. All the 24 items were subjected to 
factor extraction using SPSS 12.0 for windows. Data generated were assessed to 
ensure that they were suitable for factor analysis. The correlation matrix generated 
was inspected for coefficients o f 0.30 and above, the value of the Bartlett’s test of 
sphericity (Bartlett, 1954) and the Kaiser-Meyer-Olkin (KMO) measure o f sampling 
adequacy (Kaiser, 1970; Kaiser, 1974) calculated were checked for their level of 
significance.
Three statistical rules were taken into consideration to determine the number of 
factors to extract; 1) Kaiser’s criterion, 2) scree test and, 3) parallel analysis. Kaiser’s 
criterions should display components with Eigen values o f 1 or more in order to be 
considered. In the Scree plot generated by SPSS, sharp demarcations in the shape of a 
plot were looked for and only components above these points were retained for 
further exploration (Catell, 1966). Parallel analysis was performed by using Monte 
Carlo PCA for parallel analysis. With this technique, a list o f Eigen values generated 
in Total Variance Explained table were used along with the number of variables 
analysed (in this case 24) and the number of subjects in the sample data (in this case 
160). Also the number o f replications was specified at 100 as a default. The 
programme further generated 100 sets of random data o f the same size as the original
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real data file (24 variables x 160 cases). The average Eigen values for these 100 
randomly generated samples were calculated. The first Eigen value obtained in SPSS 
with the corresponding first value from the random results generated by parallel 
analysis was systematically compared. SPSS factor values larger than the criterion 
values from parallel analysis were retained, while the least values were rejected.
Factor rotation
Rotation of the data was performed after the numbers o f factors had been determined. 
This was done by “rotating” the factors in order to present the pattern of loadings in a 
manner that would be easier to interpret. The varimax rotation technique was initially 
used and the results were then compared to oblique (Direct Oblimin) rotation. The 
outputs generated were checked for interpretation.
Internal consistency reliability test o f the extracted factors
The internal consistency o f items within a factor was estimated using the reliability 
coefficient (Cronbach’s coefficient alpha). This is to indicate the strength of the 
relationship o f each item within the factor. Ideally, the Cronbach alpha coefficient 
should be above 0.7 which would imply that 70% o f the measured variance is reliable 
and 30% is owing to random error. In some cases however, due to the sensitivity of 
the values to the number o f items in a scale, the Cronbach coefficient values may be 
lower than expected (Pallant, 2002). In this case, it may be more appropriate to report 
the mean inter-item correlation for the items. An optimal range for the inter-item 
correlation o f 0.2 to 0.4 is commonly recommended.
RESULTS 
Socio - demographic characteristics
A total number o f 160 / 175 (91.4%) patients from five community pharmacies 
completed and returned the questionnaire. The age range was 37 to 81 with a mean of 
55.6. Table 5.1 shows the socio-demographic characteristics of those who participated 
in the pilot study. Seventy-six (47.5%) were male, 90 (56%) were mainly on 
antihypertensive drugs and the mean duration o f their medical condition was 64.7 
months. 122 (76.3%) were employed and over 53% were earning between £20,000 
and £30,000 annually.
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Table 5.1 Socio-dem ographic characteristic o f  the study participants
Variables F requency(n ) Percentage (% )
Sex
Male 76 47.5
Female 84 52.5
Medical condition
Hypertension 90 56.3
Heart failure 5 3.1
High cholesterol 9 5.6
Angina 14 8.8
Heart attack 11 6.9
Diabetes 5 3.1
Hypertension and diabetes 18 11.3
Hypertension and others 8 5.0
Education
Primary school 1 0.6
High school 99 61.9
University degree 60 37.5
M arital status
Single 3 1.9
Married 136 85.0
Living with a partner 5 3.1
Separated 4 2.5
Divorced 5 3.1
Widowed 7 4.4
Employment status
Employed 122 76.3
Retired due to health 1 0.6
Retired not due to health 33 20.6
Employed and receive income support benefit 3 1.9
Employed and receive other social support 1 0.6
Annual income
£10.000 < E < £20.000 8 5.0
£20,000 < E <£30.000 86 53.8
£30.000 < E < £40.000 40 25.0
E > £40.000 26 16.3
i
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Correlation and Component Matrix results
Generation o f the correlation matrix for the 24 items o f the SEIP was followed by a 
check for evidence of coefficients greater than 0.30. Tabachnick and Fidell (2001) 
suggested that if few correlations above this level were found, then factor analysis 
may not be appropriate. SPSS also generated two statistical measures to help assess 
the factorability o f the data: Bartlett's test o f sphericity and the Kaiser-Meyer-Olkin 
(KMO) measure o f sampling adequacy. According to Tabachnick and Fidell (2001), 
the Bartlett's test o f sphericity should be significant (P< 0.05) for the factor analysis 
to be considered appropriate, and the KMO index should range from 0 to 1, with 0.6 
suggested as the minimum value for a good factor analysis.
In this study, the Kaiser-Meyer-Olkin measure o f adequacy value was 0.82 (Table
5.2), exceeding the recommended value o f 0.60 and the Bartlett’s Test o f sphericity 
reached statistical significance (P < 0.001). The correlation matrix result for the 160 
completed questionnaires o f the Socioeconomic Impact Profile (SEIP) revealed the 
presence o f some coefficients o f 0.3 and above (Table 5.3) thereby fulfilling one of 
the criteria for suitability o f factor analysis. Variables that do not have a correlation of 
greater than 0.30 should be considered for removal from subsequent factor analysis. 
Although values greater than 0.3 in the component matrix were accepted as 
significant, in this factor analysis, 19 out o f 24 o f the questions produced values > 
0.40 indicating the robustness o f the solution.
Table 5.2 Assessment o f the suitability o f items in the SEIP for factor analysis
Kaiser-Meyer-Olkin Measure of Sampling Adequacy. 0.82
Bartlett's Test o f Sphericity Approx. Chi-Square 
Df
P value
1070.87
276
0.0001
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Table 5 3  Correlation matrix* between the 24- items of the initial version of the SEIP
Al A2 A3 A4 A5 A6 A7 A8 A9 A10 A ll AI2 AI3 Bl B2 B3 B4 B5 B6 Cl C2 C3
Al 1.00
A2 0.41 1.00
A3 0.42 0.45 1.00
A4 0.73 0.55 0.72 1.00
A5 0.70 0.31 0.32 0 26 1.00
A6 0.81 0.48 0.72 0 77 0 44 1.00
A7 0.63 0.50 0.99 041 0 4.1 0.98 1.00
A8 0.52 0.45 0.52 0 19 0 40 0.65 -0 08 1.00
A9 0 25 -0 1.1 -0 02 0.11 0 29 0 14 0 27 -0 10 1.00
AI0 0.40 0.50 0.36 0.36 0.7| 0 18 -0.38 0.77 00 6 1.00
A ll 0 29 0.57 0.56 0.39 -0.81 0.74 -0 20 0 04 O il 0.72 1.00
AI2 0 28 -0 04 0 26 0 18 -0 24 0JI -0.33 0 25 0 2 7 -0 29 02 7 1.00
AI3 0.89 0.81 0.37 0.57 0.39 0.36 -0.38 O il 0 24 0.50 0.70 0 15 1.00
Bl 0.41 0.45 0.35 0.41 0.42 0 10 0.70 0.58 -0 06 0.44 -0.35 -0 27 0.71 1.00
B2 0.86 0.64 0.42 -0.77 0.48 0 18 0.31 0.87 -0.32 -0.30 -0.94 -0 25 0.67 0.33 1.00
B3 0.75 0.91 0.76 0.36 -0.33 0.48 0.38 -0.49 0.35 -0 15 -0.47 -0.35 0 15 0 18 0 13 1.00
B4 0.71 0.44 0.33 0.72 -0.60 0.56 -0 94 0.69 0 25 0.89 0.32 0 29 0.30 0.90 0..45 0.49 1.00
B5 0.53 0.88 0.43 0.89 -0.39 0.88 -0 12 0.72 02 2 0.99 0 25 0 29 0 29 0.76 0 14 0.84 0.67 1.00
B6 0 29 -023 -0 22 -0.30 0 20 -0 19 -0.13 -027 031 -0 27 0 12 0.38 0 20 0 27 0 13 0.37 0 08 0.63 1.00
Cl 0 19 0.32 0.39 -0.37 0.70 0 0 9 0.90 •0.68 02 2 •0.48 -0.51 -0 25 0.71 0.32 0.86 0.31 0.54 0.52 0 27 1.00
C2 -0.68 0.78 0.31 -0.71 0.71 0.36 0 16 0 0 6 -0 19 -0.46 -0.43 -0 12 0 11 0..3I 0.52 0 19 0.68 0.42 0.38 0.82 1.00
C3 0 2 9 0.83 0.35 -0.60 0 26 0.86 0.39 0.38 -0 25 -0 28 -0.89 -0 15 0.49 0.43 0.63 0.71 0 23 0.73 0.30 0.44 0.57 1.00
D -0 12 -0 24 0 25 -0.39 0 29 021 -O il -0 17 0 28 -0 22 -0 15 0 12 0..38 0 22 0.37 0.30 0 26 021 0 17 0.30 0 13 0 25
E 0 2 8 02 5 0 18 0 2 0 -0 12 -0.33 0 12 0.23 -0.30 -0 16 -0 19 -0 26 0 14 0.23 02 3 02 2 024 005 0 II 0 2 8 0.45 0 27
*Spearman rank correlation coefficient, rs
K
1.00
1The matrix produced by factor analysis is rotated to give the maximum number of 
items loading on the minimum number of factors. Furthermore, the results of the 
initial extraction with Principal Components Analysis (PCAs) revealed nine 
components with Eigen values greater than 1 with percentage of variance 14.69, 
12.82, 8.04, 6.46, 6.19, 5.74, 4.87, 4.48 and 4.24 respectively (Table 5.4). These nine 
components explain a total of 67.52 percent o f the variance (see Cumulative % 
column). The eigen values determine which components remain in the analyses 
because those factors with an eigen value of less than one are excluded.
Table 5.4 Principal Component Analysis describing the Total Variance Explained
Component Initial Eigen values Extraction Sums of Squared Loadings
Total
% o f
Variance
Cumulative
% Total
% o f
Variance
Cumulative
%
1 3.53 14.69 14.69 3.53 14.69 14.69
2 3.08 12.82 27.51 3.08 12.82 27.51
3 1.93 8.04 35.55 1.93 8.04 35.55
4 1.55 6.46 42.01 1.55 6.46 42.01
5 1.48 6.19 48.19 1.48 6.19 48.19
6 1.38 5.74 53.93 1.38 5.74 53.93
7 1.17 4.87 58.80 1.17 4.87 58.80
8 1.07 4.48 63.28 1.07 4.48 63.28
9 1.02 4.24 67.52 1.02 4.24 67.52
10 0.96 3.98 71.49
11 0.84 3.51 75.00
12 0.79 3.27 78.28
13 0.70 2.93 81.21
14 0.68 2.84 84.04
15 0.61 2.54 86.58
16 0.56 2.34 88.92
17 0.52 2.16 91.08
18 0.48 1.98 93.06
19 0.38 1.57 94.63
20 0.33 1.38 96.00
21 0.31 1.29 97.29
22 0.26 1.10 98.39
23 0.22 0.92 99.31
24 0.17 0.69 100.00
Extraction M ethod: Principal C om ponent Analysis.
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Table 5.5 below shows component matrix with loadings of each of the items on nine 
components. The factors extracted account for a certain proportion of the total test 
variance, i.e. the combined variance demonstrated by all the items in the 
questionnaire. It is visible from this table that most o f the items loaded quite strongly 
(above 0.30) on the first six components. SPSS suggested that any loadings above this 
value should therefore be considered for further exploration
Table 5.5 Component Matrix (nine components extracted*) of SEIP
Component
1 2 3 4 5 6 7 8 9
C3. Work limitation 0.72 0.09 0.02 0.12 -0.15 0.28 -0.07 -0.03 -0.12
A3. Feel of energy loss 0.67 0.27 0.05 -0.09 0.11 -0.35 -0.02 0.18 0.00
A2. Loss of interest 0.62 -0.01 0.38 -0.12 0.17 -0.16 -0.17 0.03 0.10
C2. Day off due to sickness 0.60 -0.16 0.18 0.42 0.42 0.05 0.26 -0.06 0.11
Cl. Reduce workload due to 0.56 -0.13 0.32 0.24 0.06 0.05 0.42 -0.06 0.36
fatigue
B4. Appointment with GP -0.24 0.79 0.22 0.17 0.17 0.01 0.11 -0.06 0.07
B5. Appointment with practice 
nurse
-0.09 0.72 0.26 0.06 0.10 -0.15 -0.18 0.03 -0.04
A12. Fatigue -0.33 0.49 0.33 0.39 0.19 0.24 0.00 -0.03 0.07
A4 N ightmares and terror 0.03 0.48 -0.13 -0.40 0.00 0.26 0.17 -0.09 0.18
A6. Cough 0.23 0.47 0.15 0.01 -0.12 -0.18 -0.04 -0.01 -0.31
A13. Memory loss -0.03 0.46 -0.10 0.03 -0.17 -0.01 -0.13 -0.40 0.33
E. Satisfaction 0.31 -0.37 0.20 -0.35 0.32 0.31 -0.07 -0.19 0.03
Bl. Hospital admission 0.38 0.35 -0.64 0.18 0.07 -0.19 0.05 -0.03 -0.04
A5. Cold in hands and feet 0.33 0.21 -0.54 0.20 -0.17 0.36 -0.02
0.20 0.19
D. Medication change -0.05 -0.03 0.16 0.49 -0.42 -0.15 -0.43 0.06 0.26
Al. Anxious and tense 0.39 0.33 0.35 -0.40 -0.04 -0.03 -0.31 0.21 -0.04
B3. NHS Direct call 0.35 0.16 0.33 -0.23 -0.53 -0.00 0.15 -0.13 0.04
A7. Headache 0.47 -0.09 -0.02 -0.06 -0.50 0.14 0.23 -0.02 -0.21
A8. Loss of sexual drive 0.30 0.31 -0.34 -0.18 0.17 0.51 -0.37 -0.02 0.14
A10. Slurred speech 0.12 0.39 -0.42 -0.27 0.24 -0.48 0.29 -0.01 0.05
A9. Erection problem -0.12 0.33 0.05 0.06 -0.35 0.15 0.39 0.38 -0.02
B6 Enquiry with pharmacist -0.12 -0.04 0.08
-0.09 0.19 0.12 0.00 0.75 0.16
B2. Hospital stay 0.45 0.03 -0.14 0.40 0.17 0.07 -0.15 0.02 -0.52
All. Pain in calf -0.33 0.33 0.22 -0.06 0.13 0.38 0.21 -0.09 -0.38
‘ Extraction Method: Principal Component Analysis.
i
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Scree test
Many studies have shown that too many components (factors) are often extracted 
using the Kaiser criterion (Tabachnick and Fidell, 2001), it is therefore recommended 
to also look at the Scree plot generated by SPSS. As described in chapter two, scree 
test was another approach that was used in deciding the number o f factors to retain. 
According to Taberchnick and Fidell (2001), this method involved plotting each of 
the eigen values of the extracted factors and inspecting the plot to find a point at 
which the shape o f the curve changes direction and becomes horizontal. Cattel (1966) 
recommended retaining all factors above the elbow, or break in the plot, as these 
factors contribute the most to the explanation o f the variance in the data set.
In this result, a study o f the scree plot showed breaks after the third, the fourth and 
seventh components (Figure 5.1). The demarcation after the fourth component was 
sharper than the demarcation at the seventh component. An evaluation o f scree plot 
results therefore suggested that either three or six factors could be retained for further 
exploration.
Parallel analysis
Parallel analysis o f the results was also performed and the initial results (Table 5.6) 
supported the decision from the screeplot to retain six components; the first six 
factors were the only ones with Eigen values exceeding the corresponding criteria 
values for a randomly generated data matrix o f the same size (24 variables x 160 
respondents). Guided by the scree plot, and parallel analysis results, six factors 
initially extracted yielded Eigen values o f 3.53 (14.7%), 3.08 (12.8%), 1.93 (8.0%), 
1.55 (6.5%), 1.48 (6.2%). and 1.38 (5.7%), explaining 53.9% of the total variance. 
Comparing the eigen values from the parallel analysis results with the eigen values 
from the PCA, the first six eigen values from the PCA were higher than from the 
parallel analysis. These six components were therefore retained for further 
explorations (Table 5.7).
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Figure 5.1 Scree Plot for the Socioeconomic Impact Profile
Scree Plot
Eigenvalue
12 13 14 15 16 17 18 19 20 21 22 23 247 8 9 10 111 2 3 5 64
Component Number
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Table 5 .6  Parallel analysis o f  the SEIP using Monte Carlo PCA method
Eigenvalue Random Eigenvalue Standard Dev
1 1.78 0.07
2 1.65 0.06
3 1.55 0.05
4 1.46 0.04
5 1.39 0.03
6 1.32 0.04
7 1.26 0.03
8 1.20 0.03
9 1.14 0.03
10 1.09 0.03
11 1.04 0.03
12 0.98 0.03
13 0.93 0.03
14 0.88 0.03
15 0.83 0.02
16 0.79 0.02
17 0.75 0.03
18 0.71 0.03
19 0.66 0.03
20 0.62 0.03
21 0.57 0.03
22 0.53 0.03
23 0.48 0.03
24 0.41 0.03
Factor rotation and its interpretation
Following determination o f the number of factors, the next step was an attempt to 
interpret them. In this case, Varimax and Direct Oblimin rotation methods were used. 
Initially, six factors were identified from the rotated factor. These factors accounted 
for 53.9% of the total variance and are shown in Table 5.8 along with the percentages 
of total variance explained. The first factor accounted for the highest proportion of 
variance (11.7%) o f any o f the factors and this is because this type o f analysis often 
produces a general factor which in this case includes two subgroups (statins and its 
impact on healthcare service utilization). Factor two accounted for 10.7% of the total 
variance explained. Factor three accounted for 9.2% o f the Total Variance Explained, 
factor four = 8.3%, factor five = 7.8% and factor six accounted for 6.3%. It is
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important to note that the cumulative total variance explained (53.9%) does not 
change after rotation, just the pattern o f distribution among the six factors in 
comparison with Table 5.4 described earlier.
Table 5.7 C om parison  o f  Eigen values from  principal com ponen ts analysis (PC A ) and 
the co rresp o n d in g  criterion  values obtained  from  parallel analysis._____________________
Component number Actual Eigen value 
from PCA
Criterion value 
From parallel 
Analysis
Decision
1 3.53 1.78 Accept
2 3.08 1.65 Accept
3 1.93 1.55 Accept
4 1.55 1.46 Accept
5 1.48 1.39 Accept
6 1.38 1.32 Accept
7 1.17 1.26 Reject
8 1.07 1.19 Reject
9 1.02 1.14 Reject
Table 5.8 Total variance explained for each factor based on 24 item SEIP
Factor Rotation Sums o f Squared Loadings
Total % of Variance Cumulative %
1 2.81 11.69 11.69
2 2.56 10.66 22.34
3 2.21 9.22 31.56
4 1.99 8.28 39.84
5 1.88 7.83 47.67
6 1.50 6.26 53.93
Extraction Method: Principal Component A nalysis.
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Varimax rotation of the six-factor solution of the SEIP
In the Rotated Component Matrix table (Table 5.9), there were factors with a number 
o f strong loadings above 0.40 and most variables loaded substantially on component 1 
to 4 with fewer cross loadings on some components.
Table 5.9 Varimax Rotated Component Matrix (a) for SEIP (Pairwise method)
Component
1 2 3 4 5 6
Appointment with GP 0.87
Fatigue 0.77
Appointment with practice nurse 0.74
Pain in calf 0.49
Memory loss 0.33
Erection problem
Day off due to sickness 0.87
Reduce workload due to fatigue 0.64
Loss of interest 0.55 0.45
Hospital stay 0.54 0.30
Work limitation 0.49 0.41 0.46
NHS Direct call 0.75
Anxious and tense 0.64
Headache 0.50 0.30
Cough 0.35 0.36
Cold in hands and feet 0.79
Loss of sexual drive 0.66 0.40
Slurred speech 0.81
Hospital admission 0.53 0.63
Feel of energy loss 0.44 0.43 0.53
Medication change -0.64
Satisfaction -0.31 0.59
Nightmares and terror 0.34 0.35
Enquiry with pharmacist
Extraction M ethod: Principal C om ponent Analysis. Rotation M ethod: V arim ax w ith K aiser N orm alization.
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To allow the six components to be correlated with one another, it was decided to 
perform Oblimin rotation-another rotation technique frequently used. Generally, it is 
very vital to consider three tables from the Oblimin rotation output: Pattern Matrix, 
Structure Matrix and Component Correlation Matrix (Pallant, 2001). However, in this 
study, the Direct Oblimin rotation did not support the expected six dimensions since it 
failed to generate any values. Therefore Three-factor solution as another option was 
considered for exploration.
The Rotated Component Matrix and the Total Variance Explained of the three 
components are presented in Tables 5.10 and 5.11, respectively. Table 5.10 shows 
that factor 1 is accounted for 13.2% of the total variance explained while factor 2 and 
3 explain 12.5% and 9.9% respectively o f the total variance. The factor pattern / 
structure coefficients for the three components are shown in table 5.12 and 5.13 
respectively while table 5.14 shows its Component Correlation Matrix. The Total 
Variance Explained describes how the deviation from the mean responses can be 
explained in terms o f each o f the components defined in the Pattern Matrix. Thus, 
13.17% o f the total variance (deviation from the mean) o f correlations between items 
can be explained by Component 1, 12.52% of the total variance can be explained by 
Component 2, and 9.86% o f the total variance can be explained by Component 3.
Table 5.10 Three factors o f the SEIP with its total variance explained
Factor Rotation Sums of Squared Loadings
Total % of Variance Cumulative %
1 3.16 13.17 13.17
2 3.01 12.52 25.69
3 2.37 9.86 35.55
Extraction M ethod: Principal C om ponent Analysis.
The interpretation of the rotated component matrixes o f the three factors by varimax 
method in Table 5.11 is similar to the six extracted factor solutions on Table 5.9. 
There are strong loadings on the three components with very few cross loadings. The 
first seven items, under Component 1 indicate medication side effects and impacts on 
productivity. The issue o f productivity loss is significant in this component, possibly
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because many cardiovascular patients with medication-related side effects may be 
prone to taking time off work as a result.
Table 5.11 R otated C om ponent M atrix  (a) o f  the th ree ex tracted  com ponents
Component
1 2 3
Loss of interest 0.73
Work limitation 0.64 0.32
Feel o f energy loss 0.63 0.34
Reduce workload due to fatigue 0.63
Day off due to sickness 0.60
Anxious and tense 0.53 0.32
NHS Direct call 0.48
Headache 0.39
Hospital stay 0.33 0.31
Appointment with GP 0.85
Appointment with practice nurse 0.77
Fatigue 0.63
Pain in calf 0.45
Cough 0.31 0.43
Memory loss 0.40
Nightmares and terror 0.40
Satisfaction 0.34 -0.36
Erection problem 0.35
Hospital admission 0.82
Cold in hands and feet 0.67
Slurred speech 0.54
Loss o f sexual drive 0.52
Medication change
Enquiry with pharmacist
Extraction M ethod: Principal C om ponent Analysis. Rotation M ethod: V arim ax with K aiser Norm alization, 
a = Rotation converged in 5 iterations.
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The second component may be considered as impact o f medication side effects on 
healthcare service utilization while the third component may relate to side effects to 
antihypertensive drugs and its impact on hospital admission. It is also visible that two 
items did not load on any o f the components (medication change, and enquiry with 
pharmacist). The reasons for these are unclear. Further exploration is therefore 
required to confirm their removal from the questionnaire.
The Pattern Matrix (Table 5.12) showed similarity to the Rotated Component Matrix 
(Table 5.11) provided in the Varimax rotation solution. The value o f a pattern matrix 
is that it allows grouping of variables into like elements to compare with each other. 
The factor loadings o f each o f the items were comparable to the Varimax rotation 
solution and could be interpreted in the same way. This standardized correlation 
matrix shows three main clusters o f factors, grouping together factors that show 
common correlations to each other and to other factors. To further examine the 
Pattern coefficients o f the three components extracted, seven out o f eleven items on 
factor 1 possessed high factor loadings (above .40). Factor loadings < 0.40 were 
suppressed to build a tighter set o f fewer variables. Likewise, half o f the items loaded 
strongly on factor 2 while all items on factor 3 yielded negative factor pattern 
coefficients. It should also be noted that the sign of the loading indicates the direction 
o f the relationship between the factor and the variable.
Overall, 35.6% o f the expressed variance was contained in these three components. 
The results o f  the Pattern matrix further confirmed the assumption that the two items 
that did not load on any o f the factors should be removed. (“Medication change” and 
“Enquiry with pharmacist”). The Structure Matrix (Table 5.13) was slightly similar in 
the sense that eighty percent o f all items on factor 1 were strongly loaded, likewise 
with factor 2 where seven out o f nine items possessed factors above 0.40. Half of all 
items on factor 3 were strongly loaded
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Table 5.12 Pattern Matrix (a) o f  the three extracted com ponents
Component
1 2 3
Loss o f interest 0.74
Reduce workload due to fatigue 0.63
Work limitation 0.62
Feel o f energy loss 0.62
Day off due to sickness 0.60
Anxious and tense 0.55 0.34
NHS Direct call 0.50
Headache 0.38
Satisfaction 0.34 -0.34
Hospital stay 0.30
Appointment with GP 0.85
Appointment with practice nurse 0.77
Fatigue 0.64
Pain in calf 0.46
Cough 0.32 0.44
Memory loss 0.39
Nightmares and terror 0.39
Erection problem 0.35
Hospital admission -0.82
Cold in hands and feet -0.67
Slurred speech -0.54
Loss o f sexual drive -0.51
Medication change
Enquiry with pharmacist
E xtraction M ethod: Principal C om ponent Analysis. Rotation M ethod: O blim in with K aiser N orm alization, 
a Rotation converged in 8 iterations.
What is unique about this analysis is that from the Component Correlation Matrix 
(Table 5.14), the values generated showed that the correlation between the three 
components was quite low (-0.08, -0.14 and -0.06), confirming the assumption that 
the three components were not related (it should be noted that for the components to 
be strongly correlated, the values would have to be above 0.30).
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Table 5.13 Structure Matrix o f  the extracted three com ponents
Component
1 2 3
Loss o f interest 0.72
Work limitation 0.66 -0.36
Feel of energy loss 0.65 -0.39
Reduce workload due to 
fatigue 0.63
Day off due to sickness 0.61
Anxious and tense 0.52
NHS Direct call 0.47
Headache 0.41
Hospital stay 0.35 -0.33
Appointment with GP 0.85
Appointment with practice 
nurse 0.76
Fatigue 0.63
Pain in calf 0.45
Cough 0.42
Memory loss 0.41
Nightmares and terror 0.41 -0.31
Satisfaction 0.34 -0.38
Erection problem 0.35
Hospital admission -0.82
Cold in hands and feet -0.67
Slurred speech -0.54
Loss o f sexual drive -0.53
Medication change
Enquiry with pharmacist
Extraction M ethod: Principal C om ponent Analysis. Rotation M ethod: O blim in w ith K aiser N orm alization.
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Table 5,14 C om ponen t C orre la tion  M atrix  o f  oblim in ro tation  for the three com ponents 
Component 1 2 3
1.00 -0 .0 8 -0 .1 4
2 -0 .0 8 1.00 -0 .0 6
3 -0 .1 4 -0 .0 6 1.00
With regards to this three-factor solution, items from '‘domain one” o f the instrument, 
for instance, had factor Pattern / Structure coefficients associated equally with Factors 
1, 2 and 3. Domain two items Pattern / Structure coefficients were also associated 
with Factors 1, 2 and 3; whereas domain three items factor Pattern / Structure 
coefficients were linked with only Factor 1. These results therefore suggested that no 
clear domain emerged from the factors due to the large number of factor Pattern / 
Structure coefficients (>0.40) being associated simultaneously with more than one 
factor. Items which did not load significantly on any factor (i.e. F >0.40) were 
assessed further using the internal consistency o f the extracted factors.
The internal consistency of the extracted factors
After thorough consideration, it was decided to further explore the three factor 
solutions previously extracted because o f strong loadings of items on them. Internal 
consistency o f the extracted factors was also examined. Items “appointment with GP”, 
“ fatigue”, appointment with practice nurse” and “pain in c a lf ’ were strongly 
associated with factor 1 (Table 5.15).
The statements with low values (less than 0.30) o f item-total correlation were 
considered for deletion from the scale because this may be an indication that the item 
is measuring something different to the scale as a whole and as such can reduce the 
value o f alpha coefficient. Consequently, it was decided to remove the item “pain in 
the c a lf ’ and to explore its impact on the Cronbach alpha value for this factor. This 
produced a better cronbach alpha value (0.77) (Table 5.15).
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Table 5 .1 5 :  Item-Total Statistics for factor 1 before items deletion
Scale 
Mean if 
Item 
Deleted
Scale 
Variance if 
Item 
Deleted
Corrected
Item-Total
Correlation
Cronbach's Alpha if 
Item Deleted
Appointment with GP 12.62 1.57 0.71 0.57
Fatigue 11.56 1.57 0.57 0.65
Appointment with 
practice nurse 12.42 1.88 0.53 0.68
Pain in calf 11.29 2.03 0.34 0.77
The result shown in Table 5.16 demonstrates similarity to factor 1. The values for the 
corrected item-total correlation suggested that removal o f item “hospital stay” was 
justified due to its low value (0.26). This removal led to increase in the value of 
Cronbach alpha coefficient from 0.69 to 0.71.
Table 5 .1 6 : Item -T otal S tatistics for factor 2 before item  deletion
Scale Mean Scale Corrected Item- Cronbach's
if  Item 
Deleted
Variance if 
Item Deleted
Total
Correlation
Alpha if 
Item Deleted
Day off due to sickness 18.76 0.51 0.69 0.53
Reduce workload due 
to fatigue 18.77 0.57
0.50 0.62
Work limitation 18.72 0.71 0.45 0.65
Loss o f interest 18.79 0.53 0.43 0.68
Hospital stay 19.71 0.81 0.26 0.71
The reliability scores for factor 3 suggested that seven items with low values (less 
than 0.30) o f corrected items-total correlation should be removed in order to increase 
the alpha coefficient value o f the factor (Table 5.17). However, there was a dramatic 
reduction in the value o f Cronbach alpha from 0.62 to 0.55 following items deletion. 
This therefore explained a weak to moderate association between factor 3 and its
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items. It was therefore decided not to remove any items from this component. The 
overall cronbach alpha values for the three factors are therefore 0.77, 0.71 and 0.62.
Table 5 .1 7 :  Item -T otal S tatistics for factor 3 before item  deletion
Scale M ean if 
Item D eleted
Scale 
V ariance if  
Item D eleted
C orrected  Item - 
T otal C orre la tion
C ronbach 's A lpha 
if  Item D eleted
L oss o f  sexual drive 49.65 4.67 0.35 0.58
C ough 50.08 4.88 0.28 0.60
A nxious and tense 49.48 5.06 0.32 0.59
Feel o f  energy  loss 49.69 4.32 0.42 0.56
H ospital adm ission 50.30 5.55 0.45 0.59
C old  in hands and 
feet
49.48 4.96 0.31 0.59
N H S D irect call 50.26 5.97 0.20 0.62
H ospital stay 50.28 5.89 0.18 0.61
M em ory loss 49.48 5.30 0.19 0.62
N igh tm ares and terror 49.47 5.22 0.30 0.59
Slurred  speech 49.31 5.56 0.28 0.60
H eadache 49.30 5.78 0.18 0.61
Correlation between factors
Figure 5.2 shows the final outcome o f the exploratory factor analysis o f the three 
factor structures o f the SEIP. The relationship between factor 1 and factor 2 was 
investigated using Spearman’s rho -  a non parametric correlation technique. The 
results showed weak association between these two factors (Table 5.18). Similarly, 
there was a weak correlation between factor 1 and factor 3, and between factors 2 and 
3 (Tables 5.19 and 5.20, respectively). However, further exploration o f the factor 
scores indicated that there were strong correlations between an individual factor and 
items they contained (i.e. within factor correlation). For example, a large correlation 
was found between “appointments with GP and fatigue” and “appointments with 
nurse and fatigue” in factor 1. This therefore suggested a strong relationship between 
them (Table 5.21). There were also strong relationships between factor 2 and its items 
(Table 5.22) and between factor 3 and its items (Table 5.24).
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Table 5.18 Correlations between factor 1 and 2 (n= 160)
Variables Factor 2
Factor 1 Day off 
due to sickness
Reduce workload 
due to fatigue
Work
limitation
Loss of 
interest
Appointment with GP -0.10 -0.13 -0.14 -0.18*
Fatigue -0.01 -0.09 -0.09 -0.20*
Appointment with practice nurse -0.13 -0.15 0.01 0.01
*P<0.05
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Table 5.19 Correlations between factor 1 and factor 3 (n= 160)
Variables 
Factor 3
Factor 1
Fatigue Appointment with GP Appointment with practice nurse
Anxious and tense 0.09 0.15 0.26*
Feel of energy loss -0.08 0.05 0.16*
Nightmares and terror 0.16* 0.30** 0.20*
Cold in hands and feet -0.04 0.05 0.02
Cough 0.16* 0.33** 0.33**
Headache -0.21** -0.20* -0.13
Loss of sexual drive 0.09 0.15 0.13
Slurred speech -0.05 0.21** 0.22**
Memory loss 0.19* 0.29** 0.25**
Hospital admission -0.13 0.10 0.08
Hospital stay -0.05 -0.04 0.02
NHS Direct call -0.08 0.05 0.09
**P<0.01; *P<0.05
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Table 5.20 Correlations between factor 3 and factor 2 (n= 160) 
Variables Factor 3
Factor 2 Anxious
and
tense
Feel of 
energy 
loss
Headache Loss of
sexual
drive
Cold in 
hands 
and feet
Cough Nightmares 
and terror
Slurred
speech
Memory
loss
Hospital
admission
Hospital
stay
NHS Direct 
call
Loss of interest 0.28** 0.43** 0.28** 0.12 -0.06 0.24** -0.03 -0.06 -0.07 0.04 0.10 0.27**
Reduce 
workload due to 
fatigue
0.09 0.26** 0.30** -0.08 0.03 0.02 -0.02 -0.05 -0.06 0.05 0.11 0.29**
Day off due to 
sickness
-0.06 0.23** 0.08 -0.06 -0.03 -0.06 -0.13 -0.05 -0.12 0.07 0.30** -0.02
Work limitation 0.26** 0.26** 0.36** 0.19* 0.05 0.15 0.02 -0.03 0.13 0.15 0.24** 0.49**
**P<0.01; *P<0.05
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Table 5.21 Spearman's rho correlations between factor 1 and its items (n=160)
Appointment 
with GP
Fatigue Appointment with 
practice nurse
Appointment with GP 1.00
Fatigue 0.65(**) 1.00
Appointment with 
practice nurse 0.65(**) 0.40(**) 1.00
** P<0.0I
Table S.22 Spearman's rho correlations between factor 2 and its items
Day off due to 
sickness
Reduce workload 
due to fatigue
Work
limitation
Loss of 
interest
Day off due to sickness 1.00
Reduce workload due to 
fatigue 0.65(**) 1.00
Work limitation 0.14 0.43(**) 1.00
Loss of interest 0.43(**) 0.47(**) 0.40(**) 1.00
• •  P<O.OI
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Table 5.23 Spearman's rho correlations between factor 3 and its items (n= 160)
Anxious 
& tense
Feel of 
Energy 
loss
Nightmares
&
terror
Cold in 
hands 
& feet
Cough Headache Loss of
sexual
drive
Slurred
speech
Memory
loss
Hospital
admission
Hospital
stay
NHS
Direct
call
Anxious & 
tense 1.00
Feel of energy 
loss 0.37" 1.00
Nightmares & 
terror 0.20* 0.08 1.00
Cold in hands 
& feet 0.04 0.15 0.14 1.00
Cough 0.17* 0.24** 0.20* 0.05 1.00
Headache 0.08 0.17* 0.04 0.09 0.09 1.00
Loss of sexual 
drive 0.17* 0.11 0.41** 0.36** 0.14 -0.01 1.00
Slurred
speech 0.07 0.31** 0.17* 0.09 0.09 -0.04 -0.08 1.00
Memory loss 0.19* 0.09 0.18* 0.23** 0.13 -0.02 0.12 0.09 1.00
Hospital
admission -0.02 0.20* 0.06 0.31** 0.10 0.09 0.20* 0.41** 0.20* 1.00
Hospital stay 0.04 0.11 -0.08 0.05 0.10 0.16* 0.08 -0.03 -0.07 0.33** 1.00
NHS Direct 
call 0.20* 0.15 0.16 -0.04 0.14 0.37** -0.06 -0.02 0.16* -0.02 -0.01 1.00
**P<0.01 *P<0.05
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Figure 5.2 Exploratory factor analysis o f adjusted three factor structure underlying the SEIP
0.140.060.08
Factor 2 Factor 3Factor 1
0.630.790.870.87 0.660.64
0.640.77 0.49
0.75
0.360.41 0.530.810.540.550.74
0.50
0.34
Note: 14 = NHS Direct number; 3= Loss o f energy; 15=Appointment with GP; 10=Pain in calf; 17='Work schedule & fatigue
16=Appointment with nurse; 2=Loss o f interest; 12=Hospital admission; l=Anxious; 18=Day off sick; 13=Hospital stay 
7=Headache; 6=Cough; 5=Cold hand & feet; 8=Loss o f sexual activity; 9=Slurred speech; 4=Nightmares & terror 
U =M em ory loss: 19=Work limitation
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DISCUSSION
Factor analysis is an appropriate method for scale development when analysing a set 
o f interval-level, non-dichotomous variables. It is a mathematically complex method 
o f reducing a large set o f variables to a smaller set o f underlying variables referred to 
as factors (De Vaus, 2002). The basic aim of factor analysis is to examine whether, on 
the basis o f people’s answers to questions, a smaller number o f more general factors 
that underlie answers to individual questions can be identified. Using factor analysis 
in research is therefore aimed at reducing data to make analysis simpler, to be able to 
identify which variables belong together and to have a method o f combining these 
variables into scales. In this study, two important methods involved in factor analysis 
were used: factor extraction, and factor rotation.
Suitability o f  factor analysis
When selecting variables to be factor analysed, De Vaus (2002) suggested that these 
variables should have at least reasonable correlations with some other variables in the 
analysis. This author suggested further that at the variable selection stage, a 
correlation matrix o f potential variables should be obtained, inspected and those 
variables that do not correlate with any others in the analysis should be excluded. In 
this study, correlation matrix results demonstrated intercorrelations o f items within 
the questionnaire and therefore fulfilling one o f the conditions for factor analysis. 
Tabachnick and Fidell (2001) suggested that the use o f factor analysis in 
psychometric evaluation o f a new scale should be reconsidered if there were no 
correlation coefficient o f 0.30 and above in the correlation matrix. In this case, many 
o f the values generated were above 0.30 and therefore it was considered appropriate 
to use factor analysis in establishing the robustness o f the new measure.
There are other ways o f assessing whether a set o f variables in a correlation matrix is 
suitable for factor analysis (Tabachnick and Fidell, 2001). Among these is a statistic 
called Kaiser-Meyer-Olkin (KMO) measure o f sampling adequacy. This statistic has 
been well documented in chapter two o f this thesis. The value o f KMO ranges from 0 
to 1. If this statistic yields high values above 0.70, then the correlations, on the whole, 
are sufficiently high to make factor analysis suitable. On the other hand, the KMO 
values below 0.50 mean that factor analysis would be inappropriate for that set of
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variables. KMO value in this study was 0.82, therefore confirming the suitability of 
factor analysis in this study.
Initial factor extraction
The main aim o f exploratory factor analysis is to see whether a smaller number of 
common factors can account for the pattern o f correlation between a large numbers of 
variables. The question that comes to the mind o f a researcher is: do the individual 
variables co-vary because they have underlying factors in common? De Vaus (2002) 
suggested that before extracting factors, it is advisable to work out how many factors 
to extract. Since the aim o f factor analysis is to represent a set o f variables as simply 
as possible, the best factor analysis will have as few factors as necessary (De Vaus, 
2002). One common way o f determining which factors to keep is to use a statistic 
called Principal Component Analysis (PCA) and Eigenvalue. The eigenvalue is a 
measure that attaches to factors and indicates the amount o f variance in the pool of 
original variables that the factor explains. The higher this value, the more variance the 
factor explains (De Vaus, 2002). To be retained, factors must have an eigenvalue 
greater than 1. Generally in factor extraction, “eigenvalue greater than 1” criteria is 
the most commonly used extraction technique (Henson and Roberts, 2006) and 
therefore it was decided to engage this method in this study.
The use o f Principal Component Analysis (PCA) in factor extraction in this study 
revealed nine components with eigenvalues > 1. The eigenvalue o f a factor is the 
amount o f variance in all the variables that is explained by that factor. This figure is 
obtained by squaring the correlations in the factor matrix and then adding each of 
these squared figures in the column. Sometimes a large number o f factors with 
eigenvalues greater than 1 may be generated, but for the sake o f simplicity, not all the 
factors may be retained. How do we decide which o f the factors with eigenvalues 
greater than 1 to retain? Considering suggestions o f Reio and wiswell (2006) that 
eigenvalue > 1 criteria sometimes overestimate the number o f factors to be retained 
especially when the number o f variables being examined exceeds 30, two ways as 
described in chapter two are to perform a scree test and a parallel analysis. Scree test 
results in this study suggested that six out o f the nine extracted components would be 
suitable to keep for factor rotation in order to ensure their easy interpretations. Parallel
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analysis results also showed that the initial decision to consider these six extracted 
factors for further exploration was appropriate.
Extracting the final factors (factor rotation)
Rotation o f factors is performed to clarify which variables most belong' to each other 
once the decision on how many factors to retain has been made in order to make the 
factors more interpretable. The initial extraction o f factors did not make it clear which 
variables belong most clearly to which factors as many variables loaded on several 
factors and some factors had almost every variable loading on them. There are a 
number o f methods o f “rotating” variables; these have been described extensively in 
chapter two. One of the most widely used methods o f rotation is varimax rotation. 
Although, opinion varies on how high a coefficient should be before a variable is said 
to load on a factor, De Vaus (2002) suggested that it would be unusual to use 
variables with coefficients below 0.30.
Varimax rotation results o f the six-factor solution revealed strong loadings especially 
on factors 1 to 5. Basically if, in data analysis, there is no possibility to assume the 
independence o f the underlying factors, the use o f Oblique rotation is suggested 
(Tabachnick and Fidell, 2001). For example direct oblimin method. This study 
however, showed that direct oblimin rotational method o f the six factors could not 
confirm that the six factors were not related. On the other hand, three factor solutions 
were considered for exploration and these yielded high loadings and the results of the 
component correlation matrix of the three factors using oblimin rotation revealed very 
low correlation between them.
Further psychometric evaluation o f SEIP through the examination o f internal 
consistency showed the independence of the three-factor solutions with strong 
relationships (r > 0.40) between individual items and their respective domains. The 
reliability coefficients tests o f the extracted factors both before and after item 
deletions showed varying Cronbach alpha values. It was therefore decided to consider 
factors with higher Cronbach alpha coefficients. Low correlation coefficients between 
factor 1 and factor 2 and between factor 1 and factor 3 showed that the two factors 
were measuring a distantly-related concept and therefore independent o f one another.
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On the other hand, there were some high correlations o f items between factor 2 and 3, 
the reason may lie in the fact that these items were measuring similar concepts. For 
example, items “anxious and tense” in factor 3 and “loss of interest” in factor 2 with 
correlation coefficient of 0.28. Despite this, majority o f items in both factors showed 
lower correlation values, therefore indicating their degree of independence. In 
addition to these, majority o f items in all the three factors showed high correlations 
within their domains. This outcome therefore provided enhanced confidence in the 
psychometric properties o f SEIP.
Factor analysis o f SEIP therefore produced three underlying components 
representing: 1) the impacts o f statins on healthcare services use; 2) emotional distress 
and impacts on productivity; and 3) socio-emotional symptoms and use o f healthcare 
services. The factor rotation results suggested the removal o f two items from the 
questionnaire: “medication change” and “enquiry with pharmacist” . This was quite 
surprising especially when taking into consideration that most o f patients with 
medication-related problems consider pharmacists as their first place to seek advice 
about their medication use and side effects to them. One explanation for this could be 
because o f lack o f time for consultation and counselling as many pharmacists in the 
UK are now involved with enhanced services in order to increase their earnings.
As with other studies, there are limitations to this study. For example, the sample size 
used which could be considered as borderline for factor analysis (n = 160) may have 
affected the results produced. In order to achieve high loading marker variables such 
as 0.80 and above, many researchers suggested that the sample size should be 300 or 
more (Gorsuch, 1983; Tabachnick and Fidell, 2001; Hogarty et al., 2005).
Overall, the results o f factor analysis have provided support for the psychometric 
properties o f the SEIP as a promising socioeconomic related tool especially in 
cardiovascular patients with medication-related problems. The results also suggested 
the reduction o f the 24-item s questionnaire to 19 (this include item “enquiry with 
pharmacist”). The final version o f SEIP therefore consists of 19 items with three 
domains (Figure 5.3).
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Future work should focus on: 1) its test -  retest reliability; 2) demonstrate criterion,
convergent / divergent validity with other available instruments; 3) its applicability
and responsiveness.
Summary
• The factor analysis o f SEIP was carried out on a sample o f 160 cardiovascular 
patients from five community pharmacies in England and Wales.
•  Principal component analysis suggested consideration o f nine factors for factor 
extractions;
• Three statistical rules: eigenvalue > 1, scree test and parallel analysis suggested 
six factors should be considered for factor rotation for easy interpretations;
• Rotation o f six factors (varimax and oblimin methods) produced three-factor 
solutions with many high loading items (>0.40);
•  Internal consistency reliability tests o f the three factor solutions produced 
Cronbach alpha values o f 0.74, 0.71 and 0.62 respectively therefore supporting 
psychometric property o f SEIP;
•  Spearman rho correlation coefficient results indicated low relationships between 
factor 1 and factor 2, factor 1 and 3 but low- moderate relationships between 
factor 2 and 3; however, high correlation values were indicated among items 
within each o f the three domains, therefore supporting the notion that each factor 
measures similar concept and are independent o f one another.
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Figure 5.3 -
Final version of the Socioeconomic Impact
Profile (SEIP
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Confidential
To be com pleted on ...................................................
Patient Identification number...........................
Socio-Econom ic Im pact Profile (SEIP)
INSTRUCTIONS
This survey asks for your view s about your medications and any side effects that you may 
experience and in what ways are these side effects affecting your quality o f life in general.
The information you provide will help your pharmacist keep track of how you feel and how 
well they can help to minimise the impact o f medication side effects on your life, hence 
improve the quality of care they offer you. All responses will be treated in the strictest 
confidence.
Answer every question by ticking the appropriate box, if  you are unsure about how to answer 
a question, please give the best answer you can and feel free to make comments as you wish.
About Yourself
Age I LYears Sex..J I M ale  Q  Fem ale
What is your medical condition?...............................Duration: Year Months...........
Education...................  Q ]N o n e  I I P rim ary  school I I H igh school I I U niversity  degree
Marital Status..Q  Single Q  D ivorced  Q  M arried  Q  W idow ed  Q  L iv ing  w ith a partner
Employment Status...J I E m p lo v ed .J  I U nem ployed . ■♦Due to your health? I lYes I I N o
f~l S elf-em ployed
I I R etired  ♦  is this due to your health? I lYes [ ]  N o
I | R eceive  Incom e S upport B enefit
n  R eceive o th er social support, p lease  state.
What is your annual income..J I L ess than  £ 1 0 ,000?
I | M ore than  £ 1 0 ,000  but less than £20 ,000
I | M ore than £ 2 0 ,000  but less than £30 ,000
1 1 M ore than £30 ,000  but less than 40 ,000
I I M ore than  £40 ,000
About your medication: D o you take any  p rescrip tion  m edicine(s) regularly?
f~~lYes I I No.
If  yes, w hat are the m ed ic in es you  are  tak ing  fo r? ........................................................................
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Social interaction and emotional behaviour
The following statements are about side effects you might experience if you take some 
medicines for blood pressure, high blood cholesterol and heart. If so, tick the appropriate 
box below.
How often have you experienced any of the following problems? Do you think it is due to a
side effect of your medicine?
Do you think 
it is due to a 
side effect of 
your medicine?
Never A little of 
the time
Some of 
the time
Most of 
the time
All of
the
time
Yes No
Not
sure
1.1 have felt anxious and tense 
inside for no obvious reason...
5
□
4
□
3
□
2
□
1
□ □ □ □
2. 1 have lost interest in things I 
usually enjoy...........................
□ □ □ □ □ □ □ □
3.1 have felt like all of the 
energy drained out o f me. ...
□ □ □ □ □ □ □ □
4. 1 have had horrible 
nightmares and night terrors..
□ □ □ □ □ □ □ □
5. 1 have felt unpleasantly cold 
in my hands and feet..............
□ □ □ □ □ □ □ □
6 1 have had a troublesome 
cough that won’t go away.....
□ □ □ □ □ □ □ □
7.1 have had a constant 
headache after my medicine..
□ □ □ □ □ □ □ □
8. 1 have lost interest in sexual 
activity.....................................
□ □ □ □ □ □ □ □
9 . Mv speech is slurred............ □ □ □ □ □ □ □ □
10. 1 have severe pain in my 
calf 1 could hardly walk.....
□ □ □ □ □ □ □ □
I l l  have no memory of events 
or things 1 did on the 
previous day..........................
□ □ □ □ □ □ □ □
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[5] Use of health services
How often have you made use o f any of the following services as a result o f side effect o f  
your medication?
Never Seldom Frequently More frequently
4 3 2 1
12. I have been admitted to hospital.................... □ □ □ □
13.1 have stayed in hospital for some days........ □ □ □ □
14.1 was so worried about the side effect I
suffered after taking my medicine that I had to 
call the NHS Direct number for advice.......
□ □ □ □
15.1 was so worried about the side effect I
suffered after taking my medicine that I had to 
make an urgent appointment with my local 
general practitioner (GP)................................
□ □ □ □
16.1 was so worried about the side effect I
suffered after taking my medicine that I had to 
make an urgent appointment with the practice 
nurse in my local surgery..............................
□ □ □ □
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| c ]  Work
The following questions are about how much your working life has been affected as a result 
o f  medication side effects.
No, not at 
all
Seldom Sometimes A little A lot
5 4 3 2 1
17. I have cut down my work schedule 
because of fatigue...............................
□ □ □ □ □
18. 1 have taken some days off sick....... □ □ □ □ □
19. I am limited in the kind of work I 
can do..................................................
□ □ □ □ □
Date: thank you for your time and help.
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CHAPTER 6
Evaluation of Practicality and Reliability of 
the Socioeconomic Impact Profile (SEIP)
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INTRODUCTION
In the development o f new measures such as the SEIP, testing of their applicability 
and practicality in the target population is o f paramount importance. Similarly, 
establishment o f the degree o f measurement error (reliability) o f the new measure is 
o f equal importance. Reliability is the extent to which a test is repeatable and yields 
consistent scores. In the context o f this research, measures o f reliability are considered 
as an indication o f what extent an instrument truly captures the attributes of health 
status rather than an existing measurement. However, according to some authors, the 
size o f random measurement error should be taken into consideration while assessing 
the reliability o f the new measure (Walker, 2002). All measurement procedures have 
the potential for error, so the aim is to minimise it. In general, an observed test score 
is made up o f the true score plus measurement error. The goal o f estimating reliability 
is therefore to determine how much o f the variability in test scores is due to 
measurement error and how much is due to variability in true scores 
(http://wilderdom.com, 2004).
W hat is acceptable reliability for a m easurem ent instrument?
A measure is judged to be reliable when it consistently produces the same results, 
particularly when applied to the same subjects at different time periods when there is 
no evidence o f change (Bowling, 2005b). A reliability score (coefficient) o f one 
indicates that no measurement error is present (McHomey et al., 1994). The 
following reliability coefficients have been published as guidelines in determining 
reliability (http://wilderdom.com, 2004):
0.90 = high reliability 
0.80 = moderate reliability 
0.70 = low reliability.
High reliability is required when: 1) tests are used to make important decisions; 2) 
individuals are sorted into many different categories based upon relatively small 
individual differences. On the other hand, lower reliability is acceptable when: 1) tests 
are used for preliminary rather than final decisions; 2) tests are used to sort people 
into small number o f groups based on gross individual differences. Reliability
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estimates o f 0.80 or higher are typically regarded as moderate to high. Reliability 
estimates below 0.60 are usually regarded as unacceptably low. According to 
McHomey et al (1994), a reliability coefficient o f  0.70 implies that 30% of the score 
for health status is made up o f measurement error.
Types o f reliability
There are a number o f ways to ensure that a newly developed measure is reliable. The 
different modes of assessing reliability o f the instrument have been described 
extensively in chapter two o f this study. However in this chapter, two o f these tests 
will be revisited: 1) test-retest reliability and; 2) internal consistency reliability.
Test-retest reliability
Test-retest reliability measures the stability o f a score derived from serial 
administration o f a measure by the same rater (Kulich et al, 2008). This type of 
reliability test is estimated when the same test is administered to the same sample on 
two different occasions (usually referred to as test 1 and test 2). This approach 
assumes that there is no substantial change in the construct being measured between 
the two occasions. However, the amount o f time allowed between tests 1 and 2 is 
critical. For example, if the same thing is measured twice, the correlation between the 
two observations will depend partly on how much time elapses between the two 
measurement occasions. The shorter the time interval between T1 & T2, the higher 
the correlation; the longer the interval, the lower the correlation.
Internal consistency reliability
This is the most frequently used statistical test for assessing reliability of an 
instrument. This is normally established through a single administration o f the 
instrument to a sample from the intended population. In effect, the reliability o f the 
instrument is judged by estimating how well the items that reflect the same construct 
yield similar results. This method also looks at how consistent the results are for 
different items for the same construct within the measure. There are a wide variety of 
internal consistency tests that can be used for measurement instruments. These will be 
described below.
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Average Inter-Item  Correlation
The average inter-item correlation uses all o f the items on an instrument that are 
designed to measure the same construct. It indicates the extent to which the items in a 
scale are inter-related and that the items in each subscale seem to be measuring the 
same dimension (McHomey et al., 1994). For example, in a computation of 
correlation between each pair o f items in a six item instrument, 15 different item 
pairings can be generated (i.e. 15 correlations) (Table 6.1). The average inter-item 
correlation is simply the average or mean o f all these correlations.
Table 6.1 An example o f an Average Inter-Item Correlation o f a 6-item measure
Measure items Average Inter-Item Correlation
I. I2 I3 I4 Is I6
Item 1 I. 1.00
Item 2 I2 0.89 1.00
Item 3 I3 0.91 0.92 1.00
Item 4 I4 0.88 0.93 0.95 1.00
Item 5 I5 0.84 0.86 0.92 0.85 1.00
Item 6 I6 0.88 0.91 0.95 0.87 0.85 1.00
Average Item-Total Correlation
This approach also uses the inter-item correlation. In addition to the example in Table 
6.1, a total score for the six items is computed and that is used as a seventh variable in 
the analysis. These figures give an indication o f the degree to which each item 
correlates with the total score. Low values (less than 0.30) indicate that the item is 
measuring something different to the scale as a whole (Pallant, 2002)
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Cronbach’s Alpha
Internal consistency commonly measured as Cronbach’s Alpha (based on inter-item 
correlations) is often described as being mathematically equivalent to the average of 
all possible split-half estimates (Pallant, 2002). The greater the number of similar 
items are, the greater the internal consistency and hence, the higher the Cronbach’s 
value. Generally, alpha o f 0.80 is considered as a reasonable benchmark. As Pallant 
(2002) noted, in order to be valid, a test must be reliable; but reliability does not 
guarantee validity. In this chapter, it is hoped to establish practicality, test-retest and 
internal consistency reliability o f the SEIP.
The concepts examined were:
•  The completion time o f the SEIP should not be more than 10 minutes;
•  The questions and instructions should be clear, easy to understand and 
comprehensive enough to the respondents;
•  The SEIP should not be difficult, unsuitable or distressing to complete for 
patients and be able to respond to the items with a reasonable degree of 
spontaneity.
•  The SEIP should demonstrate high internal consistency and high test-retest 
reliability values.
M ETHODS  
Study design and selection of patients
This was a prospective study to examine the practicality and reliability properties of 
the SEIP. Patients were recruited in 2007 over a 3 month period (March-June). 
Patients suffering from three cardiovascular disease states (hypertension, myocardial 
infarction and angina pectoris) were recruited from five community pharmacies in 
South West England and Wales. Those patients who met the following inclusion 
criteria were enrolled in the study: community managed cardiovascular patient from 
one o f the above-mentioned patient groups; receiving three or more repeat 
prescriptions from the participating pharmacies for at least three months prior to the 
study; and be able to complete the questionnaire.
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Study procedure 
Practicality of the SEIP
A newly developed measure is expected to have the right emphasis for the purpose 
being developed and should be acceptable to the target population. For these reasons, 
it was decided to seek patients’ views, perceptions and comments about the SEIP 
questionnaire. Patients on repeat prescriptions were approached by the research 
pharmacist while waiting to collect their repeat medications from the participating 
pharmacies. These patients were invited to participate in the study and the protocol of 
the research study was explained to them in order to seek their consent. Patients who 
agreed to take part were given a pre-paid envelope containing a yellow form with six 
practicality questions (see Appendix 7); two SEIP questionnaires for the test-retest 
reliability study and a Patient Information Sheet. They were advised to complete the 
first SEIP questionnaire on the day o f recruitments and the second SEIP questionnaire 
seven days apart. They were also advised to fill in the details on the yellow form and 
make any additional comments that they wished in the space provided on the sheet. 
Patients were asked to return the completed questionnaires and the yellow form in the 
pre-paid envelope provided. Finally, they were thanked for their co-operation and 
participation.
Test-retest reliability of the SEIP
Patients for this study were the same group o f patients recruited for the practicality 
study as outlined above. During their recruitment, emphasis was placed on the need to 
complete the first SEIP questionnaire (Test 1) on the day o f recruitment and the 
second questionnaire (Test 2) seven days after the first questionnaire. All SEIP item 
scores were tested together and each domain o f the SEIP was also assessed separately 
for its internal consistency reliability.
Data Processing and Analysis
Statistical analyses were performed with SPSS 12 for Windows. Descriptive statistics 
were used to present demographic characteristics o f the study participants as well as 
most o f the results for the practicality study. The internal consistency reliability of the 
SEIP and its sub domains were determined by calculation o f Cronbach’s alpha (a). In 
order to determine whether the mean scores o f items measured on the two occasions
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of the test-retest reliability were statistically significant, non-parametric Wilcoxon 
Signed Rank Test was engaged. Spearman rank correlation coefficient was employed 
to examine the relationship between Test 1 and Test 2. The probability of committing 
type 1 error was set at p<0.05.
RESULTS  
Dem ographic characteristics o f the study participants
A total o f 150 patients were administered the SEIP and the yellow form with 
practicality questions. Ninety-three (62.0%) patients returned the questionnaires in 
pre-paid envelopes provided o f which 92 pairs o f the SEIP were evaluable for test- 
retest reliability analysis. One patient was excluded because her returned SEIP 
questionnaires were incomplete. A follow up contact was made by the research 
pharmacist to those who did not return the questionnaires through the participating 
pharmacies.
Table 6.2 shows the demographic characteristics o f the study participants o f whom 
fifty (54.3%) were male. The age o f participants ranged from 39 to 78 years with a 
mean age o f 57.7 years. Sixty-three patients (67.7%) were married, 46 (48.9%) had a 
high school education, 37 (40.2%) had a university degree and 10 (10.9%) had a 
primary education. Sixty-five (69.9%) were employed and over one-third o f the 
participants earned between £10,000 and £20,000 annually. Fifty-nine (63.4%) were 
hypertensive while 23 (24.7) suffered from another concomitant medical condition. 
These included diabetes (typel or type II), asthma, COPD, arthritis and depression.
Practicality o f the SEIP
The mean time taken to complete the SEIP was 5.7 minutes (SD=2.8). Twenty-eight 
(30.4%) patients completed the SEIP in 5 minutes, 26 (28.3%) patients in 3 minutes 
and 18 (19.6%) in 10 minutes. It took 1 (1.1%) patient about 15 minutes to complete 
it (Table 6.3).
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Table 6.2 Sociodemographic characteristics of the study participants (n=92)
Variables Number (%)
Sex
Male 50(54.3)
Female 42 (45.6)
Age
Range 39-78
Median 57.0
Mean 57.7
Medical condition
Hypertension 59(64.1)
High cholesterol 2(2.2)
Angina 2 (2.2)
Heart attack 6(6.5)
Hypertension and others 23(25)
Education
Primary school 10(10.9)
High school 45 (48.9)
University degree 37(40.2)
Marital status
Single 14(15.1)
Married 63 (67.7)
Divorced 6(6.5)
Widowed 9 (9.7)
Employment status
Employed 65 (69.9)
Retired due to health 2 (2.2)
Retired not due to health 21 (22.6)
Self employed 4(4.3)
Annual income
E< £10000 19(20.7)
£10000 <E<£20000 32 (34.8)
£20000 < E <£30000 8(8.7)
£30000 < E < £40000 23 (25)
E > £40000 10(10.8)
Table 6.3 Time taken by the participants to complete the SEIP (n=92)
Time (in minutes) No o f participants
2 3 (3.3)
3 26 (28.3)
4 1 (1.1)
5 28 (30.4)
6 9 (9.8)
7 5 (5.4)
8 1 (1.1)
10 18(19.6)
15 1 ( l.D
When patients were asked whether the instructions to the questions were clear and 
understandable, 15 (16.3%, n=92) patients agreed that the questions and instructions 
were “very clear”, 74 (80.4 %,) agreed they were “clear”, and 3 (3.2 %,) reported that 
they were “not clear”. Only one patient did not respond to this part of the 
questionnaire (Figure 6.1).
When they were asked whether the SEIP items were comprehensive enough to 
measure their social and economic well-being including quality of life, the majority of 
patients, (73(78.5% )) responded positively. In contrast, 20 (21.5%) patients disagreed 
with the statement. Those who chose the “No” response option were asked to state 
any additional questions they would like to be included about the effects of their 
medications on the quality o f life. Table 6.4 lists some suggestions and comments by 
these participants.
Almost all the patients agreed that hardly any o f the questions in the SEIP were 
unsuitable, difficult or distressing to answer (89 (96.7% ) patients). Only 3 (3.3%) 
patients agreed otherwise. One patient considered the item asking about annual 
income” as inappropriate because o f its personal nature. Another patient wished the
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phrase “do you think" in one o f  the column in the social interaction and emotional 
behaviour domain o f  the SEIP (asking whether respondents think the problems they 
were experiencing was due to a side effect o f  their medications) to be changed to “I 
believe”.
Figure 6.1 Patients’ perception of clarity of the SEIP items
Clarity o f  instruction & items
□  Very clear
□  Clear
□  Not clear
Test-retest reliability'
The reliability o f  the 19-item SEIP was estimated using the internal consistency while 
the level o f  agreement between Test 1 (T l)  and retest (T2) was determined using the 
W ilcoxon Signed Rank test. Overall, the items mean score for each SEIP domain 
showed that they were not normally distributed. All domains showed negative 
skewness values indicating that scores were clustered to the right at the high end 
(Figures 6.2, 6.3 & 6.4). The SEIP item mean scores were high for all categories 
(Table 6.5).The magnitude o f  correlation between Tl and T2 would depend on the 
closeness o f  the two mean scores o f  each category. Therefore, if  the gap between the 
two mean scores in test-retest was wider, this would reflect on the correlation 
coefficient (rho).
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Table 6.4 Comments and suggestions from patients who responded “NO” to question3 of
the practicality exercise (n=20)
Q3: Do you think the questions asked are comprehensive enough to measure your social 
and economic well-being including quality of life?
Selected samples of “No” respondents Comments and suggestions of questions to 
be included
ID 747/29
ID 6439/14
ID 747/31 
ID 6439/22
ID 6547/64
1. Excessive sleepiness in early evening
2. Tingling in fingers On waking in the 
morning
“I would like to see- explain how you think 
the medication affects you.... And were 
possible side effects explained to 
you...multiple choice questions are fine for 
symptoms but don’t give the whole picture”
“Before you took the medication, were the 
symptoms there?
“Presumably the questions only relate to the 
particular medication presented now- may be 
if previously to which answers would be 
different”
1. Do you regularly swim/walk/other 
exercise?
2. Do you read books/daily newspaper/do 
crossword etc daily?
3. Do you engage in any social activity 
outside your home e,g. dancing, sport, 
craft, art etc?
4. Do you tend your own garden/home 
decorating?
5. Do you worry about paying bills?
6. Do you run a car and what is your annual 
mileage under?
7. Do you go on holiday once, twice, thrice 
or more times per year?
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In this study, the low test-retest correlation coefficients (rs=0.39 and 0.22) for the two 
SEIP items (i.e. “slurred speech” and “NHS Direct Number call” respectively) could 
be explained by the wideness o f their Tl and T2 mean scores.
Figure 6.2 Distribution characteristics of “social interaction & emotional behaviors” 
domain scores for Tl
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Figure 6.3 Distribution characteristic o f “use o f healthcare services” domain for Tl
7 0 -
6 f t -
5 0 -
u
- f i
E
3z
4 0 -
3 0 -
20 -
Mean = 1 9 .5  
Std. Dev. = 1.2 
N = 922019181716
Mean scores
169
Figure 6.4 Distribution characteristic of “work” domain scores for Tl
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Based on this result, it was decided to use the non-parametric Wilcoxon Signed Rank 
test to confirm any significant difference between the SEIP scores o f  Tl and T2. 
Results o f  The Wilcoxon Signed Rank Test showed that there was a significant 
differences (P<0.05) in the SEIP category scores between Tl and T2 (Table 6.6). This 
significant trend is indicated by the negative direction o f  the scores probably due to 
the lower mean SEIP scores o f variables at Test 2.
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Table 6.5 Correlations between T l & T2 mean SEIP scores (test-retest reliability o f  the SEIP)
(n = 92)
SEIP items M ean scores (SD)
Score
R ange*
Spearm an 's
C orrelation
rhoTest 1 Test 2
Anxious 4.25 (0.96) 4.12 (0.89) 1.00-5.00 0.85
Loss o f interest 4.37 (0.81) 4.28 (0.83) 1.00-5.00 0.87
Loss o f energy 4.27 (0.94) 4.13 (0.93) 1.00-5.00 0.82
Nightmares & terror 4.93 (0.25) 4.82 (0.38) 1.00-5.00 0.90
Cold hands & feet 4.37 (0.79) 4.25 (0.80) 1.00-5.00 0.89
Cough 4.34 (0.91) 4.32 (0.89) 1.00-5.00 0.96
Headache 4.88 (0.47) 4.74 (0.57) 1.00-5.00 0.82
Loss o f sexual activity 4.28 (0.89) 4.35 (0.84) 1.00-5.00 0.94
Slurred speech 4.17 (0.24) 3.26 (0.38) 1.00-5.00 0.39
Pain in calf 4.86 (0.55) 4.78 (0.51) 1.00-5.00 0.92
Loss o f memory 4.91 (0.33) 4.84 (0.43) 1.00-5.00 0.94
Hospital admission 3.89 (0.35) 3.79 (0.44) 1.00-4.00 0.90
Hospital stay 3.89 (0.35) 3.79 (0.44) 1.00-4.00 0.90
NHS Direct Number call 3.99 (0.11) 3.02 (0.38) 1.00-4.00 0.22
Appointment with GP 3.86 (0.35) 3.77 (0.42) 1.00-4.00 0.95
Appointment with nurse 3.83 (0.38) 3.79 (0.41) 1.00-4.00 0.97
Work schedule & fatigue 4.63 (0.81) 4.48 (0.90) 1.00-5.00 0.77
Day off sick 4.83 (0.53) 4.68 (0.65) 1.00-5.00 0.77
Work limitation 4.70 (0.89) 4.53 (0.98) 1.00-5.00 0.73
* 1 = the lowest possible score and 4 or 5 = the highest possible score
Table 6.6 Test-retest reliability- Comparison* o f Testl and Test 2 (N -92)
Social in teraction  & 
em otional behaviours 
dom ain total scores a t 
Test 2 -  Test 1
Use o f healthcare 
services dom ain 
total scores a t Test 2 
-  Test 1
W ork dom ain total 
scores a t Test 2 -  
Test 1
Z -2.33(a) -2.91(a) -3.30(a)
Asymp. Sig. 0.02 0.004 0.001
(2-tailed)
a Based on positive ranks. * Wilcoxon Signed Ranks Test
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Internal Consistency Reliability
The internal consistency reliability as determined by Cronbach’s a  o f the whole 19- 
item SEIP domains was high for both Test 1 and Test 2. The alpha values ranged 
between 0.77-0.95 (Table 6.7). The overall internal consistency reliability at Tl and 
T2 yielded a very high value o f Cronbach’s alpha coefficient (a=0.91and 0.93 
respectively). The Alpha coefficient value o f greater than 0.70, supports strong 
internal consistency reliability o f the SEIP.
Table 6.7 Internal consistency reliability o f SEIP for Test 1 and Test 2 (n=92)
SEIP C ro n b ach ’s a  coefficient
domains Test 1 Test 2
Overall SEIP score 0.91 0.93
Social interaction & emotional behaviours 0.87 0.88
Use o f healthcare services 0.77 0.95
Work 0.84 0.89
Test 1
The information of interest is the column marked Corrected Item-Total Correlation 
(Table 6.8), indicating the degree to which each item correlated with the SEIP total 
score. Generally, low values (< 0.30) indicate that the item is measuring something 
different to the scale as a whole. Some authors have suggested that if the overall 
Cronbach’s alpha o f a scale is less than 0.70, one should consider removing items 
with low Item-Total-Correlations (Pallant, 2002). In the column headed Cronbach’s 
alpha If Item Deleted, the impact o f removing each item from the scale is given. 
Furthermore, it has been suggested to consider removing any item with higher alpha 
value than the overall alpha value from the scale (Pallant, 2002). In this study, the 
Corrected-Item-Total correlations o f all 19 items in the SEIP ranged from 0.28 to 
0.84. Only question 11 (loss o f memory) had a Corrected Item-Total-Correlation 
value less than 0.30. However, based on Pallant’s suggestion, the deletion of this item 
(loss o f memory) did not increase the Cronbach’s value (Table 6.8). Thus, it was 
decided not to remove this question from the SEIP.
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Table 6.8 Item correlations o f overall SEIP domains with total scores for Test 1
SEIP domains & corresponding SEIP SEIP Corrected Cronbach'
items Mean if Variance if Item-Total Alpha if
Item Item Correlation Item
Deleted Deleted Deleted
Social interaction & emotional
behaviours
Anxious 79.79 51.02 0.46 0.91
Loss o f interest 79.67 48.75 0.78 0.90
Loss o f energy 79.77 47.48 0.76 0.90
Nightmares & terror 79.11 55.57 0.69 0.91
Cold hands & feet 79.67 51.96 0.50 0.91
Cough 79.71 48.39 0.71 0.90
Headache 79.16 52.56 0.80 0.90
Loss o f sexual activity 79.76 47.28 0.69 0.91
Slurred speech 79.08 56.97 0.33 0.91
Pain in calf 79.18 51.54 0.81 0.90
Loss o f memory 79.13 56.71 0.28 0.91
Use of healthcare services
Hospital admission 80.15 54.42 0.71 0.91
Hospital stay 80.15 54.42 0.71 0.91
NHS Direct Number 80.05 57.63 0.33 0.91
Appointment with GP 80.18 55.43 0.50 0.91
Appointment with nurse 80.22 56.02 0.35 0.91
Work
Work schedule & fatigue 79.41 50.09 0.65 0.91
Day off sick 79.22 51.58 0.84 0.90
Work limitation 79.35 49.07 0.67 0.91
The social interaction & emotional behaviours domain, with 11 questions such as 
‘Moss o f interest, nightmares and night terrors" etc, also indicated a good internal 
consistency with a Cronbach alpha coefficient o f 0.87 (Table 6.7). The mean scores 
ranged between 4.25-4.97 (Table 6.9) while the inter-item correlations ranged from
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average (0.30) to excellent at (0.80) (Table 6.10). It was decided not to remove the 
weaker item in the social interaction& emotional behaviours domain (loss of memory; 
Corrected Item-Total Correlation=0.30) from the domain as this would have minimal 
impact on the alpha value. In addition to this, the mean score could be interpreted as 
showing homogeneity o f the items as most o f the responses to the questions were 
similar.
Table 6.9 Social interaction & em otional b eh av io u r dom ain  m ean scores for T est 1 (n=92)
M ean Std. Deviation
Anxious 4.25 0.96
Loss o f interest 4.37 0.81
Loss o f energy 4.27 0.94
Nightmares & terror 4.93 0.25
Cold hands & feet 4.37 0.79
Cough 4.34 0.91
Headache 4.88 0.47
Loss o f sexual activity 4.28 0.89
Slurred speech 4.97 0.24
Pain in calf 4.86 0.55
Loss o f memory 4.91 0.33
The use o f healthcare services domain mean scores showed similar trend to the social 
interaction & emotional behaviours domain, as most responses from the participants 
were similar. The mean scores ranged between 3.83-3.99 (Table 6.11). The initial 
Cronbach alpha value was 0.77 and the Corrected-Item-Total correlations also ranged 
between poor (0.14) to a very good 0.79 (Table 6.12). However, due to the low value 
o f Corrected-Item-Total Correlation o f Item 14 o f the SEIP (NHS direct number), it 
was suggested to remove this item from the scale. Interestingly, the Cronbach alpha 
coefficient o f the four remaining components o f the use o f healthcare services domain 
improved considerably to 0.82 (Table 6.12).
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Table 6.10 Social interaction & emotional behaviours domain item correlations with
the total scores for Test 1
Domain 1 items
SEIP Mean 
if Item 
Deleted
SEIP 
Variance if 
Item Deleted
Corrected
Item-Total
Correlation
Cronbach's 
Alpha if Item 
Deleted
Anxious 46.18 21.58 0.56 0.87
Loss o f interest 46.07 21.18 0.76 0.85
Loss o f energy 46.16 19.89 0.80 0.84
Nightmares & terror 45.50 25.81 0.64 0.87
Cold hands & feet 46.07 22.81 0.55 0.86
Cough 46.10 21.67 0.59 0.86
Headache 45.55 23.94 0.73 0.86
Loss o f sexual activity 46.15 19.80 0.72 0.85
Slurred speech 45.47 26.58 0.35 0.88
Pain in calf 45.58 23.30 0.74 0.86
Loss o f memory 45.52 26.41 0.30 0.87
Table 6.11 Use o f healthcare services domain mean scores for Test 1 (n=92)
Domain 2 items Mean Std. Deviation
Hospital admission 3.89 0.35
Hospital stay 3.89 0.35
NHS Direct Number 3.99 0.10
Appointment with GP 3.86 0.35
Appointment with nurse 3.83 0.38
Table 6.12 Use o f healthcare services domain item correlations with the total scores
for Test 1 (n=92)
Domain 2 items
SEIP Mean 
if Item 
Deleted
SEIP 
Variance if 
Item 
Deleted
Corrected
Item-Total
Correlation
Cronbach's 
Alpha if 
Item 
Deleted
Hospital admission 15.57 0.75 0.79 0.63
Hospital stay 15.57 0.75 0.79 0.63
NHS Direct Number 15.47 1.31 0.14 0.82
Appointment with GP 15.60 0.86 0.57 0.72
Appointment with nurse 15.63 0.89 0.43 0.78
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Similarly, items in the work domain such as “work schedule and fatigue, day off sick, 
and work limitation” displayed high internal consistency. The Cronbach’s alpha value 
of this 3-item domain was 0.84. The mean scores were also homogeneous and ranged 
between 4.63-4.83 (Tables 6.13) and the Inter-item-Correlations was from 0.61 to an 
excellent 0.81 (Table 6.14).
Table 6.13 Work domain mean score for Test 1 (n=92)
Mean Std. Deviation
Work schedule & fatigue 4.63 0.81
Day off sick 4.83 0.53
Work limitation 4.70 0.89
Table 6.14 Work domain item correlations with the total scores for Test 1
SEIP
SEIP Mean Variance if 
if Item Item 
Deleted Deleted
Corrected
Item-Total
Correlation
Cronbach's 
Alpha if 
Item 
Deleted
Work schedule & fatigue 9.52 1.59 0.81 0.67
Day off sick 9.33 2.57 0.61 0.88
Work limitation 9.46 1.44 0.78 0.71
Retest (Test 2)
In this study o f 93 cardiovascular patients who re-completed the SEIP questionnaire at 
one week interval to the first assessment, data analysis o f the retest was based on 92 
valid and completed SEIP. One patient was excluded from analysis because of 
incomplete SEIP data. The internal consistency reliability results for test 2 (a= 0.93) 
did not show any significant difference to Test 1. Table 6.15 shows the expected SEIP 
items mean scores for test 2. In addition, Corrected-Item-Total Correlations ranged 
between 0.44-0.86 (Table 6.16). Compared to Testl, these figures showed similarity 
in pattern indicating that responses were similar. Internal consistency reliability was 
also calculated for each domain o f the SEIP.
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Table 6,15 Expected SEIP mean scores for Test 2 (n=92)
Domains & its items Mean Std. Deviation
Social interaction & emotional behaviours
Anxious 4.12 0.89
Loss o f interest 4.37 0.80
Loss o f energy 4.13 0.93
Nightmares & terror 4.82 0.38
Cold hands & feet 4.25 0.80
Cough 4.32 0.89
Headache 4.74 0.57
Loss o f sexual activity 4.35 0.84
Slurred speech 4.86 0.38
Pain in calf 4.78 0.51
Loss o f memory 4.84 0.43
Use of healthcare services
Hospital admission 3.79 0.44
Hospital stay 3.79 0.44
NHS Direct Number 3.82 0.38
Appointment with GP 3.77 0.42
Appointment with nurse 3.79 0.41
Work
Work schedule & fatigue 4.48 0.90
Day off sick 4.68 0.65
Work limitation 4.53 0.98
The cronbach’s alpha coefficient value for the social interaction & emotional 
behaviours domain was 0.88 as compared to 0.87 in Test 1. This means that there was 
no significant difference in response behaviours o f participants at both periods. The 
mean scores also ranged between 4.12-4.85 (Table 6.17) and the Corrected-Item-total 
correlations were between 0.49-0.76 (Table 6.18). In contrast to the results o f Testl, 
question 11 o f the SEIP (loss o f memory) showed an increased value of the 
Corrected-Item-total correlation (0.56), thereby confirming the decision not to remove 
this item from the SEIP.
The use o f healthcare services domain with five items, displayed an excellent internal 
consistency with Cronbach’s alpha coefficient estimated at 0.95.
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Table 6,16 Item correlations with the total scores o f overall SEIP for Test2 (n=92)
Domains & its items
SEIP 
Mean if 
Item 
Deleted
SEIP 
Variance 
if Item 
Deleted
Corrected
Item-Total
Correlation
Cronbach's 
Alpha if 
Item 
Deleted
Social interaction & emotional 
behaviours
Anxious 78.12 65.09 0.44 0.93
Loss o f interest 77.87 61.63 0.79 0.92
Loss o f energy 78.11 60.98 0.71 0.93
Nightmares & terror 77.42 67.14 0.78 0.93
Cold hand & feet 77.99 64.81 0.53 0.93
Cough 77.92 62.81 0.61 0.93
Headache 77.51 65.16 0.72 0.93
Loss o f sexual activity 77.89 65.34 0.46 0.93
Slurred speech 77.38 68.68 0.53 0.93
Pain in calf 77.46 65.25 0.81 0.92
Loss o f memory 77.41 67.62 0.62 0.93
Use of healthcare services
Hospital admission 78.45 66.63 0.76 0.93
Hospital stay 78.45 66.63 0.76 0.93
NHS Direct Number 78.42 67.07 0.79 0.93
Appointment with GP 78.47 67.87 0.59 0.93
Appointment with nurse 78.45 67.90 0.61 0.93
Work
Work schedule & fatigue 77.76 61.63 0.69 0.93
Day off sick 77.56 62.89 0.86 0.92
Work limitation 77.71 60.58 0.70 0.93
The mean scores value ranged between 3.77-3.82 (Table 6.19) and the Corrected- 
Item-Total Correlations were estimated between 0.83-0.90 (Table 6.20). The 
Cronbach's alpha coefficients for internal consistency reliability o f work domain was 
0.89 and the item correlations with the total scores were variable ranging between 
0.69-0.88 (Table 6.21). The mean scores pattern was similar to the scores attributable 
to other domains. The values ranged between 4.48-4.67 (Table 6.22).
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Table 6.17 Social interaction & emotional behaviours domain mean scores for Test 2 
(n=92)___________________________
Domain items Mean Std. Deviation
Anxious 4.12 0.88
Loss o f interest 4.37 0.79
Loss o f energy 4.13 0.93
Nightmares & terror 4.82 0.39
Cold hands & feet 4.25 0.79
Cough 4.32 0.89
Headache 4.73 0.58
Loss o f sexual activity 4.35 0.83
Slurred speech 4.85 0.39
Pain in calf 4.77 0.52
Loss o f memory 4.83 0.44
Table 6.18 Item correlations with total scores o f the social interaction & emotional 
behaviours domain for Test 2 (n=92)_________________________________________
Domain items
SEIP Mean 
if Item 
Deleted
SEIP 
Variance 
if Item 
Deleted
Corrected
Item-Total
Correlation
Cronbach 
's Alpha if 
Item 
Deleted
Anxious 45.40 21.83 0.54 0.87
Loss o f interest 45.15 20.94 0.76 0.85
Loss o f energy 45.39 19.93 0.76 0.85
Nightmares & terror 44.71 24.39 0.66 0.87
Cold hands & feet 45.27 22.09 0.59 0.87
Cough 45.21 21.97 0.52 0.87
Headache 44.79 23.22 0.64 0.87
Loss o f sexual activity 45.17 22.19 0.54 0.87
Slurred speech 44.67 25.01 0.49 0.87
Pain in calf 44.75 23.22 0.72 0.86
Loss o f memory 44.70 24.48 0.56 0.87
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Table 6.19 Use o f healthcare services domain mean scores for Test 2 (n=92) 
Domain i t e m s ___________________ Mean Std. Deviation
Hospital admission 3.79 0.44
Hospital stay 3.79 0,44
NHS Direct Number 3.82 0.38
Appointment with GP 3.77 0.42
Appointment with nurse 3.79 0.41
Table 6.20 Use o f healthcare services item correlations with the total scores for Test 2
SEIP Mean 
if Item 
Deleted
SEIP 
Variance 
if Item 
Deleted
Corrected
Item-Total
Correlation
Cronbach's 
Alpha if Item 
Deleted
Hospital admission 15.18 2.28 0.89 0.93
Hospital stay 15.18 2.28 0.89 0.93
NHS Direct Number 15.14 2.41 0.90 0.93
Appointment with GP 15.20 2.38 0.82 0.95
Appointment with nurse 15.18 2.41 0.83 0.94
Table 6.21 Work domain mean scores for Test 2 (n=92)
Mean Std. Deviation
Work schedule & fatigue 4.48 0.90
Day off sick 4.67 0.65
Work limitation 4.52 0.98
Table 6.22 Work domain item correlations with the total score for Test 2 (n=92)
Scale Mean 
if Item 
Deleted
Scale 
Variance if 
Item 
Deleted
Corrected
Item-Total
Correlation
Cronbach's 
Alpha if 
Item 
Deleted
Work schedule & 
fatigue 9.20 2.20
0.88 0.75
Day off sick 9.00 3.30 0.69 0.93
Work limitation 9.15 2.02 0.85 0.79
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Patients9 views about the relationship between side effects and their 
medication
When patients who completed the questionnaire were asked whether the side effects 
they experienced were due to their medications, the majority o f the respondents did 
not think the side effects were medication-related (Table 6.23)
Table 6.23 Response rate o f participating patients to questions in domain 1 o f the SEIP
Type of medication 
side effects
No. of patients 
that suffered 
side effect
No of patients 
without side effect
Do you think it is 
due to side effect of 
your medicine?
Yes No Unsure
Anxious 54 38 0 28 26
Loss o f interest 50 42 0 39 11
Loss o f energy 54 38 9 33 12
Nightmares & terror 17 75 0 17 0
Cold hand & feet 52 40 0 31 21
Cough 49 43 8 26 15
Headache 18 74 1 15 2
Loss o f sexual activity 39 53 0 24 15
Slurred speech 9 83 0 9 0
Pain in calf 18 74 0 17 1
Loss o f memory 14 78 1 11 2
DISCUSSION
As the SEIP was designed for use with community- managed cardiovascular patients 
on repeat medication therapy, the hypothesis was that there should be no dramatic 
change(s) in these patients medical conditions, since most o f them would have been 
taking their medication for three months and above and hence have stable medical 
conditions with minimum or no side effects o f drug therapy. With this in mind, the 
expectation was that SEIP items should be consistent and should measure the same 
dimensions o f impact of medication side effects among these cardiovascular patient 
groups.
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A total o f 93 (62.0%) patients returned the questionnaires by pre-paid envelope to 
both test 1 and 2 in this study. Their sociodemographic characteristics showed that 
63.4% were on drug therapy for hypertension, and 24.7% suffered from other medical 
conditions in addition to hypertension. This is an indication that the majority of these 
patients were highly involved in the management o f their condition. Applicability and 
practicality results showed that one-third of the respondents actually completed the 
questionnaires in three minutes and the fact that the mean time taken to complete the 
questionnaire was 5.7 minutes indicated patients’ acceptability o f the measure. To 
support this notion, the majority of the respondents (96.7%) found the SEIP 
questionnaire to be clear and understandable and 78.5% patients thought that the SEIP 
questions were comprehensive enough to measure their socioeconomic wellbeing, 
while almost all the respondents agreed that the SEIP questionnaire was not difficult 
or distressing to complete. These findings therefore supported the arguments for the 
practicality o f  the measure among cardiovascular patients.
The fact that a great majority o f the patients who returned the questionnaires 
completed all parts of the questions indicates its reliability and relevance among 
cardiovascular patient populations managed in the community setting. The reported 
overall Cronbach’s alpha and the Corrected Item-Total Correlation coefficients in 
both Test 1 and Test 2 supported the homogeneity of the SEIP in measuring the 
socioeconomic impacts o f medication side effects of cardiovascular drugs. 
Homogeneity o f the items in this scale was further affirmed, as deletion o f any items 
with low Corrected-Item-Total Correlation coefficient yielded negligible 
improvement in the alpha coefficient (Boyle, 1999).
With regards to the test-retest reliability results measured with the Spearman’s 
correlation coefficients, SEIP demonstrated significant item correlations in both Test 
1 and Test 2. Most items showed high Spearman’s rho with the exception o f two 
items (“slurred speech” and “NHS Direct Number”) that indicated low values of 
Spearman’s rho = 0.39 and 0.22 respectively.
Findings o f this study supported the SEIP as a valid and reliable instrument for 
evaluation o f the socioeconomic impacts o f medication-related problems of
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cardiovascular drugs. The internal consistency reliability results yielded close to 
perfect correlation coefficients. Such indication of robustness of the SEIP provides an 
extremely encouraging impetus to build upon in generating confidence for its use in 
practice.
It should be emphasised that this study tested the psychometric properties of the SEIP 
among community-managed cardiovascular patients on repeat medication 
prescriptions with intact cognitive ability. The majority o f these patients were 
hypertensive and were 57 years and above. Limitations therefore exist in generalising 
the results o f this study to other cardiovascular populations who are not community- 
pharmacy managed and o f younger age or with impaired cognitive function.
SUMMARY
• The test-retest reliability property o f the SEIP as well as its practicality were 
carried out in a total o f 150 community-managed cardiovascular patients out of 
which 93 (63.0%) responded.
• The mean time taken to complete the SEIP was 5.7 minutes; the majority o f the 
respondents agreed that the questions were comprehensive, clear and easy to 
administer.
•  Overall, all SEIP domains demonstrated high evidence o f internal consistency 
reliability as well as test-retest reliability.
•  Future work should focus on generalising the study to other categories of 
cardiovascular diseases which are not community managed in order to determine 
the test-retest reliability o f the SEIP and its responsiveness.
The next chapter o f this thesis will focus on further psychometric properties o f the 
SEIP such as its validity (discriminant and convergent).
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CHAPTER 7
Validation of the Socioeconomic Impact 
Profile (SEIP) - Convergent and Divergent
Validity
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INTRODUCTION
The necessity for a comprehensive and yet practical tool with which to assess 
medication-related socioeconomic problems in community managed cardiovascular 
patients has prompted development and validation of such measure as described in the 
previous chapters. Nevertheless, its utility can only be confirmed after relevant 
psychometric properties for such instrument are established (Guillemin et al., 1993; 
Bernhard et al., 1996). Any measurement scale or instrument must possess a sound 
reliability and validity in order to widen its acceptability for use in research as well as 
in practice routine (Bootman et al., 2005). Chapter 6 described the reliability of SEIP 
among patients on cardiovascular drugs in the community setting. This chapter will 
therefore explore its validity.
Validity refers to the extent to which differences in test scores reflect the true 
differences in individuals under study (Bowling, 2005b). This technique has been well 
documented in chapter two o f this thesis. Moreover, the types of validation necessary 
and most applicable to health measures should include content, construct and criterion 
validity. Evidence of content validity of SEIP has been provided in chapter 4 in terms 
o f mean scores for agreement level (1 to 4) for each item of the SEIP and also kappa 
coefficient (k) for level o f agreement among experts panel who validated the 
instrument. Chapter 5 provides evidence of construct validity of SEIP by using a 
factor analysis technique to identify items that are highly correlated with each other 
but exhibit low levels of correlation with other variables in the measure thereby 
indicating potential underlying structure o f the instrument.
Construct validity has been extensively described in chapter 2. Understanding this 
technique provides knowledge o f behaviour o f the instrument and its validity. 
Construct validity is determined by comparisons between measures and examining the 
relationships between the measure and characteristics of the population being 
assessed. The following aspects should be considered when establishing construct 
validity of a new health measure (Walker, 2002):
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•  The measured variable should display low correlation with related measures 
but different constructs (divergent validity).
• The measured variable should show positive correlation with related and 
similar constructs (convergent validity).
Aims o f the present study
In this chapter, it is hoped to examine the followings:
•  The convergent validity of the SEIP patient scores by comparisons with 
MIDAS patient scores;
• The divergent validity of the SEIP patient scores by comparison with SF-12 
patient scores.
•  The relationship between SEIP patient scores and some sociodemographic 
characteristics such as age, gender and duration o f condition;
M ETHODS  
The outcome measures
The outcome measures used in this validity study included the MIDAS and the SF-12. 
These two health measures have been well described in chapter 2; however, a 
summary o f these will be described here for the purpose o f clarity and completion.
The myocardial infarction dimensional assessment scale (MIDAS)
The MIDAS has been fully described in chapter 2. It is a self-administered cardio- 
specific quality o f life instrument measuring seven areas o f health status. It takes 5 to 
10 minutes to complete using a 5-point Likert scale response option. The MIDAS 
includes 35 questions grouped into seven domains, namely: physical activities (12 
items), insecurity (9 items), emotional reactions (4 items), dependency (3 items), diet 
(3 items), concern about medications (2 items) and side effects o f medications (2 
items). The structure and maximum possible score for each domain are shown in 
Table 7.1. The MIDAS was chosen for use in this study because of its high face, 
internal and constructs validity and has been validated among the same patient group 
as this study.
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Table 7.1 Structure of the MIDAS
Domain No of items Maximum score
Physical activity 12 60
Insecurity 9 45
Emotional reaction 4 20
Dependency 3 15
Diet 3 15
Concerns over medication 2 10
Side effects 2 10
Total 35 175
Medical Outcomes Study Short Form-12 health survey (SF-12)
The SF-12 as described in chapter 2 is an established generic health measure that has 
been used in cardiovascular patients. It is designed in responding to the need for 
development o f a shorter instrument to the original SF-36. It has been used as a self­
administered questionnaire and takes about 2 minutes to complete (Bowling, 2005b). 
The SF-12 includes eight health concepts such as physical functioning (PF), role 
functioning physical (RFP), bodily pain (BP), general health (GH), vitality (VT), 
social functioning (SF), role functioning emotional (RFE), and mental health (MH). 
Each concept is scored on a 0-100 scale with 0 and 100 corresponding to worst and 
best HRQOL respectively. These 8 concepts are used to monitor overall physical and 
mental health outcomes known as the Physical Component Summary (PCS-12) and 
the Mental Component Summary (MCS-12) respectively. Scale scores are estimated 
for four o f the health concepts (PF, RFP, RFE, and MH) using two items each, 
whereas the remaining four (BP, GH, VT, and SF) are represented by a single item. 
All 12 items are used to calculate the physical and mental component summary scores 
(PCS-12 and MCS-12) by applying a scoring algorithm empirically derived from the 
data o f a US general population survey (Ware et al., 1995). It has been recommended 
that the US-derived summary scores, which yield a mean o f 50 and SD o f 10, be used 
in order to facilitate cross-cultural comparison o f results (Gandek et al., 1998).
It should be noted that reverse scoring o f four items is required so that a higher item 
value indicates better health for all SF-12 items and summary scales. Four SF-12 
items are therefore reverse scored because higher precoded item values for these items
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indicate a poorer health state. The four items that are reversed scored are: GH1 (item 
1), BP2 (item 8), MH3 (item 9), and VT2 (item 10). For example, the highest 
precoded value for the item “How much o f the time did you feel calm and peaceful” is 
“6-None o f the time”, which indicates a poor health state (Appendix 15).
The 12 items o f the SF-12 yield the eight-scale profiles o f the SF-36, but with fewer 
levels and with less precise scores. This has been considered as its limitation in 
different published studies. The SF-12 was chosen for use in this study on the grounds 
of its wider acceptability as a generic health measure especially in the cardiovascular 
patient group. It is also less time consuming to complete with minimum burden on 
patients. This was an important factor to consider since patient were to be asked to 
complete three questionnaires.
Study procedure
Cardiovascular patients on repeat prescriptions were recruited from two community 
pharmacies in South West Wales. The questionnaires were administered with a 
personalised covering letter to maximise the response rate. Order o f completion of the 
questionnaires was randomised in order to remove training effects on patients. 
Patients were asked to return the completed questionnaires in a pre-paid envelope 
included in the pack. All data from the questionnaires were entered into the SPSS 12 
data package for analysis.
Data processing and analysis
The data were analysed using SPSS statistical package. Patients’ demographic data 
were entered along with the patient identification number, followed by the response 
data. Missing values were assigned a score o f “999” and a quality control check was 
carried out to ensure the accuracy o f data entry. Validity was measured using non- 
parametric techniques. The following relationships were examined using appropriate 
statistical tests:
•  The relationship o f SEIP scores and other outcome measures scores with 
patient gender using the Mann Whitney U Test;
•  The relationship o f SEIP scores and other outcome measures scores with 
patient age using the Mann Whitney U Test.
188
• The relationship of SEIP scores and other outcome measures scores with the 
duration o f condition using the Mann Whitney U Test.
•  The association between SEIP scores, MIDAS scores and SF-12 scores using 
Spearman’s rank correlation test (rs values ranging 0.10-0.29 = weak, 0.30- 
0.49 = moderate, and > 0.50 = strong).
RESULTS
A total o f 175 patients were recruited into the study o f which 96 returned their 
questionnaires giving an overall response rate o f 54.8%. Table 7.2 shows the 
demographic characteristics o f the respondents. Forty-nine patients (51.0%) were 
males. The mean age was 63.1 years and the mean duration o f condition was 124.4 
months. The age o f participants ranged from 39 to 84 years with a median age of 63 
years. Fifty-nine patients (61.5%) were married, 49 (51.0%) had a high school 
education, 27 (28.1%) had a university degree and 14 (14.6%) had a primary 
education. Thirty-seven (38.5%) were employed and over one-third of the participants 
earned between £10,000 and £20,000 annually. Twenty-four (25.0%) were 
hypertensive while 43 (44.8%) suffered from another concomitant medical condition. 
These included diabetes (typel or type II), asthma, COPD, arthritis and depression.
The SEIP scores
Table 7.3 &7.4 show the mean scores for the SEIP and other outcome measures used 
in the study. The overall mean score o f the SEIP for all patients was 82.4 (91.6%). 
The mean scores o f domain 1 to 3 o f the SEIP were 48.61 (88.4%), 19.44 (97.2%), 
and 13.57 (90.5%), respectively indicating low impacts of MRPs on patients’ 
socioeconomic wellbeing (Figure 7.1). Both MIDAS and the SF-12 displayed high 
scores out o f the maximum possible scores. This indicates that medication-related 
problems in the observed populations had low negative impacts on their 
socioeconomic wellbeing. The SF-12 item and summary descriptive statistics are 
presented in Table 7.4. Four o f the items were recoded so that higher scores 
correspond to better health. The PCS-12 and MCS-12 summary scores were 
negatively skewed since respondents scored towards the higher end o f the health 
spectrum.
Table 7.2 Demographic characteristics of the study patients
Variables Number (percentage)
Age (years)
Mean 63.1
Median 63.0
Range 39-84
Gender
Male 49 (51.0)
Female 47 (49.0)
Duration of condition (in months)
Mean 124.4
Median 84.0
Range 3-612
Medical condition
Hypertension 24 (25.0)
Heart failure 1 (1.0)
High cholesterol 1 (1.0)
Angina 5 (5.2)
Heart attack 8(8.3)
Heart attack and others 4 (4.2)
Hypertension and others 43 (44.8)
Non cardiovascular -related 5 (5.2)
Education
None 2(2.1)
Primary school 14(14.6)
High school 49(51.0)
University degree 27(28.1)
Marital status
Single 11 (11.5)
Divorced 7(7.3)
Married 59 (61.5)
Widowed 18(18.8)
Separated 1 (1.0)
Employment
Employed 37(38.5)
Unemployed due to health 8(8.3)
Unemployed not due to health 1 (1.0)
Retired due to health 23 (24.0)
Retired not due to health 22 (22.9)
Self employed 4 (4.2)
Annual income
<£10000 38(39.6)
£10000 <E  <£20000 31 (32.3)
£20000 < E < £30000 7(7.3)
£30000 < E < £40000 10(10.4)
E > £40000 3(3.1)
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Figure 7.1 The SEIP mean scores
o -
Social interaction & Use of healthcare Work
emotional behaviors services
SEIP Domains
Table 7.3 Mean scores for SEIP & MIDAS (n=96)
D om ains No o f 
item s
M ean scores 
(SD)
M edian
R ange
S E IP
Social interaction & em otional behaviours 11 48.61 (6.30) 30-55
Use o f  healthcare services 5 19.44 (1.16) 15-20
W ork 3 13.57 (2.73) 3-15
M ID A S
Physical activity 12 49.82 (10.87) 15-60
Insecurity 9 41.19 (7.53) 11-45
Em otional reaction 4 16.71 (4.13) 4-20
D ependency 3 13.59 (2.64) 5-15
Diet 3 11.59 (2.87) 3-15
C oncerns over m edication 2 8.63 (2.02) 2-10
M edication side-effects 7 8.43 (1.96) 2-10
191
Comparisons of patients' demographic characteristics for SEIP, MIDAS and SF- 
12
Mann Whitney U Test was used to compare patients’ gender, age and duration of 
disease for the three outcome measures.
Gender
The SEIP, MIDAS and SF-12 scores for males and females were compared. There 
were no statistically significant differences (P>0.05) between the scores for males and 
females (Table 7.5). The female patient group showed a trend toward worse 
socioeconomic wellbeing as indicated by lower SEIP scores. Lower MIDAS scores of 
the subscales o f dependency, diet, and concerns over medication indicated that female 
patient group experienced poor health state as a result o f medication side effects. On 
the other hand, males patient group scored higher than their female counterpart for 
both summary scores. Higher scores of the physical component scales (PCS-12) and 
the mental component scales (MCS-12) indicate better state of health among the male 
patient group.
Age
The procedure for performing this analysis involved the splitting of patient age along 
the median to produce two approximately equal groups. All those aged under 64 years 
were included in one group and all those that were 64 years and above were included 
in smother group. The SEIP, MIDAS, and SF-12 scores for these two groups were 
then compared (Table 7.6). No statistically significant differences (P>0.05) were 
observed between the SEIP scores of patients below 64 years and those above 64 
years. However, the scores for all three domains o f the SEIP were higher for < 64 
years. This trend indicated that the patients group under 64 years had better 
socioeconomic wellbeing than the > 64 years patient group. In contrast, the results 
showed varying significance levels among scores of MIDAS scales and the SF-12.
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Table 7.4 SF-12 item and summary descriptive statistics (n=96)
Item description (scale) Mean (SD) Median Response frequencies (%)
1 2 3 4 5 6
Moderate activities (PF) 2.27 (0.76) 2.00 18.8 35.4 45.8 - - -
Climb several flights (PF) 1.97 (0.75) 2.00 29.2 44.8 26.0 - - -
Accomplished less (RFP) 1.47 (0.50) 1.00 52.1 46.9 - - - -
Limited kind of work (RFP) 1.49 (0.50) 1.00 50.0 49.0 - - - -
Pain interferes* (BP) 3.95 (1.35) 5.00 52.1 13.5 8.3 16.7 5.2 -
Health in general* (GH) 2.70 (0.83) 3.00 1.0 13.5 43.8 32.3 6.3 -
Energy* (VT) 3.59(1.45) 4.00 4.2 32.3 12.5 22.9 14.6 9.4
Social time (SF) 1.99(1.38) 1.00 2.1 5.2 9.4 9.4 16.7 53.1
Emotional problem (RFE) 1.24 (0.43) 1.00 76.0 24.0 - - - -
Less work &emotional problem (RFE) 1.22 (0.42) 1.00 74.0 20.8 - - - -
Calm & peaceful* (MH) 4.28(1.36) 5.00 20.8 30.2 10.4 26.0 6.3 2.1
Felt down / sad (MH) 2.11 (1.27) 2.00 - 5.2 14.6 7.3 27.1 41.7
Summary statistics PCS-12 MCS-12
Mean (SD) 48.42(1.26) 47.23 (2.15)
Median 48.00 46.00
Skewness -0.23 -0.28
* Item recoded so that higher scores correspond to better health.
Table 7.5 Comparisons of patients’ gender for mean scores o f SEIP, MIDAS & SF-12
Outcome measures Mean rank Scores Mann Whitney U 
Test
Male Female Z* P value
SEIP
Social interaction & emotional behaviours 42.96 46.19 +0.59 0.55
Use of healthcare services 50.68 43.39 -1.75 0.08
Work 47.90 42.17 -1.27 0.20
MIDAS
Physical activity 42.43 46.66 +0.79 0.43
Insecurity 38.40 47.23 + 1.80 0.07
Emotional reaction 43.54 49.73 + 1.16 0.24
Dependency 47.21 45.73 -0.34 0.73
Diet 45.11 42.81 -0.43 0.67
Concerns over medication 47.14 44.78 -0.46 0.65
Medication side-effects 44.76 48.40 +0.69 0.49
SF-12
Physical Component Summary (PCS) 48.95 47.44 -0.17 0.87
Mental Component Summary (MCS) 48.10 46.90 -0.33 0.74
Z*= median o f  distribution
There was a significant difference in the scores o f MIDAS subscales physical activity 
(P<0.001), diet (P<0.04) and medication side-effect (P<0.02). This significant trend 
may indicate that patients < 64 years do not suffer medication side effects to a degree 
that will affect their physical activities. Significantly lower mean PCS-12 (P<0.01) 
were observed among those above 64 years, compared to those less than 64 years. In 
contrast, those above 64 years showed higher mean MCS-12 (P<0.05) than those less 
than 64 years. These significant trends are indicative o f the discriminative ability of 
the SF-12 since for every health problem, at least one summary score was 
significantly lower in the observed group.
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Table 7.6 Comparisons of patient age for SEIP, MIDAS, and SF-12 scores.
Outcome measures Mean rank scores 
(years)
Mann Whitney U 
test
<64 £ 6 4 Z P value
SEIP
Social interaction & emotional behaviours 46.55 41.92 -0.85 0.39
Use of healthcare services 50.40 43.22 -1.72 0.09
Work 47.74 41.93 -1.29 0.19
MIDAS
Physical activity 52.33 35.93 -3.05 0.001
Insecurity 43.79 41.01 -0.57 0.57
Emotional reaction 46.96 46.00 -0.18 0.86
Dependency 49.19 43.57 -1.31 0.19
Diet 38.69 49.43 +2.02 0.04
Concerns over medication 43.97 48.27 +0.83 0.41
Medication side-effects 52.41 40.06 -2.35 0.02
SF-12
Physical Component Summary (PCS) 45.64 38.71 -2.81 0.01
Mental Component Summary (MCS) 42.37 50.43 +2.02 0.04
Com parisons of patients9 duration o f disease for the SEIP, MIDAS, 
and SF-12
In order to perform this, duration o f disease was split along the median to produce two 
approximately equal groups. All those with duration of medical condition less than 85 
months formed one group and those with disease duration o f 85 months or more 
populated the other group. The Mann Whitney U Test was used to perform 
comparison o f SEIP, MIDAS, and SF-12 scores for these two groups (Table 7.7). 
There were no significant differences (P>0.05) observed between SEIP scores of 
patients with a duration o f condition less than 85 months and those with longer. 
However, the trend o f the scores for the three domains o f the SEIP to all move in a 
negative direction meant those scores for the SEIP domains were lower for patients 
with a longer duration o f disease. This trend may indicate that those with a longer
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duration o f disease did experience medication side effects with negative impacts on 
their socioeconomic wellbeing. Similarly, those with longer duration of disease 
showed lower scores in all subscales o f the MIDAS. This is an indication o f poor 
health status among this patient group.
In contrast, there were significant differences between a duration o f condition less 
than 85 months and those that were 85 months and longer for most of the SF-12 
subscale including Physical functioning (P<0.001), Social Functioning (P<0.01), 
Vitality (P<0.001), and Mental Health (P<0.01). This indicated that those patients 
with a longer duration o f medical condition showed significantly greater impairment 
in Physical Component Summary Scales (PCS-12) but did reasonably well with the 
Mental Component Summary scales (MCS-12). This trend may indicate that those 
with a longer duration o f disease have an intact cognitive status.
Internal validity o f the SEIP
The relationships between SEIP items and their domains was examined using 
Spearman’s Rank Order Correlation. When comparisons were made between items in 
the SEIP and its domains, strong correlations were observed in most cases (Table 7.8). 
Social interaction and emotional behaviour items (1-11) produced moderate to strong 
correlations with their own domains (rs = 0.32-0.86) and in most cases showed weak 
correlations with the use of health services domain and work domain. Similar trends 
were observed with items in the other domains. All items (12-16) correlated stronger 
with the use o f healthcare services domain (rs= 0.40-0.80) than with other domains. In 
addition, items (17-19) showed stronger correlations (rs=0.58-0.89) with work domain 
than other domains of the SEIP. This suggests the internal stability o f the SEIP.
Table 7.7 Comparisons o f patients' duration o f disease for SEIP, MIDAS & SF-12
Outcome measures Mean rank Mann Whitney U
scores (months) Test
<85 £  85 Z P value
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SEIP
Social interaction & emotional behaviours 49.74 40.49 -1.67 0.09
Use of healthcare services 47.88 45.69 -0.51 0.61
Work 46.82 43.11 -0.79 0.43
MIDAS
Physical activity 49.39 40.70 -1.58 0.11
Insecurity 43.16 41.27 -0.38 0.71
Emotional reaction 47.43 45.15 -0.42 0.68
Dependency 51.01 43.01 -1.81 0.07
Diet 44.52 42.90 -0.29 0.77
Concern about medication 50.62 42.39 -1.55 0.12
Medication side-effects 46.79 45.53 -0.24 0.81
SF-12
General Health 49.82 44.64 -0.96 0.34
Physical Functioning 59.75 41.45 -3.18 0.001
Social Functioning 38.82 52.42 +2.68 0.01
Role Functioning Physical 50.52 43.49 -1.61 0.11
Role Functioning Emotional 40.95 48.13 + 1.74 0.08
Vitality 56.23 40.18 -3.05 0.001
Bodily Pain 43.66 41.33 -1.29 0.19
Mental Health 39.21 52.20 +2.56 0.01
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Table 7.8 C orrelations t  between SEIP items and their corresponding domains
SEIP
D om ains
Social interaction & emotion behaviours domain Use of healthcare services 
domain
Work domain
Item
1
Item
2
Item
3
Item
4
Item
5
Item
6
Item
7
Item
8
Item
9
Item
10
Item
II
Item
12
Item
13
Item
14
Item
15
Item
16
Item
17
Item
18
Item
19
1 0.82** 0.78** 0.86** 0.45** 0.53** 0.40** 0.32** 0.66** 0.43** 0.58** 0.51** 0.28 0.22 0.12 0.10 0.06 0.12 0.28 0.21
2 0.26* 0.38** 0.23 © 00 «- -» 0.22 0.22 0.26* 0.31** 0.30** 0.33** 0.03 0.80** 0.80** 0.38** 0.61** 0.40** 0.03 0.18 0.15
3 0.27* **o© 0.05 0.21 0.09 0.07 0.17 0.30** 0.16 0.02 0.07 0.26** 0.35** 0.11 0.01 -0.06 0.85** 0.58** 0.89**
tSpearman’s rank correlation coefficients (rs). **P< 0.01; *P< 0.05.
Domain 1= Social interaction and emotional behaviour 
Domain 2= Use of health services 
Domain 3= Work
Item 1= Anxious, item 2= Loss of interest, item 3= Loss of energy, item 4= Nightmares & terror, item 5= Cold hands & feet 
Item 6= Cough, item 7= Headache, item 8= Loss of sexual activity, item 9= Slurred speech, item 10= pain in calf,
Item 11= Loss of memory, item 12= Hospital admission, item 13= Hospital stay, item 14= NHS direct use,
Item 15= Appointment with GP, item 16= Appointment with nurse, item 17= Work schedule & fatigue,
Item 18= Day off sick, item 19= Work limitation.
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Convergent validity o f the SEIP
The construct validity of some o f the SEIP domains was examined by testing their 
associations with the relevant dimensions o f the MIDAS scales (Table 7.9). Most 
subscales o f the MIDAS correlated well (P<0.05 to P<0.01) with the SEIP domains. 
The MIDAS subscale relating to physical activity (MIDAS 1) correlated moderately 
(rs= 0.44; P<0.01) with the SEIP 1 (social interaction and emotional behaviour) and 
weakly with the use of health services domain (rs= 0.26; P<0.05) and work domain 
(rs= 0.29; P<0.01) of the SEIP. The insecurity subscale (MIDAS 2), the emotional 
reaction subscale (MIDAS 3), and the dependency subscale (MIDAS 4) all correlated 
moderately with the social interaction and emotional behaviour domain of the SEIP 
(rs= 0.32-0.35; P<0.01).
There was no significant correlation observed between the diet subscale of the 
MIDAS and the social interaction and emotional behaviour domain o f the SEIP (rs= 
0.16; P>0.05). However, a weak correlation was observed between the diet subscale 
o f MIDAS and the work domain o f the SEIP (rs= 0.26; P<0.05). Furthermore, the 
medication side effects subscale o f MIDAS demonstrated a moderate correlation with 
the social interaction and emotional behaviour domain o f the SEIP (rs= 0.31; P<0.01).
The insecurity subscale, the emotional reaction subscale, the dependency subscale, the 
diet subscale and the concerns over medication subscales o f the MIDAS all 
demonstrated poor correlations with the use o f health services domain of the SEIP 
(rs= 0.02-0.19). Furthermore, SEIP domain 3 (work) produced weak correlations with 
all other scales of the MIDAS (rs=0.22- 0.29; p<0.05) except dependency subscale 
(MIDAS 4) for which correlation was poor (rs =0.17). The result o f this exercise 
suggests that the SEIP possesses an acceptable convergent validity.
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Table 7.9 C o rrela tio n st between domains of the SEIP and MIDAS subscales
Domains SEIP 1 SEIP 2 SEIP3 MIDAS 1 MIDAS 2 MIDAS 3 MIDAS 4 MIDAS 5 MIDAS 6 MIDAS 7
SEIP 1 1.00
SEIP 2 0.34** 1.00
SEIP 3 0.37** 0.27* 1.00
MIDAS1 0.44** 0.26* 0.29** 1.00
MIDAS 2 0.35** 0.19 0.23* 0.72** 1.00
MIDAS 3 0.35** 0.16 0.23* 0.78** 0.83** 1.00
MIDAS 4 0.32** 0.16 0.17 0.63** 0.57** 0.69** 1.00
MIDAS 5 0.16 0.02 0.26* 0.33** 0.38** 0.55** 0.30** 1.00
MIDAS 6 0.27* 0.09 0.28* 0.34** 0.51** 0.46** 0.28** 0.75** 1.00
MIDAS 7 0.32** 0.24* 0.22* 0.59** 0.51** 0.63** 0.47** 0.38** 0.30** 1.00
tSpearm an’s rank correlation coefficients (rs) 
**P<0.0l; *P<0.05
Note:
SEIP 1= Social interaction and emotional behaviour SEIP 2= Use of health services domain SEIP 3= Work domain 
MIDAS I = Physical activity domain MIDAS 2= Insecurity domain MIDAS 3= Emotional reaction 
MIDAS 4= Dependency MIDAS 5= Diet MIDAS 6= Concerns over medication MIDAS 7= Medication side effects
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Divergent validity of the SEIP
Comparisons o f scores were made for the SEIP and the Short Form-12 (Table 7.10). 
Moderate to high correlations (rs= 0.32-0.45; P<0.01) were observed between the 
social interaction and emotional behaviour domain o f the SEIP and all but one of the 
SF-12 domains (i.e. physical functioning, general health, social functioning, physical 
role functioning, role functioning emotional, vitality and mental health). In contrast, 
domain 2 o f the SEIP (the use o f health services) did not correlate significantly with 
any o f the categories on the SF-12 (rs= 0.04-0.21) except the vitality domain which 
showed a weak correlation (rs= 0.23; P<0.05). Furthermore, with the exception of the 
social functioning domain and the vitality domain o f the SF-12, all other categories 
did not show any significant correlations (rs= 0.02-0.17) with the SEIP domain 3 
(work). This indicates that these corresponding domains of the SF-12 are not 
measuring similar underlying concepts as domain 2 and 3 o f the SEIP.
Table 7.10 Correlationst between the SEIP and SF-12 domains
SF-12 health concepts _______________________ SEIP
Social interaction & 
emotional behaviours
Use of healthcare 
services
Work
General health 0.39** 0.15 0.17
Physical functioning 0.32** 0.20 0.02
Social functioning -0.40** 0.14 -0.23*
Role functioning physical -0.45** 0.03 0.08
Role functioning emotional -0.40** -0.21 0.01
Vitality -0.44** 0.23* 0.27*
Bodily pain -0.01 0.05 -0.03
Mental health -0.45** 0.04 -0.07
tSpearm an’s rank correlation coefficients (rs) 
**P<0.0l; *P<0.05
DISCUSSION
As suggested by Bootman et al (2005), the development and wider acceptability of 
any measurement scale or instrument will not be complete without testing of the tool’s 
psychometric properties such as reliability and validity in order to determine whether
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the instrument in question can perform as expected before its implementation in the 
target population at large. The SEIP questionnaire has been shown in the previous 
chapters o f this study to be reliable both in terms o f internal consistency and test- 
retest reliability in the target population o f community-managed cardiovascular 
patients. Content validity o f the SEIP has also been addressed in chapter 4 by 
developing items on the basis o f in depth discussions with experts in the area of 
community pharmacy practice and with cardiovascular patients. The content of the 
SEIP addresses experiences o f great importance to individuals on cardiovascular drug 
treatment such as lack o f energy, depression, insomnia and libido. Such experiences 
are quite distinctively associated with some cardiovascular medication side effects.
The results in this chapter has undoubtedly demonstrated the validity of the SEIP 
through measuring what it was intended to measure in patients on cardiovascular drug 
treatments. In addition to the results of construct validity (factor analysis) described in 
chapter five, this chapter has further demonstrated evidence o f the construct validity, 
in particular that of convergent and divergent validity.
The high domain scores o f SEIP and the two health measures (MIDAS and SF-12) 
demonstrated that majority of the observed populations did not consider medication- 
related problems as impediments to their socioeconomic wellbeing. Also, it was 
shown that neither age nor gender o f the observed patients has any significant effect 
on the impacts o f MRPs on their socioeconomic wellbeing. However, the results of 
the relationship between age and scores o f the other two patient-reported outcome 
measures showed significant correlation for patient age and scales of MIDAS 
(physical activity, diet and medication side effects) as well as SF-12 domains 
(physical functioning, social functioning, role functioning emotional, vitality and 
mental health items). This is not surprising as published studies had demonstrated that 
both the physical and mental scales (PCS-12 and MCS-12) o f the SF-12 are able to 
discriminate between age groups (Lim and Fisher, 1999), providing evidence of its 
construct validity. The finding that MCS scores increased with increasing age is 
consistent with the majority o f the literature that notes that MCS scores tend to 
improve with increasing age (as opposed to PCS scores which generally decline).
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Furthermore, the results of the relationship between patient’s duration of medical 
condition and the scores of the other patient-reported outcome measures demonstrated 
that SF-12 is also able to discriminate between patients’ physical and mental scale and 
duration o f condition. In this study, those patients with medical condition longer than 
85 months showed worse impairments in Physical Component Summary than those 
with medical condition less than 85 months but better health status in terms of the 
scores for the Mental Component Summary.
Further evidence for the validity o f SEIP was demonstrated with its comparison with a 
widely used generic health measure (SF-12) and a cardio-specific instrument 
(MIDAS). Correlations with the SF-12 were of poor to weak magnitude especially 
with the use o f health services domain and work domain o f the SEIP indicating that 
these domains were measuring distantly related concepts. The social interaction and 
emotional reaction domain of the SEIP was strongly related with the physical and 
mental scale o f the SF-12 and the physical activity scale of the MIDAS. This 
demonstrated that these domains were measuring closely related concepts.
Finally, the findings of this chapter have demonstrated that the SEIP, a questionnaire 
designed to assess socioeconomic impacts o f cardiovascular drug-related problems 
has acceptable validity in the observed cardiovascular patient groups and can be 
recommended as a patient-reported health outcome measure for use in routine practice 
and in conjunction with medicine use review (MUR).
SUMMARY
• The observed associations between the social interaction and emotional 
behaviour domain o f the SEIP and the subscales of MIDAS on physical 
activity, insecurity, emotional reaction, dependency, concern over medication 
and medication side effects, support the construct validity of the SEIP;
•  With the exception of the social interaction and emotional behaviour domain 
o f the SEIP (rs= 0.32-0.45), the other two domains demonstrated weak to poor
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correlation (rs= 0.02-0.27) with both the physical and mental scale of the SF- 
12 indicating the divergent validity property o f the SEIP.
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Chapter 8
General Discussion
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The importance o f measurement of health-related social and economic wellbeing in 
patients with cardiovascular conditions has been widely recognised (Treasure, 1999; 
Dempster and Donnelly, 2000; Smith, et al., 2000), though, to date, systematic 
attempts to assess social and economic impacts of cardiovascular medication-related 
problems from the perspective o f the patients have been relatively limited. Modem 
medicines have contributed to longer life spans, improved health and better quality of 
life. Medication is the most common treatment for many diseases and conditions seen 
in chronically ill individuals (Donohue and Pincus, 2007). Medicines now not only 
treat and cure diseases that were untreatable just a few years ago, they aid in the early 
diagnosis o f  disease; prevent life-threatening illnesses; relieve pain and suffering, and 
allow people with terminal illnesses to live more comfortably during their last days 
(Fillenbaum et al., 2004). However, prescribed medication, over-the-counter 
medication, social drugs such as alcohol, and herbal remedies/alternative medicines 
can be a double-edged sword. When not used appropriately, effectively and safely, 
medication can have devastating consequences.
In the past decade, it has been recognised that a patient’s perspective is as important 
as a clinician’s professional opinion in the process o f treatment decision taking. As a 
testimony to this, various techniques have been developed for measuring patients’ 
perspective (Geigle and Jones, 1990; Leplege and Hunt, 1997). In the western world 
today, the incidence and prevalence o f cardiovascular disease is steadily increasing 
(Carlberg et al., 2004). Not only do these patients suffer from highly distressing 
symptoms o f their medical condition such as fatigue, depression and insomnia, they 
also experience various medication-related side effects (Westerlund et al., 2003). 
Cardiovascular drug-related problems if  not well managed often cause distress and 
impairment o f social wellbeing for patients and economic burden for the health 
services. Many people are more likely to suffer medication-related problems (MRPs) 
as a result o f  multiple drug therapy due to their condition (Hammerlen et al., 2007). 
Such situations would have double jeopardy economic consequencies for the health 
services.
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Nevertheless, research has shown that medication-related problems are often 
preventable. Caregivers can play a key role in helping to identify when an actual or 
potential MRP is occurring. This assistance can help prevent the costly and unwanted 
negative consequences o f medication use, such as admission to acute care hospitals, 
assisted living facilities or nursing homes. About one quarter of all nursing home 
admissions are due at least in part to the inability to take medication correctly (Bell et 
al., 2006). An important step to preventing problems is for health care professionals, 
patients and caregivers to understand what medication-related problems are, to 
recognize the signs and symptoms o f actual and potential MRPs, and to identify 
appropriate steps that can be taken to reduce the incidence of these common and 
costly problems. It is important to keep in mind that medication effects can directly 
impact the daily functioning o f the chronically ill, such as cardiovascular patients. 
These effects or “symptoms" o f MRPs may include:
• Excessive drowsiness
• Confusion
• Depression
• Insomnia
• Muscle weakness
• Loss o f appetite
• Falls and fractures
• Changes in speech and memory.
When these symptoms appear, they should be considered “red flags” to caregivers that 
an MRP may be happening.
The importance of the need to assess the impact o f medication-related problems on 
patients’ social and economic wellbeing has been demonstrated by an increasing call 
for the incorporation o f sound medication-related assessment tools in community 
practice (Buurma et al., 2007; Hammerlen et al., 2007). Health-related social and 
economic wellbeing assessment measures have been shown as having the ability to 
predict treatment outcome and thus, can be used to plan individualised menu driven 
care and provide comprehensive assessment o f therapeutic outcomes (Dixon, et al, 
2000). Several studies have demonstrated that compliance with drug treatment is 
largely dependent on the impact o f patients’ feelings on well being (Viktil, et al.,
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2004). Anecdotal evidence suggests strong correlations between self-reported 
psychosocial distress and pharmacotheapeutic concordance, as well as hospital re­
admission. Furthermore, there is low concordance between the patient and the 
physician regarding drug treatment and health evaluations due to distressing 
medication side effects (Testa et al., 1993). In many cases, low concordance has 
resulted in drug treatment withdrawal or low compliance. Clearly, the impact of 
MRPs on social and economic wellbeing constitute a major outcome variable and 
should be measured by means o f a valid, reproducible and sensitive instrument.
In the general introduction to this thesis, a number o f instruments were reviewed. The 
shortcomings o f these instruments as discussed in chapter one fell into the following 
categories: some instruments assessed a concept related to but not the same as social 
and economic impacts of medication-related problems concept. Some measures were 
too lengthy and burdensome for cardiovascular patient groups. Currently, there are a 
number o f cardio-specific disease instruments available for measuring HRQoL as 
humanistic outcomes. These play an important role in the long term management of 
such patient population. However, these instruments were not considered in this 
present study due to lack of relevance to the overall assessment o f MRPs’ impact on 
patients’ social and economic wellbeing. As described in chapter two, the existing 
cardio-specific HRQoL instruments are actually measuring an outcome that is related 
but different to the concept underpinning socioeconomic impact.
As the incidence and prevalence o f medication-related problems in patients on 
multiple drug therapy increase, costs, both direct and indirect, due to MRPs will also 
rise dramatically. Incorporating a sound medication-related problem assessment tools 
as part o f  multiple strategies will help to reduce the costs o f medication-related 
problems, especially in the community setting. As described in chapter one, the aim of 
this study was to develop an instrument to assess the social and economic impact of 
medication-related problems in three cardiovascular patient groups. This was the first 
attempt to conduct this type o f research in such patient groups.
As part o f a developmental process o f a new instrument, its applicability, practicality, 
reliability and validity were assessed. Findings o f this study therefore supported the 
SEIP as a valid and reliable instrument for evaluating the social and economic impacts
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of medication-related problems o f cardiovascular treatments in community setting. As 
demonstrated in the relevant chapters, this 19-item SEIP questionnaire is easy to 
administer and has been shown to be reliable (both in terms of internal consistency 
reliability and test-retest reliability) and valid. More research is of course needed to 
determine the applicability o f this measure to individual patients in secondary care. 
Nevertheless, in the absence of a standardised, validated, medication-related problems 
socioeconomic measure, it is hoped that the SEIP would serve as a ‘gold standard'. 
This o f course would be possible only on the strength of its robustness, 
comprehensiveness, and sound measurement properties which in turn would underpin 
its acceptability and use by researchers as well as practitioners in the field.
As many patients do not know whether the side effects they experience are 
medication-related or due to their medical condition, the SEIP can be used in clinical 
judgement because it relates to all aspects o f social interactions and emotional 
behaviour side effects of cardiovascular drugs. Thus, adoption of SEIP in the 
community setting may improve patients’ compliance with their medications.
Chapter one o f this thesis deals with issues related to medication-related problems and 
implementation o f its assessment tools. Some o f these risk assessment tools have been 
applied in clinical practice to identify and document medication errors (Westerlund et 
al., 2003). This chapter also demonstrated that only few of these assessment tools 
have been used in the community settings to identify and resolve medication-related 
problems (Hammerlen et al., 2007). Documentation and implementation o f these 
MRPs risk assessment tools in the community setting could possibly be improved by 
developing pharmacists' versions o f some o f the existing MRPs risk assessment tools. 
The overall goal and objectives o f developing these risk assessment tools were to 
facilitate better prescribing and improved outcomes, especially in the community.
For several years, the health policy agenda o f many countries around the world has 
focussed on measuring and assessing the quality o f health care services. In Britain for 
example, this policy was reinforced by the introduction o f the National Patient Safety 
Agency and the commitment o f the Department o f health to reducing medical error by 
40% (Morris et al., 2003). To achieve this, the use o f medication-related assessment 
tools in the community setting is one important starting point. At present in the UK,
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as a result o f implementation o f the new pharmacy contracts, pharmacists, especially 
those involved in community practice, now face many challenges as their practice 
changes from providing product centred to patient-oriented services (Van Mil, 2004) 
such as medication review, medicines management, minor ailment schemes etc in 
order to minimise negative outcomes o f medication-related problems. In addition to 
all o f these new initiatives and challenges, as drug prescribing and its use is 
increasingly becoming complex resulting in a variety o f medication-related problems 
(Paulino et al., 2004), pharmacists have the responsibility of evaluating 
appropriateness of medication including dose before dispensing. This of course falls 
well within pharmacists’ theoretical and practical training. Lack o f pro-activeness on 
the part o f pharmacists in the community setting may result in dispensing 
errors/medication errors. In the UK for example, current pharmacy practice is based 
on re-activeness largely due to pharmacies not having access to patient’s notes and 
health record. This may result in lack o f continuity o f care which in turn leads to 
undetected medication-related problems.
The results from chapter three demonstrated that cardiovascular patients on multiple 
drug therapy do experience medication-related side effects. Many o f the pharmacists’ 
interventions were not dependent on the pharmacists possessing specialist knowledge 
about cardiovascular illness, but rather their ability to review peoples’ drug regimens 
as a whole. Recent literature has highlighted the importance o f developing strategies 
to better manage chronic illness such as cardiovascular disease (Bell et al., 2006). 
Although most of the medication-related problems, according to Paulino et al. (2004), 
may seem not to have direct clinical consequences, they could be associated with 
compliance problems which indirectly may reduce therapeutic benefits. Whenever 
medications are administered, there are possibilities for occurrence o f certain 
problems that may compromise therapeutic benefits and diminish a patient’s quality 
o f life. Based on the results in chapter three, this study has demonstrated that 
chronically ill patients and hypertensive patients in particular, should be an important 
target group for pharmacists’ interventions.
Chapter four described all stages involved in the development of SEIP and also 
established its content validity. During the developmental stages of SEIP, the expert 
panel reviewed the initial 31 items and raised issues related to conceptual and
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linguistic aspects of the new instrument. These were subsequently resolved to the 
satisfaction o f the panel members. Furthermore, content validity was addressed by 
developing items on the basis o f a focus group with experts from various professional 
backgrounds as well as in-depth interviews with patients. The content of SEIP 
addresses experiences of great importance to cardiovascular patients such as social 
and emotional impacts o f medication side effects, use o f healthcare services and the 
impact o f medication side effects on productivity. Such experiences are quite 
distinctively associated with medication-related problems.
One o f the major areas o f concern during the developmental stages of SEIP was 
whether the linguistic tone was fit for purpose. In fact individuals from various 
socioeconomic backgrounds who participated in the initial study observed no 
difficulties in comprehending and understanding SEIP statements. Furthermore, 
chapter four results confirmed that the SEIP is applicable and practical with an 
acceptable burden to both patients’ and professionals’ time. The results also 
confirmed that the use and administration o f the SEIP required little explanation other 
than that given on the cover page of the questionnaire. As no published study had 
focused on defining social and economic implications o f medication-related problems 
relevant to cardiovascular patients on multiple drug therapy, the content o f SEIP was 
therefore developed primarily from a literature review. SEIP items therefore focused 
primarily on how patients’ perception o f medication side-effects impacted their 
physical, emotional and social functioning.
Since the objective o f this study was to construct and validate an instrument to 
measure the social and economic impact o f medication-related problems of 
cardiovascular drugs in the community setting, the study used both quantitative and 
qualitative methods to identify items, leading to the establishment of the initial 
twenty-four-item SEIP, consisting of: a thirteen-item domain covering “medication- 
related problems and socio-emotional distress”; a six-item domain covering “impacts 
on healthcare services utility”; a three-item domain focussing on “work and 
productivity”; a one-item domain covering “change in medication”; and a one-item 
“satisfaction with change in medication treatment” domain. Principal components 
analysis was conducted to assess construct validity o f this initial 24-item SEIP. As 
described in chapter five, exploratory factor analysis revealed factors representing
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social and emotional burdens of medication-related problems, the impact on 
healthcare resources utilization and productivity. As Fayers and Hand (1997) 
suggested, the fundamental aim of factor analysis is to identify groups of highly 
correlated variables which are relatively independent from other variables. Based on 
this result, the number of items in the initial version o f SEIP was reduced from 24 to 
19 and grouped in three domains found important to cardiovascular patients on 
multiple drug therapy. The scores obtained from the factor analysis were found to be 
internally consistent with Cronbach’s alphas ranging between 0.62 and 0.74.
One important factor that makes SEIP unique among other available health measures 
is that its first domain includes a column that asks the respondents to comment 
whether they think the side effects they experience are medication-related or due to 
their medical condition. Consequently, most o f the respondents who experienced 
medication side-effects did not think that some o f the side-effects they perceived were 
as a result o f  this drug therapy. In fact, some were unsure as to whether the side- 
effects were due to their medication or their medical condition.
SEIP questionnaire was developed in order to be sufficiently short and simple in 
format so that it would be applicable to cardiovascular patients in the community 
setting as well as acceptable to pharmacy practice professionals. As described in 
chapter six, cardiovascular patient groups under observation in the study found that 
SEIP is easy to understand and complete. It only took most o f the respondents on 
average five minutes to complete. The reliability o f a new instrument is based on the 
assumption that the concept being measured remains constant in value. However, 
according to Bailey (1994), if the concept being measured does change in value, a 
reliable instrument should detect that change. The reliability o f the SEIP was 
established in this study by internal consistency and test-retest reliability. The results 
in chapter six demonstrated that all SEIP domains possess high evidence o f internal 
consistency as well as test-retest reliability. The reported Cronbach’s alpha and the 
corrected item-to-total correlation coefficients supported the homogeneity o f the SEIP 
in measuring the construct o f an assessment tool. Homogeneity o f the items was 
further affirmed, as deletion o f any individual item did not increase the Cronbach’s 
alpha by more than 0.1. Furthermore, the fact that a great majority of the patients who 
returned the SEIP questionnaire in the reliability study completed all parts of the
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questions indicates its reliability and relevancy among cardiovascular patient 
populations.
Comparing the SEIP with some HRQoL instruments in an effort to evaluate its 
validity proved to be a challenging pursuit. It should be noted that SEIP was 
developed to measure the impact o f medication-related problems on patients’ social 
and economic wellbeing. Most o f the existing health measures today are measuring 
disease impacts on patients’ health-related quality o f life. As a result, the choice of 
another measure for a comparison study with the SEIP was limited. In this study, a 
generic SF-12 and a cardio-specific MIDAS scales were chosen against which to test 
the validity o f  the SEIP. Nevertheless, the validation results o f the SEIP described in 
chapter seven produced an encouraging result in terms o f convergent and divergent 
validity. The validity results also indicated that participants who experienced one or 
more side-effects did not think these were medication-related. The results described in 
chapter 7 further demonstrated that the SEIP scores were not influenced by the 
patients’ age and gender. However, the results o f the comparison study with MIDAS 
scales showed that individuals above 64 years were more limited in physical activities 
and experienced more medication-related side-effects. The results also confirmed the 
already published hypothesis that both the physical and mental scales o f the SF-12 are 
able to discriminate between age groups.
The daunting prospect o f any study o f such nature would be ending up with a non- 
valid instrument, which could compel one to go back to the drawing board. However, 
in this present study, the level o f correlations between domains o f the SEIP, SF-12 
and the MIDAS left no doubt about the validity o f the SEIP. One plausible question 
however could be: can the MIDAS scale used in the convergent validity o f the SEIP 
be considered as a ‘gold standard’ measure? Although answering this question would 
require full re-examination o f MIDAS, it suffice to reiterate that MIDAS was 
considered to be the most closely related measure to the SEIP among all the existing 
cardio-specific HRQoL measures available at the time. In addition, what is important 
and must be noted is the consistency of results from different types of validity tests 
carried out in this study. It is this collective evidence that gives support to the validity 
claim for the SEIP.
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The aging population in Western countries means that the proportion of the 
population with chronic illness, especially cardiovascular disease, will increase due to 
lifestyle and environmental factors. This also means that the proportion of the 
population with cardiovascular disease will increasingly be on multiple drug therapy 
and inevitably prone to medication—related problems. In such scenarios, pharmacists 
play an important role in effective management o f medication-related problems 
leading to optimisation o f outcomes and improvement in patients’ health-related 
quality o f life.
Study Implications
The major outcome of this study was the development o f a new instrument to measure 
social and economic impacts o f medication-related side effects o f cardiovascular 
drugs. In the absence o f a ‘gold standard’ instrument o f such nature, one of the 
primary implications of the SEIP will be encouragement o f further research in this 
area o f pharmaceutical care in chronic conditions. In addition, due to lack of social 
and economic assessment tools in this area, it gives an impetus to the use o f the SEIP 
in both research and practice and places the SEIP in an ideal position for further 
refinement. Undoubtedly, with such background, the SEIP could also play a leading 
role for development o f socioeconomic assessment tools in other chronically ill 
patients prone to medication-related problems.
Clearly, development o f the SEIP has made philosophical contribution to the field of 
socioeconomic research. Indeed, the most effective way o f increasing awareness 
about the concept o f social and economic impacts o f medication-related problems, as 
a patient-focussed outcome measure, would be through its application in community 
practice. Without well-designed and properly conducted studies, it would be difficult 
to demonstrate the value o f such a novel outcome measure. Clearly, development of 
the SEIP has set a precedent in terms o f influencing some o f the attitudinal barriers 
towards the use of health measures in the community setting.
Study Limitations
Following completion o f any piece o f research, the hindsight benefits allow one to 
reflect on the whole events that have taken place. On reflection, any researcher will
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think o f a number o f areas o f his/her research that could have been done differently. 
Thus reflection on this piece of research has produced the following limitations:
• Sample size: the sample size used in chapter 3 and the validity study in 
chapter 7 was relatively small. A number o f community pharmacists who 
were approached for collaboration did not show positive response probably 
due to their heavy workload.
• It should also be emphasized that the psychometric properties o f the SEIP are 
established in most of the cases, from sample o f elderly patients ( > 6 0  years) 
who had intact cognitive ability. Limitations therefore exist in generalizing the 
results o f this study to other cardiovascular populations who are community 
dwelling, of younger age (<50years) or with impaired cognitive function.
• As this study presents data obtained from three cardiovascular patient groups 
with majority o f them being hypertensive and are from one to five community 
pharmacies across South West England and South Wales, caution should be 
exercised in the extrapolation o f these results to other patient groups of 
cardiovascular disease in other parts o f England and Wales.
•  Although, the primary objective o f this study was to evaluate both social and 
economic implications o f medication-related problems in the community 
setting, however, this study did not evaluate comprehensively the economic 
impacts in terms o f monetary costs o f MRPs, instead it focuses on economic 
demand o f MRPs on health services.
Future work
As the mean age o f participants in the validity study was 63 years, future studies need 
to be conducted on other age group o f cardiovascular patients, for example, 40 years 
hypertensive patients, to further examine the validity o f the SEIP. Furthermore, future 
work should be aimed at promoting the use of the SEIP as part o f the new community 
pharmacy initiatives in the UK for evaluation of treatment outcomes in patients with
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medication-related side-effects. In addition, future work on this project should focus 
on economic evaluations of medication-related problems in terms of its cost 
implication in the community pharmacy practice.
Notwithstanding the need for additional research, it is hoped that the SEIP will 
become a useful tool for researchers, especially those in community pharmacy 
practice and who are interested in understanding the role of medication-related 
problems in social and economic wellbeing of not only cardiovascular patients, but 
also other chronically ill patients managed in the community setting. For example, 
given the findings that majority o f the cardiovascular patients in this study did not 
think that the medication-related side effects have a major impact on their social and 
economic wellbeing such as the ability to socialise, work or how often they utilise 
healthcare services such as emergency visits to GP, nurses, pharmacists as a result of 
medication side-effects. It would be of importance to examine these attributes among 
other chronically ill patients such as those with asthma, other chronic obstructive 
pulmonary disease, and diabetes who are largely managed in the community setting.
In conclusion, it is hoped that the work presented in this thesis has made a valuable 
contribution to the limited existing body of knowledge in this area. In particular, it is 
believed that this work has enriched the much under-researched area of 
socioeconomic impacts of medication-related problems of cardiovascular drugs in the 
community setting. In addition to all efforts made in communicating the findings of 
this work during the course of this study, a full manuscript is under preparation for 
publication in reputable scientific journals in the field of community pharmacy 
practice.
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APPENDIX 1
A copy of the Pharmaceutical Care Network Europe Drug 
Related Problem Classification Scheme Version 5.00 
(PCNE_DRP classification V5)
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APPENDIX 1
DRP-Registration Form V5.00 (PCNE Classification)
Age o f patien t:..................................................  □  Male □ Female
Name o f m edication:....................................... □  Rx □ OTC
Main active substance:  □  New □ Refill
(ATC-Code(s))
No of drugs taken... □  According to patient
□According to medication record
Problem discovered □  by patient
□  by pharmacy Date: ........
□ by physician
Description & comments: Time spent on evaluation and
intervention:.................min.
Date evaluation of outcome: □  Problem solved
□ Problem partially solved
□  Problem not solved
2 4 7
TYPE OF PROBLEM (p lease  tic k  o n ly  O N E  p r o b le m )
PI. Adverse reactions
□  Side effect suffered (non allergic)
□  Side effect suffered (allergic)
□  Toxic effect suffered
P2. Drug choice problem
□  Inappropriate drug
□  Inappropriate drug form
□  Inappropriate duplication o f drug(-group)
□  Contra-indication for drug
□  No clear indication for drug 
□N o drug but clear indication
P3. Dosing problem
□  Drug dose too low or regimen not frequent 
enough
□  Drug dose too high or regimen too frequent
□  Duration o f treatment too short
□  Duration o f treatment too long
P4. Drug Use Problem
□  Drug not taken/administered at all
□  Wrong drug taken/administered
PS. Interactions
□ Potential interaction
□  Manifest interaction
P6. Adverse events
□ Side effect suffered (non allergic origin)
□  Side effect suffered (allergic origin)
P7. Patient related problems
□  Patient dissatisfied with therapy
□ Insufficient awareness o f health and 
disease
□ Unclear complaints. Further clarification 
necessary
□ Therapy failure (unknown reason)
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CAUSE OF DRP (m ax. 3 b o xes  to  be ticked)
C l. Drug or dose selection
□  Inappropriate drug selection
□  Inappropriate dosage selection
□  More cost-effective drug available
□  Pharmacokinetic problems
□  Synergistic/preventive drug required
□  Deterioration/improvement of disease state
□  New symptom/indication revealed
□  Manifest side effect, no other cause
C2. Drug use process
□  Inappropriate timing of dosing
□  Drug underused/ under-administered
□  Drug overused/ over-administered
□  Drug abused
□  Patient unable to use drug/form as directed 
C3. Information
□  Instructions for use/taking not known
□  Patient unaware o f reason for drug treatment
□  Patient has difficulties reading/ understanding
□  Patient Information Form/Leaflet
□  Patient unable to understand local language
□  Lack o f communication between health 
professionals____________________________ _
C4. Patient/Psychological
□  Patient forgets to use/take drug
□  Patient has concerns with drugs
□  Patient suspects side-effects
□  Patient unwilling to carry costs
□  Patient unwilling to bother physician
□  Patient unwilling to change drugs
□  Patient unwilling to adapt life-style
□  Burden o f therapy
□ Treatment not in line with health beliefs 
C5. Logistics
□  Prescribed drugs not available
□  Prescribing error (slip of the pen)
□  Dispensing error (wrong drug or dose 
dispensed)
C6. Others
□ Other cause
□  No obvious cause
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TYPE OF INTERVENTION (Max. 3 boxes to be ticked)
10. No intervention
11. Prescriber level
□ Prescriber informed only
□ Prescriber asked for information
□ Intervention proposed, approved by prescriber
□ Intervention proposed, not approved by prescriber
□ Intervention proposed, outcome unknown
12. Patient/carer level
□ Patient (medication) counseling
□ Written information provided only
□ Patient referred to prescriber
□ Spoken to family member/caregiver
13. Drug level
□  Drug changed t o .........................
□  Dosage changed t o ....................
□  Formulation changed t o ...........
□  Instructions for use changed to
□  Drug Stopped
□  N ew  drug started
14. Other
□  Other intervention.....................
□  Side effect reported to 
authorities
OUTCOME OF INTERVENTION (Tick one box only)
Ol. Solved 03. Problem NOT solved
□ Problem totally solved □ Lack of cooperation of patient
02. Partially solved □ Lack of cooperation of physician
□ Problem partially solved □ Intervention not effective
□ No need or possibility to solve problem
2 5 0
INSTRUCTIONS FOR COMPLETING THE DRP (DRUG-RELATED 
PROBLEM) REGISTRATION FORM.
1. Use only one form for each drug-related problem you detect.
2. You may indicate more than one cause for a particular drug-related problem (max 
3)
3. You may indicate more than one intervention made per drug-related problem (max
3)
4. If the patient’s age is not known, please estimate the age within a 5 year range
5. The drug(s) involved in the drug-related problem are entered under the ‘Name of 
medication’ section
6. If the ATC-code of the drug is not known, please enter the main active substance or 
approved / generic name of the medicine
7. Rx relates to a prescribed drug, and OTC relates to products purchased without 
prescription.
8. Complete the section ‘New’ and ‘Refill’ only if the medicine involved is a 
prescribed medicine
9. If the patient initiates the discussion of the drug problem, tick the ‘by patient’ box 
in the ‘Problem discovered:’ section.
If the drug problem is discovered by a member of the Pharmacy staff, tick the ‘by 
pharmacy’ box in the ‘Problem discovered:’ section
10. The ‘Number of drugs prescribed’ refers to the number of different prescription 
drugs taken by the patient, according to the patient medication profile or
according
to the patient
11. The ‘Time spent on intervention’ is the time spent actively involved in dealing 
with the drug problem. This includes time from the identification of the drug
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problem, time spent in discussion with the patient, with any other health care 
professional, obtaining information and final communication with the patient at 
the resolution of the drug-related problem.
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APPENDIX 2
Specimen of the letter to 
Pharmacies inviting them for 
collaboration with the study
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LETTER OF RECRUITMENT OF PHARMACIES
5th April 2005 
(Address)
Dear sir/ ma,
Evaluating socioeconomic impacts of medication-related problems of 
cardiovascular diseases management.
With regard to the above mentioned research project, I am writing to ask for 
permission to include your pharmacy in this project.
The aims of this research are : 1) to evaluate the impacts of medication-related 
problems on social and economic status of cardiovascular diseases patients and the 
role pharmacists are playing to minimize these socioeconomic consequences by their 
pro-active involvement in medicine use review, prescription interventions and active 
involvement in medication surveillance.
I am particularly focusing on three cardiovascular diseases patient groups; 
hypertension and angina patients, post- myocardial infarction patients and congestive 
heart failure patients. Literature research has been done on this subject and several 
studies about drug -related problems and pharmacists’ involvement in pharmaceutical 
care have been identified. But so far, there has been little or no published research 
about pharmacists’ involvement in minimizing social and economic consequences of 
side effects /adverse drug reactions reported by patients.
According to the NICE (2001) clinical guidelines on the treatment of myocardial 
infarction, heart failure and hypertension, post myocardial infarction patients with or 
without heart failure are offered long term treatment firstly with beta-blocker and 
antiplatelet drug such as aspirin, and then with statins and an ACE inhibitor (NICE,
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2001). Beta-blockers and ACE inhibitors are also indicated for the management of 
symptoms of CHD such as angina, and also risk factors, especially hypertension 
together with other drug groups such as calcium channel blockers, nitrates, potassium 
channel activators and diuretics.
From the short description of the nature of this research, what I would like from you 
are: 1) collaboration in identifying patient groups who are on long term treatment with 
the above mentioned drug groups. They are our potential participants. This will be 
done through medicine use review (MUR) and prescription intervention service (PIS). 
Selected patients will be contacted to request for their consents and invited for free 
medication use review with their pharmacist. As part of my research, patients will be 
asked to fill SERT (socioeconomic research tool) questionnaires to evaluate impacts 
of any medication-related problems discovered during medicine use review on their 
socioeconomic status. This should not take more than 30 minutes with each patient.
I have included a copy of study protocol with this letter with full details about your 
involvement in the study.
From 1st April 2005, a new pharmacy contract has taken effect giving pharmacists 
opportunity to offer medicine use review as part of enhanced services for which they 
will now be fully reimbursed. This is a further development of acknowledgement of 
pharmacists’ role as experts in pharmaceutical care. As a registered pharmacist 
myself, I will be willing to offer FREE OF CHARGE this medicine use review and 
other pharmaceutical care services for the patient groups involved in my research 
study at your pharmacy.
Your response is therefore very important to my research and I will be grateful for 
your interest in it.
If you would like to discuss more about this research proposal, I would be pleased to 
come to your pharmacy or to discuss with you by telephone. I can be contacted on
255
029-20668438. You can also contact my supervisor at Welsh school of pharmacy, 
centre for socioeconomic research Cardiff University.
I look forward to hearing from you,
Sincerely yours,
Tommy Aderounmu, MPharm, PharmD, MRPharmS 
PhD research student
Dr Sam Salek
Research supervisor
Reader in Pharmacoepidemiology
Director - WSP Centre for Socioeconomic Research
Director - Postgraduate Course in Pharmaceutical Medicine
Cardiff University
Redwood Building
King Edward VII Ave
Cardiff, CF10 3XF, U
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APPENDIX 3
Specimen of the invitation letter to patients for 
participation in the Medicine Use Review
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Invitation letter to patients
Dear sir / ma,
ANNUAL REVIEW OF YOUR MEDICATIONS
From April 2005, a new range of services were introduced in community pharmacies 
across England and Wales to improve quality of healthcare services offered to people. 
One of this is called “Medicine Use Review”. This service will enable people with 
long-term condition such as high blood pressure, heart problems etc. to discuss with 
their pharmacists how they have been getting on with their medications, whether any 
changes are needed and how they feel in general with their condition.
As part of routine standard of care we offer to our customers, we are inviting you to 
come forward for this review of your medications as you will surely benefit most 
from it. All you need to do is bring along all medications prescribed by your doctor 
and which you regularly take as well as any you might have bought over the counter 
for any other condition.
This review with your pharmacist should not take more than 30 minutes. Initially the 
review will be done on Wednesdays and advance booking is therefore necessary. You
can make your booking by calling to pharmacy on tel. n o .................., or in case of any
inconveniency contact our “medicine use review pharmacist” on mobile no: 
07932736616 for alternative arrangement.
Your response is greatly appreciated.
Yours sincerely,
Pharmacy manager
Tesco pharmacy
258
APPENDIX 4
Specimen of the covering letter to patients in the 
Reliability and Validity Study
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A STUDY TO SEE HOW RELIABLE IS THE SOCIO-ECONOMIC
IMPACT PROFILE QUESTIONNAIRE FOR ROUTINE USE
Dear sir / ma,
The Centre for Socioeconomic Research, Cardiff University in collaboration with 
some community pharmacies in England and Wales is carrying out a study on how 
any side effects you may experience from your medication(s) is affecting your quality 
of life in general. We would be most grateful if you could help us by answering some 
questions about those side effects of your medications.
This study will help us to understand more about medication side effects and also help 
us to keep track of how you feel and how well we can help to minimise the impact of 
medication side effects on your life.
We would be most grateful if you could complete the two enclosed questionnaires. 
The first questionnaire is to be completed today and the second 7 days after. Please 
also fill in the details on the yellow form and make any additional comments that you 
wish in the space provided on the sheet. Please return the questionnaires and the 
yellow form in the pre- paid envelope provided. If for any reason you are not able to 
complete the questionnaires, then please be assured that this will not affect the quality 
of care / service we offer you in any way.
All the information collected during this study will be kept strictly confidential. If you 
have any questions or would like any help in completing the questionnaire, we would 
be pleased to hear from you. Please feel free to contact Professor Sam Salek (tel. at 
work: 02920- 876017) or Tommy Aderounmu (tel: 07932736616).
Thank you once again for your assistance and cooperation.
Yours sincerely,
Prof Sam Salek Tommy Aderounmu
APPENDIX 5
Specimen of the Content Validity Assessment Form
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CONTENT VALIDATION OF THE SOCIOECONOMIC IMPACT PROFILE
Introduction
Cardiovascular diseases as a leading cause of death especially in developed countries 
impose significant economic, humanistic and clinical burdens on both the patients and 
the society as a whole. Majority of patients with this chronic condition are on multiple 
drug therapy hence are prone to medication-related side effects. There is the need to 
develop an instrument which will investigate the impacts of medication side effects on 
a patient’s quality of life, which will also include both social and economic 
consequences.
What is the Socioeconomic Impact Profile (SEIP)?
The Socioeconomic Impact profile (SEIP) questionnaire is a cardiovascular disease 
specific instrument designed to investigate the impact of medication-related side 
effects on socioeconomic aspects and quality of life of patients on cardiovascular 
drugs. As this instrument has not been used before in practice, it is important to test its 
applicability, reliability and validity in real patient population.
Assessment of Socioeconomic Impact Profile (SEIP)
What do you have to do?
This is the final version of the SEIP questionnaire after several amendments of its 
different drafts. Your tasks are:
A. to validate the content of this questionnaire by taking into consideration the 
following criteria listed below:
1) Clarity -  the items must be clear, unambiguous and straightforward in their 
intentions.
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2) Completeness of sentence -  the included items must show a degree of relevance 
and reflect sample areas of interest to the observed patient population.
3) Linguistic clarity- the sentences should be clearly understandable, 
straightforward and simple. This means the sentences should be understood by 
anyone with a minimum knowledge of reading and writing.
4) Relevance -  the items in each domain should be relevant to the area of interest. 
Remember that this instrument is cardiovascular drug specific and is designed to 
measure the effects of cardiovascular drugs-related side effects on socioeconomic 
aspects of these patients.
5) Scaling (response ) option -  to derive an overall quality score for each domain, 
the intention is to use Likert scaling system starting from five points to one point 
(five for “never”, four for “a little of the time”, three for “some of the time”, two 
for “most of the time”, and one for “all of the time”. Total points will be divided 
by the total possible points (the sum of the maximum points for each item) to 
yield a fraction between 0 and 1. A score of 1 represents the highest quality.
B. To rate each domain and its content in accordance with a degree of agreement 
using the above named criteria. Then complete the assessment form included.
CONTENT VALIDITY ASSESSMENT FORM
For each of the item in the questionnaire, please put a tick in the assessment box
below.
I) Title
Strongly agree Agree Disagree Strongly disagree
Clarity
Completeness
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Linguistic clarity
Relevance
Scaling option
Comments and suggestions:
2) Introduction/Instruction
Strongly agree Agree Disagree Strongly disagree
Clarity
Completeness
Relevance & 
Scaling option
Linguistic clarity
Comments and suggestions:
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3) Global question
Strongly agree Agree Disagree Strongly disagree
Clarity
Completeness
Relevance
Scaling option
Linguistic clarity
Comments and suggestions:
Source: Pei Lin Lua PhD 2002
Thank you for your time and help
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Appendix 6
A copy of the covering letter to patients for the Validity
Study
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Dear 9
The Centre for Socioeconom ic Research, Cardiff University in 
collaboration with community pharmacies in England and Wales is 
carrying out a study to assess the Socioeconom ic Impact o f  heart 
condition and its treatment on daily life. It has been suggested that 
assessment o f  quality o f  life should be integrated into health care services 
in order to allow optimal patients’ care.
I would be most grateful if  you could complete the three enclosed 
questionnaires in the presented order ( 1 , 2  and 3) and return them to the 
pharmacy in the envelope provided at your earliest convenience. If for 
any reason you are not able to complete the questionnaires, then please be 
assured that this will not affect the quality o f  care / service we offer you  
in any way.
All the information collected during this study will be kept strictly 
confidential. If you have any questions or would like any help in 
completing the questionnaire, I would be pleased to hear from you.
Thank you once again for your help and cooperation.
Kind regards, 
Massoud
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Socioeconomic Impact Profile Questionnaire
Patient ID: Date:
The questions below refer to the Socioeconom ic Impact Profile 
questionnaire which you have just completed. Please give your best 
possible answer to each question.
1) How much time (in approximate minutes) did you take to complete 
the questionnaire?
2) How clear and understandable were the instructions and questions to 
you in general?
I I Very clear Q  Clear Not clear Q  Very unclear
3) Do you think the questions asked are comprehensive enough to 
measure your social and economic well-being including quality o f
4) If your answer to no 3 is NO, please state what additional questions 
would you like us to ask/ know about the effects o f  your medications 
on your quality o f  life?
5) Did you find any question(s) to be unsuitable, difficult or distressing 
to answer?
life?
□  Yes □  No
□  Yes □  No
6) If yes, can you state which?
Thank you very much for your time and participation.
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Appendix 8
A copy of the Myocardial Infarction Dimensional 
Assessment Scale (MIDAS)
Patient Identification number
MIDAS Quality of life questionnaire
INSTRUCTIONS
This survey asks for your views about how you have been feeling during the last 2 
weeks and in what ways these affect your quality o f life in general.
All responses will be treated in the strictest confidence.
Answer every question by ticking the appropriate box, if you are unsure about how to 
answer a question, please give the best answer you can and feel free to make 
comments as you wish.
Physical activity
Please tick only one circle fo r each question
Since your medical condition, how often during the last week have you
Never Occasionally Sometimes Often Always
1. Thought twice before you 
undertook physical activity 
(e.g. housework or going to the 
shops)?
5
0
4
0
3
0
2
0
l
0
2. Had angina symptoms
(e.g. chest pain or tightness)? 0 0 0 0 0
3. Had angina (chest pain or 
tightness)
that affected your life?
0 0 0 0 0
4. Felt slowed down? 0 0 0 0 0
5. Had no energy? 0 0 0 0 0
6. Been breathless? 0 0 0 0 0
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7. had chest pain or tightness when 
undertaking physical activity?
0 0 0 0 0
8. Felt frustrated at your limitations? 0 0 0 0 0
9. Needed to rest more? 0 0 0 0 0
10. Felt you have a reduced social 
life?
0 0 0 0 0
11. Felt you cannot perform your 
domestic duties
0 0 0 0 0
12. Found the weather made your pain 
worse?
0 0 0 0 0
^  Insecurity
Please tick only one circle for each question
Since your medical condition, how often during the last week have you
Never Occasionally Sometimes Often Always
13. Felt frightened you will 
have another heart
0 0 0 0 0
attack?
14. Felt isolated? 0 0 0 0 0
15. Felt lonely? 0 0 0 0 0
16. Felt anxious about 
travelling?
0 0 0 0 0
17. Felt vulnerable? 0 0 0 0 0
18. Felt insecure? 0 0 0 0 0
19. Felt your confidence has 
been affected? 0 0 0 0 0
20. Felt anxious about 
dying? 0 0 0 0 0
21. Worried or felt anxious 
about the future? 0 0 0 0 0
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| c j  Emotional reaction
Please tick only one circle for each question
Since your medical condition, how often during the last week have you
Never Occasionally Sometimes Often Always
22. Felt irritable? 0 0 0 0 0
23. Felt down or depressed? 0 0 0 0 0
24. Felt bad tempered? 0 0 0 0 0
25. Felt stressed? 0 0 0 0 0
|d J  Dependency
Please tick only one circle for each question
Since your medical condition, how often during the last week have you
Never Occasionally Sometimes Often Always
26. Felt your family or friends are 
over protective?
27. Felt you have lost your 
independency?
28. Felt you have to rely on others?
0 0 0 0 0
0 0 0 0 0
0 0 0 0 0
|e |  Diet
Please tick only one circle for each question 
Since your medical condition, how often during the last week have you
Never Occasionally Sometimes Often Always
29. Felt concerned about your diet? 0 0 0 0 0
30. Felt concerned about your 
cholesterol level? 0 0 0 0 0
31. Felt worried about your weight?
0 0 0 0 0
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Concerns over medication
Please tick only one circle for each question
Since your medical condition, how often during the last week have you
Never Occasionally Sometimes Often Always
32. Worried about taking tablets? 0 0 0 0 0
33. Worried aboutside effects 
from your tablets? 0 0 0 0 0
Side effects
Never Occasionally Sometimes Often Always
34. Felt the cold more? 0 0 0 0 0
35. Experienced side effects (e.g. 
cold hands or feet / going to 
toilet at night) from your 
medications?
0 0 0 0 0
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A copy of the Short Form-12 health survey
questionnaire
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Short Form Health Survey Questionnaire 
SF-12
1. In general, would you say your health is
O  Excellent 
O  Very good 
O  Good 
0  Fair 
O  Poor
The following items are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much?
Limited Limited a Not limited at 
a lot little all
2. Moderate activities such as moving a 
table, pushing a vacuum cleaner, bowling 
or playing golf.
3. Climbing several flights of stairs.
0 0 0 
0 0 0
4. During the past four weeks, have you accomplished less than you would like 
as result of your physical health?
ONo 
O Yes
5. During the past four weeks, were you limited in the kind of work or other 
regular activities you do as a result of your physical health?
ONo 
O Yes
6. During the past four weeks, have you accomplished less than you would like 
to as a result of any emotional problems, such as feeling depressed or anxious?
ONo 
O Yes
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7. During the past four weeks, did you not do work or other regular activities as 
carefully as usual as a result of any emotional problems such as feeling 
depressed or anxious?
ONo 
O Yes
Not at 
all
slightly moderately Quite 
a bit
Extremely
8. During the past four weeks, how 
much did pain interfere with your 
normal work, including both work 
outside the home and housework?
0 0 0 0 O
These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling.
All of Most of A good bit Some of A little of None of 
the time the time of the time the time the time the time
9. How much time 
during the past 4 
weeks have you felt 
calm and peaceful?
10. How much of the 
time during the past 
4 weeks did you 
have a lot of energy?
11. How much time 
during the past 4 
weeks have you felt 
down?
12. During the past 4 
weeks, how much of 
the time has your 
physical health or 
emotional problems 
interfered with your 
social activities like 
visiting with friends, 
relatives etc?
0 O O O 0 0
0  O 0  0  0  o 
0  O O 0  0  o
0 O 0 0 0 0
